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Abstract 
In this thesis, the behavioral, electrographic and neurobiological effects of a period of 
kainic acid-induced status epilepticus (SE) on the C57BL/6J inbred mouse strain are 
characterised. The severity of epileptic behaviour was scored, used 
immunohistochemistry to investigate the anatomical distribution of c-Fos expression 
in the hippocampal formation following SE and recorded EEG during and after SE 
using an implantable, wireless telemetry device. Further to assessing the severity of 
SE, changes subsequent to seizures related to the emergence of chronic epilepsy 
were investigated, including reactive gliosis and synaptogenesis and epileptiform 
discharges in the EEG trace. 
 
I investigated the potential of a range of pharmacological agents for modulating the 
severity of induced seizures and disease progression. These included drugs 
targetting the NR2B subunit of the NMDA receptor (RO 25-6981), neuronal nitric 
oxide synthase (L-NPA), The post synaptic density protein 95 (Tat-NR2B9a) and 
inducible nitric oxide synthase (1400W). 
 
L-NPA, when administered prior to the induction of SE was found to profoundly 
suppress the emergence of epileptiform activity, including behavioural, 
electrographic and neurobiological indicators. Further, L-NPA’s modulation of the 
precipitating event lead to a decrease in neurobiological changes associated with 
epileptogenesis, such as reactive gliosis in the CA3 region of the hippocampus and 
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elevated synaptogenesis in th molecular layer of the hippocampus. This correlated 
with a marked decrease in epileptiform discharges in the EEG trace. 
 
A novel method of kainic acid administration was trialed, involving multiple small 
doses of the drug, titrated by the severity of behaviour. This method led to a 
decrease in mortality and an increase in the severity and inter-individual uniformity of 
SE, assessed by the analysis of behaviour, EEG and c-Fos expression in the 
hippocampus. Furthermore, this method induced neurobiological changes 
associated with epileptogenesis 3 days following SE and was associated with an 
increased frequency of epileptiform discharges for 7 days post SE. 
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1.1 Summary 
 
 
12 
 
Initially,  the clinical characteristics of seizures and epilepsy will be described and the 
mental and social problems associated with the pathology (1.2). A brief anatomical 
description of the anatomy of brain regions implicated in seizure generation will then 
be given, alongside a discussion of their physiological function (1.3). An overview of 
basic research into the epilepsies will then be given, with an emphasis on temporal 
lobe epilepsy (TLE) (1.4). Some background to the history and development of the 
methods used in our studies will be given, including animal models of seizures and 
epilepsy (1.5). The development of pharmacological interventions will be discussed, 
both in terms of their development and clinical applications (1.6). Finally, a 
discussion of the physiological and pathophysiological role of nitric oxide in a range 
of disorders of the central nervous system will be presented, with a particular 
emphasis on epilepsy (1.7), before a brief introduction to the specific aims of the 
research described in subsequent chapters (1.8).  
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1.2  Seizures and epilepsy in the clinic  
 
 
1.2.1  Overview 
Epilepsy is a brain disorder characterized by an enduring predisposition to generate 
seizures, and by emotional and cognitive dysfunction (Duncan et al, 2006). Epilepsy 
effects approximately 50 million people worldwide and is strongly linked to 
depression, both through direct physiological causation and secondary effects 
mediated by restrictions on lifestyle, living with the fear of seizures, intellectual 
deterioration, exclusion from driving and low self-esteem (Gilliam et al, 2008). 30% of 
sufferers are refactory to currently available pharmacological interventions (Kwan & 
Brodie, 2000) and, in many cases, highly invasive surgery often involving severe 
side-effects (Wiebe et al, 2001) is the only option available. 
 
1.2.2 Seizures    
The word seizure derives from the Latin ‘sacīre’ meaning simply to take hold of. A 
seizure is a paroxysmal event that can be triggered by physiological (organic) or 
psychological disturbances. Not all seizures are epileptic. Seizures that are triggered 
by events outside the brain, or psychological disturbances, are described as non-
epileptic seizures.  These include, but are not limited to: febrile convulsions in 
infants, hypoglycaemic seizures and parasomnias, such as ‘night terrors’. Seizures 
can involve involuntary muscle activity or abnormal experiences, ranging from visual 
disturbances to phenomonological experiences that defy linguistic description. 
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1.2.3 Epileptic seizures  
An epileptic seizure is, by definition, generated in the brain and involves the 
abnormal, rhythmic discharges of cortical neurons (Ricker, 2003). Epileptic seizures 
can be categorised according to either the anatomical distribution of epileptiform 
activity, or the emergent behaviour or phenomenological experiences. The challenge 
involved in creating a system of seizure classification of sufficient precision and 
breadth, however, is exemplified by the complications in the most simple dichotomy 
between partial (focal) and generalised seizures. Partial seizures are restricted to a 
specific focus in a single hemisphere, while generalised seizures effect both sides of 
the brain. The distinction, however, is blurred in cases of secondarily-generalised 
partial seizures and non-generalised, multi-focal seizures. Here follows a brief 
overview of different seizure types described by currently accepted nomenclature of 
the international league against epilepsy (ILAE) (Fisher et al, 2005) and a figure 
illustrating the hierarchical structure of seizure types (Figure 1). 
 
A simple partial seizure (SPS) is restricted to a narrow focus, described by John 
Hughlings Jackson (1890) as a ‘discharging lesion’, can often produce an ‘aura’, 
which can be used to predict more serious and potentially damaging secondarily-
generalised seizures. The site of the seizure focus largely dictates the way SPS is 
experienced, with a temporal lobe focus (most common) typically inducing  epigastric 
rising sensations, feelings of familiarity (deja vu) or unfamiliarity (jamais vu), intense 
bursts of emotion and highly vivid flashbacks of memory. A parietal lobe focus often 
causes sensations of numbness, tingling or burning. In the occipital lobe, a distortion 
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of vision, flashing lights, coloured shapes and hallucinations can be experienced, 
while, in the frontal lobes, a ‘wave’-like sensation going through the head and body is 
commonly reported.  
 
Complex partial seizures (CPS) effect larger areas of the brain, but are usually still 
restricted to a single hemisphere. A CPS can inhibit conciousness, responsiveness 
and memory of the seizure. A period of severe post-ictal confusion is often difficult to  
demarkate from the seizure itself. The temporal lobe is the most common site for 
CPS, where it often induces manual and oral automatisms.. CPS in the frontal lobe is 
often of shorter duration and and characterised by the adoption of strange limb 
postures, juddering movements and a swift post-ictal recovery. Generalised seizures 
affect both hemispheres and involve the full loss of conciousness and tonic-clonic 
convulsions. Partial seizures that spread are referred to as secondarily-generalised 
seizures.  
 
Seizures are also often defined primarily from the behavioural and experiential 
perspective. Absence seizures (petit mal), underpinned by a disruption of 
corticothalamic and thalamocortical pathways (Snead III, 1995) involve the 
temporary loss of conciousness. Typical absence seizures often last for just a few 
seconds and may often go unnoticed. Tonic, atonic, myoclonic and clonic seizures 
involve disruptions in the motor cortex and respectively produce the involuntary 
contraction, relaxation, twitching and alternating contraction and relaxation muscles. 
Tonic-clonic (grand mal) seizures involve alternate phases of tonus and clonus and 
usually result in the loss of conciousness.  A period of 30 minutes or more of either 
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continuous or repeating seizure activity is classified as status epilepticus (Treiman, 
1993). Up to 25% of seizures fail to fulfill the criteria for any seizure ‘type’ and remain 
unclassified.  
 
 
Figure 1.1. Categorisation of seizures according to the international league against 
epilepsy (Fisher, 2005).  
 
1.2.4 Epilepsy 
Epilepsy is the recurrence of unprovoked epileptic seizures, implying a permanent 
brain pathophysiology supporting abnormal hypersynchronous neuronal firing 
(Fisher, 2005). Rather than a single disorder, ‘epilepsy’ refers to a diverse group of 
syndromes with different symptoms and etiologies. Epilepsies are classified 
according to five criteria: etiology, se miology, anatomical site of seizure origin, 
syndrome and trigger (Fisher, 2005). Common epilepsy syndromes include 
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childhood absence epilepsy, caused by disruptions to thalamocortical and 
corticothalamic circuitry (Snead III, 1995) and benign familial neonatal convulsions, 
an inheritable ‘channelopathy’ effecting potassium channel kinetics (Baulac, 2010). 
Many epilepsy syndromes are idiopathic, like the relatively rare Landau-Kleffner 
syndrome (Landau & Kleffner, 1957), which involves acquired aphasia related to 
epileptiform activity during sleep. Of particular interest to us, and discussed in detail 
below is temporal lobe epilepsy (TLE). 
 
1.2.5 Temporal lobe epilepsy  
 
John Hughlings Jackson first described the semiology of what would later become 
known as TLE in the 1860 as uncinate fits; seizures arising from the uncal part of the 
temporal lobe. Gibbs, et al (1936) introduced the term psychomotor epilepsy to 
describe the same set of symptoms. In 1981, the international classification of 
epileptic seizures replaced this term with complex partial seizures and in 1985, the 
ILAE classified TLE as a condition characterised by spontaneous recurrent seizures 
(SRS) originating from the medial or lateral temporal lobe (Fisher, 1985).  
 
TLE is the most common form of new-onset epilepsy in adults and is clinically 
characterised by complex focal seizures with oral or manual automatisms and 
secondarily generalised tonic-clonic seizures (Aronica & Gorter, 2007). It is a 
condition of diverse etiologies, however, it is often precipitated by abnormalities 
within the hippocampus (Ben-Ari & Cossart, 2000). TLE is also the most common 
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indication for epileptic surgery (Berg, 2008), which can involve the resection, 
disconnection or stimulation of the temporal lobe. Electrophysiological recordings 
from the human brain during surgery and histology on resected tissues has 
contributed to our understanding of the disease, however, because patients will 
invariably have tried numerous drug treatments prior to surgery, a basic 
understanding of the ‘natural history’ of TLE in humans is lacking (Berg, 2008). 
 
An initial precipitating insult (IPI), such as traumatic brain injury, ischaemic brain 
injury or a seizure sets in motion a process known as epileptogenesis (De Lanerolle 
et al, 1989), involving a seizure-free ‘latent’ phase, followed by chronic susceptability 
to sponateous recurrent seizures (SRS). In humans, the latent phase will often last 
for years. Animal models, in vitro preparations and computational models have all 
contributed to our understanding of TLE. An overview of the contribution of basic 
research and an in depth discussion regarding the underlying biology of the condition 
is tackled later in this chapter.  
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1.3 Physiological function of brain regions implicated in seizures and epilepsy 
 
 
1.3.1 Summary 
Hughlings Jackson (1890) described seizures as a collection of neurons firing in a 
hypersynchronous manner. In order to understand this disrupted activity, it is 
necessary to first need to understand a little about how neurons and neuronal 
circuits behave under physiological conditions. Here, the basic anatomy of neurons 
and neuronal circuits is discussed, before switching emphasis to a description of the 
anatomy and physiology of brain regions implicated in TLE. A detailed discussion 
regarding the pathophysiology of epilepsy, however, is reserved for later in the 
chapter.  
 
1.3.2  Neurons – the basic unit of network activity 
 
1.3.2.1 Anatomy of the neuron 
 
Neurons are cells specialised for the integration and transmission of information 
(Hebb, 1949). This information is transmitted between neurons chiefly through 
chemical transmission at synapses, and transmitted across long-distances in the 
CNS by the progression of action potentials (APs) axons. The prototypical neuron 
(Figure 1.2) consists of dendrites, a soma (cell body), and an axon. The axon 
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arborises and forms terminal boutons on many target neurons, as well as proximate 
boutons along its length. 
 
Figure 1.2. Prototypical neuron (Drawing from Ramon Y Cajal & Azoulay, 1894) 
 
1.3.2.2 The resting membrane potential 
 
The cytosol is seperated from the extracellular environment by an insulatory lipid 
bylayer facilitating the formation of an electrochemical gradient. This gradient is 
created and maintained by an ATP-driven Na+/K- pump. A resting potential (Vm) of 
around -65mV is maintained across the lipid bilayer by the action of voltage-gated 
ion channels in the lipid membrane. This resting potential provides the store of 
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energy required for the swift transmission of information down the axon via the action 
potential (AP) (Hodgkin & Huxley, 1952). 
 
1.3.2.3 The action potential 
The AP (Figure 1.3) was first described in the giant axon of the squid, by Hodgkin & 
Huxley (1952) in four landmark papers published simoultaneously in the same issue 
of the Journal of Physiology. In the dendrites and soma, the membrane potential is 
depolarised by excitatory post-synaptic potentials (EPSPs) from excitatory input 
(typically mediated by glutamate in the CNS (Meldrum, 2000)), and hyperpolarised 
by inhibitory post-synaptic potentials (IPSPs) from inhibitory input (typically mediated 
in the CNS by Gamma-amino butyric acid (GABA) (Sivilotti & Nistri, 1991)). The 
membrane potential in this region fluctuates in a graded manner, depending on 
inputs from other neurons. An AP is produced at the axon hillock when the net effect 
of EPSPs and IPSPs is a depolarisation beyond the threshold potential, which varies 
across neurons, but is typically in the range of -40 to -55mV. 
 
Depolarisation beyond the threshold leads to the opening of local voltage-gated Na+ 
channels, further depolarising the memberane and leading to a cascade of Na+ 
influx (rising phase), a reversal in the potential (overshoot) that typically peaks 
around +40mV. At this reversal potential, Na+ channels are shut, preventing further 
influx and K+ channels open, leading to outflux of K+ and a return towards (falling 
phase) and often beyond (undershoot), Vm. Voltage-gated ion channels, particularly 
Na+ channels, propagate action potentials down an axon, with a high level of fidelity, 
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towards the pre-synaptic terminal. The great value of the AP is that it is an all or 
nothing event, translating graded inputs into a binary signal, which can be conducted 
quickly over long distances without degradation. At pre-synaptic terminals, the AP is 
translated into the vesicular release of neurotransmitters (Sudhof, 1995). 
 
Figure 1.3. Phases of the action potential 
 
1.3.2.4 Synaptic transmission 
 
Chemical signalling at the synapse was first demonstrated at the neuromuscular 
junction by Otto Loewi (1921). Subsequently, it has become clear that the vast 
majority of synaptic signalling in the CNS is mediated via chemical rather than 
bioelectrical transmission. The details and variety of synaptic transmission is a topic 
of huge and ever-expanding complexity. The basic mechanisms understood to 
underpin the signalling of a prototypical chemical synapse will be briefly outlined and 
Resting 
potential 
Resting 
potential Undershoot 
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give an account of how the synaptic machinery can be modulated to alter responses 
to excitatory and inhibitory inputs; a topic of great importance to an understanding of 
brain function and pathophysiology, including epilepsy. 
 
At the pre-synaptic terminal, neurotransmitters are stored in pools of synaptic 
vesicles. In localised nanodomains or ‘active zones’, a proportion of these synaptic 
vesicles are docked in close proximity to a high density of voltage-gated Ca2+ 
channels (Zucker, 1996). When an AP arrives down the axon, a transient and local 
influx of Ca2+ interacts with proteins associated with the vesicles and promotes the 
formation of a ‘fusion complex’ (Neher & Sakaba, 2008) involving a host of protein-
protein interactions; notably synatotagmin and synaptobrevin associated with 
vesicles and syntaxin and SNAP-25 associated with the plasma membrane. These 
fusion complexes allow for the exocytosis of neurotransmitters into the synaptic cleft 
(Sudhof, 2004). Ca2+ localised to nanodomains can mediate the fast signalling 
without triggering other pathways associated with Ca2+. Llinas et al (1992) reports a 
delay of only 0.2ms between Ca2+ channel opening and vesicular release. Other 
sources of Ca2+ can interact with this basic mechanism to effect longer-term 
modulation of synaptic transmission, providing one mechanism for synaptic plasticity 
(Kandel, 2001). 
 
Neurotransmitters released into the synaptic cleft bind to receptors on the post-
synaptic terminal, initiating a number of events. Receptors can be grouped according 
to whether they are ligand-gated ion channels or metabotropic G-protein coupled 
receptors, with the majority of neurotransmitters having receptors of both types. 
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Generally, ion channels mediate fast, transient responses, while metabotropic 
receptors mediate slower, longer term responses, such as transcription (Conn & 
Pinn, 1997). Receptors are not restricted to the post-synaptic terminal, with many 
found on the pre-synaptic terminal and at extrasynaptic sites, where they generally 
play a regulatory role (Fellin et al, 2004). Neuronal signalling depends not only on 
the release of neurotransmitters, but also on their removal or degradation. Some 
neurotransmitters, such as acetylcholine (Ellman et al, 1961) are degraded in the 
cleft while others, such as serotonin (Amara & Kuhar, 1993) are taken back up by 
reuptake channels in the pre synaptic terminal.  
 
In the adult CNS, excitatory and inhibitory transmission is generally mediated by 
glutamate  and GABA respectively (Bradford, 1995). Edward George Gray (1959) 
defined two types of synapse, based on their differing appearance in electron 
micrographs. Type I synaspes were assymetrical, with a higher synaptic density on 
the post-synaptic terminal, while type II synapses had a symetrical appearance. The 
view that type I, assymetrical synapses largely mediate excitatory, glutamatergic 
neurotransmission, while type II, assymetrical synaspes largely mediate inhibition 
through GABA has subsequently crystalised, however there are significant 
exceptions (Klemann & Roubos, 2011). Besides the two dominant amino acids, a 
broad range of CNS neurotransmitters have been discovered, including 
monoamines, such as dopamine and serotonin (Twarog, 1954), peptides, such as 
the opiods (Malick & Bell, 1976) and others, such as acetylcholine (Loewi, 1921) and 
nitric oxide (Bredt & Snyer, 1992). 
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Glutamate receptors can be grouped into three main classes; N-Methyl-D-aspartic 
acid (NMDA) receptors, 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4yl)propanoic acid 
(AMPA) receptors and kainate receptors, named according to their affinity for 
pharmacological agents. The majority of EPSPs are mediated through AMPA 
receptors, while kainate receptors are largely found at extracellular sites and at the 
pre-synaptic terminal where it is thought to play a modulatory role (Ozawa, 1998). 
The NMDA receptor functions as a coincidence detector, opening a Ca2+ channel 
only when activated by glutamate and the membrane is sufficiently depolarised to 
remove a Mg2+ block in the channel (Nowak et al, 1984). The calcium permeability of 
the NMDA receptor and its ability to function as a coincidence detector allows it to 
function as a key mediator of synaptic plasticity (Tsien, 2000). 
 
The primary means of modulating glutamatergic synaptic transmission is by changes 
in the activity and abundance of post-synaptic AMPA receptors (Manilow & Malenka, 
2002). The primary mechanism for modulating this is via Ca2+ signalling through the 
NMDA receptor, which can induce long-term depression (LTD) or long-term 
potentiation (LTP) in response to different patterns of stimulation. Ca2+ influx 
through the post-synaptic NMDA receptor can also modulate activity in the pre-
synaptic terminal through retrograde NO signalling (Hawkins et al, 1998). A wide 
variety of NMDA-independent mechanisms also exist for modulting synaptic 
transmission, including alterations in pre-synaptic Ca2+ influx and subsequent 
volume of vesicle release (Kandel, 2001), Ca2+ permeable AMPA receptor-mediated 
plasticity (Mahanty & Sah, 1998), kainate receptor-mediated plasticity, particularly at 
mossy fibre synapses in the hippocampus (Bortolotto et al, 2003).  
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The synaptic and intrinsic machinery briefly described here, allow neurons to 
function as units in an information-processing system. An ever greater diversity in 
synaptic and electrophysiological properties of neurons is being discovered (Llinas, 
1992). The functional significance of this is that different neurons can respond 
differently to different inputs, depending on the frequency, ampliture and spatial 
characteristics of the input. Synaptic and intrinsic machinery allow neurons to act as 
‘resonators’, responding preferentially to certain frequencies, or even intrinsic 
oscillators (Llinas, 1992). Later, neurons functioning as units in a network will be 
described.  
 
1.3.3 The emerging importance of glia 
 
Glial cells in the CNS include microglia, which are derived from immune cells, 
astrocytes, oligodendrocytes, ependymal cells, radial glia and NG2 cells 
(Verkhratsky & Butt, 2007). Previously the unglamorous cousins of neurons and 
relegated to the role of a ‘glue’ to offer structural support, the importance of the role 
that glial cells, also called ‘neuroglia’ or simply ‘glia’, play in information processing is 
becoming increasingly clear. As well as providing metabolic support (Tsacopoulos & 
Magistretti, 1996), regulating the ionic balance of the extracellular space (Sykova & 
Chvatal, 2000), regulating development (Song et al, 2002) and mediating neuronal 
survival (Vezzani et al, 2008) and apoptosis (Bal-Price & Brown, 2001), glia also play 
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a role in synaptogenesis (Ullian et al, 2004) and synaptic plasticity (Vernadakis, 
1996).  
 
Although Glia cannot conduct an AP, they express receptors for neurotransmitters 
and release ‘gliotransmitters’ in response to intracellular Ca2+ signalling. Astrocytes 
can also communicate with each other over long distance through Ca2+ ‘waves’ that 
propagate through gap junctions in wide-ranging astrocytic syncytia (Verkhratsky & 
Kettenmann, 1996). A better understanding of communication between glia, and 
between neurons and glia is likely to yield important information regarding the way 
the brain performs computations. Rather than neural networks, neuroglial networks 
may soon be considered of greater importance.  
 
Glial cells provide an important link between neurons and the neurovascular system, 
where they can regulate the permeability of the blood-brain barrier Bannerjee & 
Bhat, 2007). Glial cells have a key involvement in every single physiological function 
that the brain performs. Likewise, they are involved in every pathophysiology. Glia 
are heavily involved in mediating the neuroinflammatory response to brain insults 
(Vezzani et al, 2008), which will be discussed in greater detail later In this chapter, 
with a particular emphasis on the glial contribution to temporal lobe epilepsy.  
 
1.3.4 Neural circuits and oscillations 
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While it is important to understand the functional units, information processing in the 
CNS can only really be understood in the context of interactions between units. 
Seizures and epilepsy, also, generally arise as a consequence of dysfunctions at a 
network level. A network made up entirely of glutamatergic, excitatory 
neurotransmission, would be of limited use for information processing. In the 
absence of inhibition, any external input would generate a unidirectional avalance of 
excitation involving the whole population (Hopfield & Tank, 1986), with propagation 
of activity independent of time, wiring complexity, strength of excitation or any other 
factor (Buzsaki, 1997). GABAergic, inhibitory input does not function purely to 
dampen excitatory activity, but allows for the emergence of non-linearity. Feed-
forward and feed-back mechanisms, highly-dependent on the specifics of wiring 
allow mixed networks of excitatory and inhibitory neurons to self-organise and 
generate complex properties (Buzsaki, 1997). 
 
In the brain, The temporal coherence of large groups of neurons is coordinated by 
GABAergic signalling, which functions as a distributed clock, decreasing the 
probability of neuronal firing outside a window of disinhibition (Buzsaki, 1997). This 
distributed clock mechanism can modulate the activity of whole networks. Rather 
than being dormant in the absence of input, the CNS generates rhythmic activity 
endogenously. Signalling in the brain is carried out in the context of a system of 
nested oscillations, with oscillations often phase-locking (Palva et al, 2005). A strong 
inverse relationship between the spatial extent of rhythms and their frequency exists, 
with high frequency rhythms occuring for short durations in relatively limited areas of 
the brain.  
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Although previously understood as the epiphenomena of neuronal signalling, the role 
that network-wide oscillations play in computation is becoming increasingly clear. 
Network oscillations effect synaptic and intrinsic mechanisms underlying functions 
such as attention (Buzsaki et al, 1997). Many pathophysiological conditions can be 
understood as an ‘oscillopathy’, including schizophrenia, depression and epilepsy 
(Uhlhaas & Singer, 2006). The hippocampus has been a focus for studies into 
oscillatory mechanisms, with the CA3 region, in particular, an important pacemaker 
for generating network-wide activity (Ben-Ari & Cossart, 2000). It may be this feature 
that makes the region so susceptable to producing the pathological paroxysmal 
discharges associated with seizures.  
1.3.5 Gamma frequency and seizures 
 
As a general rule, during normal brain function, slower oscillations tend to be of 
higher amplitude, while higher frequency oscillations tend to be of lower amplitude. 
Approximately, the amplitude of oscillations in the brain are inversely proportional to 
their frequency. These 1/f dynamics are referred to as pink noise, because when 
similar distributions of wavelengths of light are observed, the effect of the spectrum 
of colours is a pink hue (Bak et al, 1987). Under physiological conditions, gamma 
activity (20 – 70Hz), thought to play an important role in the processing of episodic 
memory, is of short duration, not widely distributed and of low amplitude. 
 
During seizure, the pink noise, 1/f dynamics of brain activity are disrupted and higher 
frequency oscillations occur at higher amplitudes than are present during normal 
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brain function. The high amplitude of these oscillations represents the pathological 
hypersynchrony of neuronal networks. Moreover, whereas oscillations in EEG during 
physiological function largely represent field oscillations reflecting EPSPs in the 
dendrites, during highly synchronous firing during seizures, the influence of action 
potentials on extracellular field potentials increases (Dudek, 2003) and is likely to 
contribute significantly to the EEG signal. Lehmuke et al (2009) demonstrated that 
the dynamic power in the gamma frequency range (20 – 70 Hz) was a good measure 
of seizure severity during KA-induced SE in rats.  
 
 
1.3.6 The hippocampal formation 
 
1.3.6.1 History of hippocampal research 
 
The hippocampus has long been of great interest to anatomists, with members of the 
alexandrian school of medicine naming the structure cornu ammonis, horn of the 
ram, in reference to its curved shape. The name hippocampus was first coined by 
venetian anatomist Giulio Cesare Aranzi around 1564, in reference to its likeness for 
the seahorse. Modern biologists have also been fascinated by the structure. As well 
as its aesthetic merits, the hippocampal formation plays an important role in many 
brain functions and its highly organised stratified structure makes it particularly 
attractive for studying universal neuronal processes.  
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The nomenclature of terms describing the anatomy of the hippocampus and 
hippocampal formation is confused, with different authors ascribing the terms 
‘hippocampus’ and ‘hippocampal formation’ to a varyingly broad array of structures. 
In this study, ‘hippocampus’ is reserved for the hippocampus proper, or ammon’s 
horn, while the ‘hippocampal formation’ refers to the hippocampus, dentate gyrus 
and the subiculum. The pre- and para- subiculum and the entorhinal cortex are also 
discussed, but are referred to as structures outside the hippocampal formation.   
 
The circuitry of the hippocampal formation (Figure 1.4) has been traditionally viewed 
in terms of an excitatory ‘trisynaptic circuit’, propagated by glutamatergic synapses 
and modulated by a broad range of GABAergic local-circuit inhibitory interneurons 
(Sik, et al, 1997; McBain & Fisahn, 2001). The ‘trisynaptic circuit’ consists of input, 
via the perforant path, from layer II of the entorhinal cortex, with synapses formed on 
dentate granule cell dendrites in the molecular layer of the dentate gyrus. Mossy 
fibre projections from the dentate gyrus form synpases with CA3 pyramidal neurons 
in the stratum lucidum. CA3 axons or ‘Schaffer collaterals’ are found in the stratum 
radiatum and stratum lacunosum-moleculare, where they form synapses with CA1 
pyramidal cell dendrites. CA1 sends projections to layer V of the entorhinal cortex 
completing the trisynaptic loop. While this is the primary pathway for transmission in 
the hippocampus, other pathways also exists, including, but not limited to, a 
projection from layer III of the entorhinal cortex, direct to CA1 dendrites in stratum 
lacunosum-moleculare and a ‘backprojection’ from the CA3 region to the dentate 
gyrus (Scharfman, 2007). The main input into the hippocampus, and therefore the 
starting point of the ‘tri-synaptic’ circuit is the dentate gyrus. 
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1.3.6.2 The dentate gyrus 
 
A coronal section of the brain reveals the dentate gyrus as a V-shaped structure, 
with the two blades of the V sandwiching the proximal pyramidal cell layer (PCL) of 
the hippocampus (Figure 1.4). The two blades of the dentate gyrus are referred to as 
the supra- (above) and infra- (below) pyramidal blades, respectively. The Dentate 
gyrus is made up of three distinct layers. The granule cell layer (GCL) is a 4 – 8 
somata thick layer of densely-packed excitatory granule neurons. Superficial to the 
GCL is the molecular layer, in which the entire dendritic tree of the granule cells is 
found, alongside the fibres of the perforant path and a small number of inhibitory 
interneuron cell bodies (Freund & Buzsaki, 1996). Subjacent to the GCL is the 
polymorphic zone (hilus) which encloses the proximal end of the CA3 PCL (Freund & 
Buzsaki, 1996). The hilus hosts a variety of neuronal cell bodies, including a range of 
inhibitory interneurons and excitatory mossy cells (Anderson et al, 2006) 
 
Perforant path afferents from the lateral entorhinal cortex layer II terminate in the 
outer molecular layer (OML) of the dentate gyrus and those from the medial 
entorhinal cortex layer II terminate in the middle molecular layer (MML), where they 
form synapses with granule cell dendrites (Freund & Buzsaki, 1996). Granule cell 
axons (mossy fibres) originate at the opposite pole of the soma and enter the hilus, 
where they give rise to several local collaterals (Anderson et al, 2006). The main 
axon of the granule cells leaves the hilar region and courses adjacent to the 
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pyramidal cell layer in stratum lucidum of the CA3 subfield, where they form giant en 
passant boutons, on the proximal dendrites of pyramidal cells.  
 
1.3.6.3 The hippocampus 
 
A coronal section of the brain reveals the hippocampus as an elongated C-shaped 
structure, with one end of the structure sandwiched between the blades of the 
dentate gyrus (Figure 1.4). The hippocampus is subdivided into regions CA1, CA2 
and CA3, with CA3 proximal to the dentate gyrus. The laminar organization of the 
hippocampus comprises the PCL, which is densely packed with excitatory pyramidal 
neurons bordered on its superficial and deep sides by the stratum radiatum and 
stratum oriens respectively. In CA3, a thin stratum, comprising the mossy fibre input 
from the dentate gyrus, stratum lucidum, separates the PCL from stratum radiatum.  
 
The stratum radiatum contains Shaffer collateral fibres, projecting from CA3 to CA1 
where they form the third synapse in the trisynaptic circuit. Both stratum radiatum 
and oriens contain high densities of associational fibres, linking pyramidal cells in the 
same subfield and commissural fibres, linking the two hippocampi across 
hemispheres. Superficial of the stratum radiatum, the thin stratum lacunosum-
moleculare is found, where Schaffer collaterals and perforant path inputs from layer 
II of the entorhinal cortex terminate on CA1 pyramidal cell dendrites. Outside the 
PCL, a variety of non-pyramidal neurons are found, including a variety of 
subpopulations of inhibitory interneurons, subdivided according to their 
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morphological characteristics and neuropeptide and calcium-binding content (Freund 
& Buzsaki, 1996). 
 
 
Figure 1.4. Hippocampal formation with main excitatory pathways. Taken from 
Moser (2011). 
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1.4 Seizures and epilepsy 
 
1.4.1 Summary 
 
I will give a brief historical perspective of the development of our understanding of 
seizures and epilepsy, and review some of the evidence for popular hypotheses  
regarding how dysfunctions in the physiological mechanisms described previously 
can contribute to ictogenesis and epilepstogenesis. The history of progress in the 
understanding of TLE will then be described and an in depth discussion of the 
mechanisms underpinning the development of chronic epilepsy will be offered. 
Research techniques specifically used in this project, pharmacological interventions 
and the contribution of nitric oxide will be touched upon, but will be covered in 
greater depth later in the chapter.  
 
1.4.2 Research in the generation of seizures  
 
The first known written accounts of the symptoms and causes of seizures and 
epilepsy were produced by the ancient Babylonians around 1000 BC. Hippocrates 
recommended a diet based method for controlling seizures that could be thought to 
anticipate the ketogenic diet, developed in the 1920s and still widely recommended 
for controlling epilepsy today (Kim & Rho, 2008). Epilepsy was referred to as ‘falling 
sickness’ during the middle ages and no significant developments in either treating 
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or understanding the disease were made through the renaissance or enlightenment. 
It was as late as the mid-19th century until significant progress was made, with the 
English physician John Hughlings Jackson building a platform for future research, 
accurately attributing seizures to the hypersynchronous firing of collections of 
neurons (Jackson, 1890). 
 
Based on clinical and electroencephalographic (EEG) evidence, Penfield and Jasper 
(1954) contributed a conceptual model for brain mechanisms responsible for 
seizures. Partial and generalised seizures were considered the consequence of 
discrete cortical abnormalities in the cortex and subcortical structures (with diffuse 
projections to the forebrain responsible for the generalised nature of EEG 
abnormalities). In this conceptual model, secondarily generalised seizures were 
understood to be caused by the spread of paroxysmal activity from the cortex to 
deeper structures. Experimental models reproducing both motor convulsions and 
epileptiform EEG activity were developed to study the roles of different brain 
structures and anatomic pathways in the development and spread of epileptic activity 
(Dichter & Ayala, 1987). 
 
In the late 50’s and early 60’s, pioneering methods for extracellular and intracellular 
and recording, first described by Brock et al (1951) began to be used routinely to 
elucidate mechanisms underlying both intrinsic neuronal excitability and synaptic 
function. This provided the platform for epilepsy research focussed at the cellular 
level. The most widely used in vivo models for seizure research in this era, such as 
the topical application of penicillin (Greenwood et al, 1983) modelled acute or 
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chronic focal epilepsies, offering the opportunity to investigate the contribution of 
individual neurons and synaptic function to ictogenesis and regional epileptiform 
activity (Dichter & Ayala, 1987).  
 
The paroxysmal depolarisation shift (PDS) was first described by Greenwood et al 
(1983). A PDS consists of a giant EPSP, enhanced by the activation of voltage-
regulated intrinsic currents (Johnstone & Brown, 1981; Timofeev et al, 2004).  PDS 
occur in neurons in chronic epileptiform foci, with spontaneous long (100-200 μs) 
and high (10-15 mV) depolarisations, representing the cellular manifestation of 
epileptiform spikes recorded from the scalp EEG (Heinemann et al, 1999; Rogawski 
& Loscher, 2004). Contributors to enhanced EPSPs include both synaptically 
mediated (Disinhibition, frequency potentiation, changes in the density and 
morphology of dendritic spines, activation of NMDA receptors and potentiation by 
neuromodulators) and intrinsic mechanisms (high-threshold Ca2+ and slowly 
inactivating Na+ currents) (Dichter & Ayala, 1987). 
 
A seizure (or ictus) requires not only the hyperexcitability of neurons, but also the 
hypersynchrony of neural circuits. Mechanisms responsible for synchronising neural 
circuits also include both synaptic and non-synaptic processes. The connectivity of 
networks can play a major role in synchronizing excitatory activity (McCormick & 
Contreras, 2001). In the healthy brain, different regions have different densities of 
recurrent connections, underlying different propensities to fire in synchrony. The 
dentate granule cells have relatively low numbers of interconnections, while the 
pyramidal cells of the CA3 region are highly interconnected, acting as a local 
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pacemaker and making the region particularly susceptible to becoming a focus of 
epileptiform activity under aberrant conditions (Colom & Saggau, 1994).  
 
Other processes that encourage synchronous firing include ephaptic interactions 
between neurons due to large currents that flow through extracellular spaces and 
changes in extracellular ionic concentrations (Jeffreys, 1995) and the diffuse 
synaptic connections of inhibitory interneurons, which allow excitatory neurons to 
‘fire’ synchronously mediated by the release of inhbibition (Von Krosigk et al, 1993; 
Pinault et al, 1998) Neuromodulators, such as ACh can also alter the spike 
thresholds for populations of neurons synchronously. A role for astrocyte-neuronal 
signalling in mediating both the excitability of neurons and the synchrony of neural 
circuits is also becoming increasingly clear. Astrocytes modulate the extracellular 
ionic balance, regulate extracellular glutamate concentrations and release 
gliotransmitters that bind to receptors at both synaptic and extrasynaptic sites, 
modulating the electrophysiological properties of neurons (Fellin & Haydon, 2005). 
 
1.4.3 Interictal epileptiform discharges 
 
The term ‘interictal spike’ is the widely-used name for what may be more 
appropriately described as a non-ictal epileptiform spike or sharp wave in the EEG 
trace. The term was initially used to describe the shape of EEG activity recorded 
from epilepsy patients and was therefore observed between ictal events; however, it 
is now recognized that it is an important predictive phenomena, prior to the first 
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seizure (Williams et al, 2006). The term ‘spike’ is inappropriate both because it 
causes confusion with the ‘spike’ referring to AP’s in individual neurons and because 
epileptiform events also include sharp-waves. Although lacking in accuracy, the wide 
use of the term ‘interictal’ means that improving the terminology is likely to cause 
more confusion than it clears up. In this work, the term ‘interictal epileptiform 
discharge’ (IED) is used to refer to both spikes and sharp waves. 
 
IEDs are high-amplitude (50 mV), EEG transients, including both ‘spikes’ (< 50ms) 
and ‘sharp waves’ (50 – 200ms) habitually followed by a slow wave that lasts several 
hundreds of milliseconds. IEDs recur periodically and may cluster in brief paroxysms 
that can remain local or spread as a result of the involvement of subcortical 
structures. Underlying an IED is a focussed PDS contained spatially and temporally 
by a large after hyperpolarisation (AHP) (Ayala et al, 1973) caused by GABA-
mediated opening of CI- and K+ channels (Kaila, 1994), voltage-sensitive K+ 
channels and Ca2+-sensitive K+ and CI- channels (Sah & Louise-Faber, 2002). The 
relative contribution of each of these mechanisms depends heavily on the specifics 
of the cell involved and dictates the dynamics on neuronal activity. Although the 
relationship between IED and ictal events is not entirely clear, the relative strength of 
the AHP may be an important difference between the two phenomena.  
 
While it was previously assumed that a seizure developed from an IED (Ralston, 
1958), more recent research has revealed that the two phenomena but are 
characterised by different EEG patterns are are, in part mediated by different 
neuronal mechanisms. The causal relationship between IEDs and seizures is far 
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from clear (Gotman, 1991; Janszky et al, 2001). Katz et al (1991) demonstrated a 
decrease in IED activity prior to seizures, while numerous studies have suggested 
that IED activity actually inhibits seizures (Engel & Ackermann, 1980; Barbarosie & 
Avoli, 1997). There is certainly a causal relationship in the reverse direction. IED 
activity is consistenly observed post seizure, with the focus diffusing away from the 
seizure focus with increasing time intervals (Kaibara & Blume, 1988; Gotman & 
Koffler, 1990).   
 
1.4.4 Temporal lobe epilepsy – overview of disease progression 
 
TLE is an acquired epilepsy, associated with a distinct pattern of neurological 
damage in the hippocampal formation. The association between the clinical features 
of TLE such progressive susceptability to complex-partial seizures and the 
underlying anatomical changes, such as neuronal cell loss and gliosis in the dentate 
hilus and the CA3 and CA1 regions of the hippocampus has been recognised for 
many years (Cazauvieilh, 1825). Following a seizure, or other IPI, a symptomless 
‘latent’ phase precedes the emergence of spontaneous reccurent seizures (SRS) 
characterising chronic epilepsy; a process referred to as epileptogenesis. The 
disease often then continues to progress beyond the point of diagnosis (Pitkanen & 
Sutula, 2002). The dominant theory is that of a circular causality between seizures 
and anatomical changes, with seizure activity causing neuronal death in the 
hippocampus and this cell loss in turn, reducing the threshold for paroxysmal activity: 
‘seizures beget seizures’ (Gowers, 1881). While there is a great deal of experimental 
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evidence to support the first part of this (Cavazos & Sutula, 1990; 1994), evidence 
that the loss of neurons exacerbates seizures is inconclusive (Sills, 2007). 
 
Seizures, or other IPI initiate an inflammatory response mediated by glial cells and 
pro-inflammatory cytokines. This inflammatory response, if sufficiently severe and of 
sufficient duration initiates a series of anatomical and physiological changes, 
including neuroinflammation (Vezzani & Granata, 2005), fibrillary gliosis, aberrant 
axonal sprouting (Buckmaster & Dudek, 1997; Sloviter, 1999), reactive 
synaptogenesis (Mori et al, 1998), dispersion of the dentate granule cell layer 
(Houser, 1990), the altered expression of neurotransmitters and their receptors 
(Koyama & Ikegaya, 2005) and a highly selective pattern of neuronal cell death 
(Buckmaster & Dudek, 1997). These changes underly  an alteration in neuronal 
excitibility and network dynamics, including intricate structural changes, reducing the 
seizure threshold and preceding the emergence of chronic epilepsy. (Pitkanen & 
Lukasiuk, 2011). 
 
Because of the high level of interconnectivity between principal neurons, the 
hippocampus is particularly susceptable to becoming a focus for ictal activity. The 
CA3 region is extremely dense in associational and collaterall fibres, consequentially 
firing with a high level of synchrony and is believed to function as a ‘pacemaker’ for 
physiological activity in the hippocampus (Dragoi & Buszaki, 2006). The same 
anatomical features make the region susceptable to peturbations in neuronal 
excitibility, the balance between excitatory and inhibitory drive and to alterations in 
network dynamics, with relatively small changes sufficient to elicit pathophysiological 
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hypersynchronised, epileptiform neuronal firing (Colom & Saggau, 1994). Following 
an IPI, neurons in the hippocampal formation have varying degrees of susceptability 
to neurodegeneration. Principal cells in the CA3 and CA1 regions of the 
hippocampus and dentage granule cells of the dentate gyrus, as well as populations 
of inhibitory interneurons are susceptable to loss, whereas neurons in CA2 are highly 
resistant.  
 
 
1.4.5 Gliosis and the inflammatory response 
 
1.4.5.1 Overview 
 
Inflammation is a homeostatic mechanism induced by innate immunity mechanisms 
in response to infection or injury in order to remove the pathogens and promote 
tissue repair (Vezzani et al, 2008). Under specific circumstances, such as allergies 
and auto-immune diseases, inflammation contributes to tissue damage, cellular 
dysfunction and apoptosis. While the CNS has traditionally been considered an 
‘immuno-privileged’ site, shielded from systemic immune responses by the BBB 
(Vezzani et al 2012), it is becoming increasingly clear that inflammatory responses, 
mediated by glial cells, play an important role in the development of a broad range of 
CNS disorders, including epilepsy (Vezzani et al 2010). Evidence from clinical and 
experimental studies indicate that brain inflammation is an intrinsic feature of the 
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hyperexcitable pathologic brain tissue in a broad range of pharmacoresistant 
epilepsies, with a variety of causes (Vezzani et al, 2011).  
 
The role of inflammatory processes in the CNS was first observed in patients with 
Rasmussen encephalitis (Rasmussen et al, 1958). Chronic brain inflammation 
involves the activation of astrocytes, microglia, endothelial cells of the BBB, 
peripheral immune cells, and the concomitant production of inflammatory mediators 
(McGeer & McGeer, 1995). In experimental models of TLE, the increased expression 
of pro-inflammatory cytokines initially occurs in neurons undergoing excitotoxic 
stress. Cytokine signalling induces the rapid hypertrophic and hyperplastic changes 
and migration to the site of insult of both astrocytes and microglia (Shapiro et al., 
2008) where they form a ‘glial scar’. Reactive glial cells amplify cytokine signalling 
(Mrak & Griffin, 2005), have a direct effect on abnormal neurotransmission and 
neurodegeneration preceding the emergence of paroxysmal discharges.  
 
Gliosis, the extensive proliferation of glia that occurs near or at the site of lesion, 
constitutes a pathological hallmark of damaged CNS tissue. The glial scar is not only 
formed by reactive astrocytes and microglia, but also complemented by the 
involvement of endothelial cells, fibroblasts and exracellular matrix factors. 
Experimental studies have shown that seizure activity per se can induce brain 
inflammation and gliosis and that recurrent seizures perpetuate chronic inflammation 
(Vezzani et al, 2010). Inflammation and gliosis also contributes to an increase in 
BBB permeability (De Vries et al, 1997), degeneration of neurons (Glass et al, 2010) 
and the direct modulation of synaptic transmission. 
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The activation of glia and cytokine signalling are mutually reinforcing phenomena 
which can contribute to either neuronal cell death or neuroprotection and can either 
exacerbate or subdue the development of chronic epilepsy (Vezzani et al, 2008). 
The manner in which gliosis might influence the neuropathological condition is 
determined by the congruence of specific factors, such as severity, duration, time 
after insult, damage location, and the specifics of inter- and intra-cellular signalling 
(Foresti et al, 2011). These factors are determined by the severity of the primary 
tissue insult and genetic and epigenetic factors. Evidence has shown that 
subconvulsive doses of KA can protect against the damage of a subsequent 
convulsive dose of KA (Kelly & McIntyre, 1994), while other kindling regimens can 
have the opposite effect. This  testifies to the dichotomous, intensity-dependent 
nature of the inflammatory response. 
 
1.4.5.2 Role of microglia in neuroinflammatory response 
 
Microglia are derived from immune cell lines (Del-Rio Hortega, 1932) and are 
effectively specialist macrophages that function as immune cells in the CNS 
(Nimmerjahn et al, 2005), forming the front line defence of the innate immune system 
(Glass et al, 2010). There are very few CNS pathologies in which a major role for 
microglia has not been proposed (Perry et al, 1993). Resident microglial cells in the 
healthy brain rest in a dormant state, characterised by a stellate shape, with 
numerous thin and highly ramified processes reaching out into the parenchyma. 
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Microglia are distributed in a highly organised manner, with fairly homogenous 
distances between cells and each cell responsible for a territorial domain of 
consistent size (Nimmerjahn et al, 2005). The morphology and distribution of 
microglia in the CNS is well adapted for the efficient surveillance of the paranchyma, 
allowing for the detection of foreign bodies, cell injury or infection (Kreutzberg, 1996).  
 
Microglia are activated in response to cell stress, such as excitotoxicity, largely 
through the detection of inflammatory cytokines and chemokines (von Zahn et al, 
1997) and through ATP-signalling (Davalos et al, 2005). Activation of microglia 
involves a profound morphological change, with the withdrawal of appendages and a 
switch to a rod-like morphology. Activated microglia migrate to the site of injury 
(Nimmerjahn et al, 2005) where they can play a role in a variety of processes of 
importance to epileptogenesis, including the amplification of inflammatory effects or 
the induction of neuronal degeneration.   
 
1.4.5.3 Role of astrocytes in neuroinflammatory response 
 
Astrocytes outnumber neurons in the CNS by a ratio of approximately 10:1 and play 
many roles in support of the normal functioning of neuronal assemblies. Traditionally, 
astrocytes have been viewed simply as the ‘glue’, providing a physical scaffold in 
order to hold neurons in place (Volterra & Meldolesi, 2005). In time, an increasingly 
broad palette of physiological functions for astrocytes have been ascribed, including 
the maintenance of ionic balance in the extracellular space, the provision of 
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metabolic support for neurons and the taking up of extracellular glutamate. They 
have, however, still been viewed primarily in a housekeeping, support role; ‘enablers’ 
of neuronal signalling, without a direct role in information processing. Evidence for 
the extent of astrocyte-astrocyte and astrocyte-neuronal communication, however, 
including the expression of receptors, the release of gliotransmitters and the ability 
for fast communication through gap junctions has led to a reappraisal of basic 
concepts and the growing inclusion of astrocytes in our understanding of information 
processing in the CNS (Volterra & Meldolesi, 2005).  
 
Besides their important role in normal physiological function, astrocytes are heavily 
involved in mediating responses to pathology. The activation of astrocytes is 
implicated in almost all pathologies of the CNS including TLE, where they act in 
tandem with microglia to mediate inflammation (Vezzani, 2008). Astrogliosis initially 
involves reversible changes in astrocytic gene expression profiles, including the 
upregulation of intermediate filament proteins such as glial fibrillary acidic protein 
(GFAP), vimentin, and nestin, followed by hypertrophic and hyperplastic changes 
(Ravizza et al, 2008; Borges et al, 2006). Finally, proliferation and migration of 
astrocytes to the site of insult, in tandem with other cell types, the rearrangement of 
tissue structure and the deposition of dense collagenous extracellular matrix leads to 
the formation of a glial scar.  
 
Many functions of reactive astrocytes are likely to be important in determining the 
tissue response to seizures. Steele & Robinson (2012) suggest a loss of function 
phenomena, where activated astrocytes have a reduced ability to perform their 
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supporting role, meaning a decreased uptake of glutamate and a greater exposure of 
neurons to excitotoxicity. Reactive astrocytes also have a gain of function effect, with 
the release of factors encouraging neuronal apoptosis (Haneka et al, 2010), the 
direct modulation of the electrochemical properties of neurons through the release of 
gliotransmitters, both at the synapse and at extrasynaptic sites and their role in 
mediating the permeability of the BBB (De Vries et al, 1997) and the release of both 
pro- and anti-inflammatory factors (Haneka et al, 2009). The net effect of the 
complex contribution of astrocytes to epileptogenesis is not well understood, 
however, it is likely that it is dependent on the severity and duration of the 
inflammatory response. 
 
1.4.5.4 Role of inflammatory cytokines 
 
While it was previously assumed that cytokines were involved only in modulating 
inflammation in response to pathology, the constitutive expression in the brain of a 
wide variety of cytokines and their receptors suggests they may contribute to normal 
physiological functions of the CNS (Lucas et al, 2006). Many Inflammatory cytokines, 
notably IL-1β and TNF-α, have been shown to play a role in CNS development 
(Stolp, 2012) and in neuronal function through the modulation of synaptic plasticity, 
neural transmission and Ca2+ signalling (Vitkovic et al, 2000). This indicates that 
increased expression of these signalling molecules in response to pathology is likely 
to have a direct effect on the behaviour of neural assemblies, independently of the 
role of cytokines in promoting or subduing inflammation.  
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A range of different brain insults can induce an increased transcription of cytokines 
and cytokine receptors, including traumatic brain injury, pathogens and seizures. 
Following a period of status epilepticus, the expression of both cytokine and cytokine 
receptors increases in response to excitotoxic stress. While astrocytes and microglia 
provide the major source of cytokines following seizures (Vezzani et al, 2008), an 
increased expression is also seen in neurons and endothelial cells. Seizures trigger 
a rapid-onset inflammatory response in glia, consisting of an increase in prototypical 
pro-inflammatory cytokines, such as lnterleukin-1β 1 (IL-1β), IL-6 and tumour 
necrosis factor –α (TNF-α) (Vezzani et al, 2008) while the IL-1 receptor is expressed 
at greatly increased levels in neurons (Ravizza et al., 2006). 
 
While IL-1β, IL-6 and TNF-α are all expressed at elevated levels in epileptic tissue, 
the role they play in promoting or subduing epileptogenesis is not entirely clear. The 
role that IL-1β plays may be dependent on concentration and the specifics of the 
tissue microenvironment that are currently insufficiently understood. IL-1β signalling 
functions with the IL-1R and the endogenous antagonist IL-1Ra which are also 
upregulated during seizures. Evidence for a proconvulsive role of IL-1b is 
compelling, but it has also been shown to have anticonvulsive properties. In a rodent 
amygdala kindling model of epilepsy, fully kindled seizures are inhibited by IL-1b, 
and daily injection of IL-1b during kindling slows the rate of kindling (Lucas et al, 
2006). The ratio between IL-1β and IL-1Ra is more important than IL-1β levels per 
se, and the location of IL-1R expression is important in mediating the outcome. While 
the role of IL-6 in the brain is fairly straightforwardly neurotoxic and pro-convulsive 
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(Li et al, 2011), the role of TNF-α is more complex. There is strong evidence 
indicating a dichotomous role for this cytokie, dependent on downstream signals and 
concentration (Li et al, 2011). Generally, high concentrations of TNF-α are pro-
convulsive, while lower concentrations inhibit seizures. 
 
In addition, overexpression of inflammatory cytokines can have long-term effects on 
brain excitability by inducing structural and functional changes in glial and neuronal 
networks. For example, IL-1β can activate mitogen-activated protein kinases (MAPK) 
and nuclear factor-κB (NF-κB) - dependent pathways. The resultant transcription of 
genes can lead to the modification of ion channels and contribute to long-term 
hyperexcitability and epileptogenesis (Bialer & White, 2010). 
 
1.4.5.5 The blood-brain barrier and peripheral mediators 
 
The BBB acts as a filter, functioning to maintain the integrity of the CNS and restrict 
access from systemic proteins, antibodies, immune cells and inflammatory 
mediators. As already discussed, following an insult, such as a seizure, the resultant 
neuroinflammatory response, cytokine signalling and glial cell activity can lead to an 
increase in BBB permeability and an influx of systemic immune cells such as 
macrophages and leukocytes into the brain paranchyma, exacerbating the 
neuroinflammatory response. The influx of immunoglobulin G and albumin into the 
brain paranchyma through a compromised BBB can also exacerbate the immune 
response. Serum albumin, when taken up, can impair astrocyte function and lead to 
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a decrease in their ability to clear extracellular glutamate and regulate extracellular 
ion homeostasis (Ralay Ranaivo & Wainwright, 2010). 
 
1.4.6 Structural changes following seizures 
 
Epileptiform firing is not just dependent on the excitibility of neurons, but also on the 
specifics of the interconnectivity between neurons. As already discussed, the CA3 
region of the hippocampus has a high level of interconnectivity, while the dentate 
granule cells have a relatively sparse interconnectivity, allowing this region to act like 
a ‘filter’ for synchronised activity. Following seizures, the structure of neuronal 
networks in the hippocampal formation can be altered to increase the possibility of 
seizures. 
 
The loss of principal cells in the CA3 region of the hippocampus removes the target 
for the axons of dentate granule cells, leading to the aberrant connections between 
these cells. Following neuonal cell loss in CA3, synapses form between dentate 
granule cells in the molecular layer of the dentate gyrus. This increased 
interconnectivity between dentate granule cells decreases the efficiency of the filter 
mechanism and leads to an increased susceptability to seizures. Following seizures 
in human patients, mossy fibres, the axons of dentate granule cells that form 
synapses in the hilus and on CA3 pyramidal cells in stratum lucidum, ‘sprout’ and 
form aberrant connections, notable in the molecular layer of the dentate gyrus 
(Sutula et al, 1989; Houser, 1990).   
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1.5 Reseach methods – Historical overview 
 
1.5.1 Summary 
 
Here, a brief historical perspective of the development of the methods used in this 
project is presented, including animal models of seizure and epilepsy with a 
particular focus on KA. 
 
1.5.2 Models of seizure and epilepsy 
 
1.5.2.1 Overview  
 
In order to understand epilepsy and find new treatments, model systems must be 
employed. For this purpose, the use of animal models has disclosed much of what 
has been learnt about epilepsy and seizures. There are many rodent models of 
epilepsy, using both Rats and Mice. The variety of models stems from the lack of 
reliability with which any particular model faithfully recreates the syndrome observed 
in humans. Important findings are best replicated between models in order to 
increase reliability. Further, the sheer breadth of  different epilepsy symptoms 
necessitates a similar variation in animal models (Fisher, 1989).  
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Models of seizures and epilepsy include both genetic models, where susceptabiliity 
to seizures has either been selected for during breeding, or specific genes are 
overexpressed or knocked out (Mita et al, 2001) and the induction of seizures in 
normal animals (Ben-Ari & Cossart, 2000). Genetic models can be further divided 
into animals showing spontaneously seizures (Sarkisova & van Luijtelaar, 2011) and 
those susceptable to seizures induced by a cue (i.e animals sensitive to audiogenic 
or photogenic seizures) under the control of an experimenter (Meldrum, 1984). 
Seizures can be induced in normal animals either electrically or chemically and 
either by directly inducing a seizure (Ben-Ari & Cossart, 2000), or by ‘kindling’; the 
process of giving multiple subconvulsive electrical stimulations or chemical doses 
until a spontaneous convulsion occurs (Lothman et al, 1985). 
 
Sarkisian (2001) lists six criteria by which the value of an animal model can be 
judged: 1. Similar electrophysiological patterns observed to human condition. 2. 
Similar etiology- human condition arising from underlying genetic predisposition 
should be modelled genetically, etc. 3. Animal model should reflect human condition 
in age of onset. 4. Animal model should replicate specific pathological changes 
observed in human conditions. 5. Animal model should respond to AEDs in similar 
way to human condition. 6. Behavioural characteristics should reflect those seen in 
human condition. Some animal models are used to investigate the generation of 
acute seizures, while others are used to investigate the development of chronic 
epilepsy. By either the induction of an IPI (usually a period of status epilepticus) or 
by electrical or chemical kindling, a chronically epileptic animal can be produced, 
acting as a model of temporal lobe epilepsy (Loescher, 2011).  
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1.5.2.2  Models of acute seizure 
 
Models of acute seizure are widely used to explore the neurophysiological 
mechanisms underlying the generation of seizures. A popular model of simple partial 
seizures is the topical application of penicillin (Fisher, 1989). By placing electrodes 
close to the site of application, and applying other pharmacological agents, 
information regarding neuronal process during seizure generation can be obtained. 
Other chemical convusants, such as bicucculine, picrotoxin and strychnine are also 
used in a similar way. Simple partial seizures can also be induced electrically by 
directly stimulating cortical tissue (Adrian, 1936) with electrical pulses through ball 
electrodes cortex. Infusion of GABA via micro-syringe can also induce seizure 
activity upon removal (Brailowsky et al, 1987). 
 
Models of acute seizures can also be used for assaying the efficacy of antiepileptic 
drugs. In the maximal electroshock test (MES), transcorneal or transauricular 
applications of suprathreshold electrical stimuli are given to normal mice or rats and 
the latency to hindlimb extension is recorded (Loescher, 2011). An alternative test is 
the administration of Pentylenetrazole (PTZ), in which the latency from drug 
treatment to seizure is recorded (Krall et al, 1978). The timepoint at which 97% of 
animals have undergone a tonic-clonic seizure of at least 5 seconds duration is the 
usual measure used. Other popular models of complex partial seizures include 
injections of pilocarpine, tetanus toxin or KA.  
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1.5.2.3 Diversity of in vivo epilepsy models  
 
Following the guidelines for animal models articulated by Sarkisian (2001), many 
preparations exist for modelling specific syndromes. Some of these include infant 
febrile seizures can be modelled by exposing neonatal rats and mice to hyperthermic 
shock (Baram et al, 1997), exposure of neonates to global hypoxia as a model for 
perinatal hypoxic encephalopathy (Ohshima et al, 2012), childhood absence 
seizures,  modelled using mutant mice, susceptable to spontaneous seizures which 
largely mimic the features of petit mal events (Puranam & McNamara, 1999) and 
epileptogenesis associated with a traumatic brain injury IPI,  modelled in rodents 
using a controlled cortical impact or fluid percussion injury (Bolkvadze & Pitkanen, 
2012). 
 
1.5.2.4 Models of temporal lobe epilepsy 
 
Models of TLE usually involve either the induction of an IPI, or kindling. Unless the 
research is concerned with seizures resulting from a particular type of insult, such as 
anoxic shock or traumatic brain injury (Kharatishvili et al, 2006), the IPI is usually a 
period of chemically or electrically induced SE. The most common chemical agents 
used to model TLE in rodents is pilocarpine, a cholinergic agonist, and KA 
(Sarkasian, 2001).  
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Kindling is a process by which the duration and behavioural involvement of induced 
seizures increases after seizures are induced repeatedly until a plateau is reached 
and so repeated stimulation lowers the threshold for more seizures to occur (Racine, 
1972). Kindling is usually carried out by focal electrical stimulation in the brain. The 
term ‘seizures beget seizures’ is often used to study this phenomenon, whereby a 
seizure may increase the likelihood that more seizures will occur. In the kindling 
model, seizures begin to occur spontaneously after repeated subconvulsive stimuli 
leading to self-sustaining status epilepticus (SSSE). However, the relevance of the 
kindling model in animals compared to epileptogenesis in humans is still widely 
debated and although there are a number of well-described anatomical changes 
associated with kindling (glial activation, decreased neuronal density, mossy fiber 
sprouting), the changes are much less pronounced and widespread than those seen 
in epilepsy in humans (Cavazos and Sutula, 1990).  
 
1.5.3 Kainic acid models 
 
KA, an excitatory amino acid and an analog of the endogenous excitatory 
neurotransmitter, glutamate (McGeer et al, 1978) naturally occurs in the seaweed, 
Digenea simplex, or red seabroom. The purplish-red plant from the family 
Rhodomelaceae has a wide global distribution and is typically found in coastal areas, 
growing on rocks at depths of around 1.5 – 7 metres, where it has traditionally been 
harvested by divers and sold for use as an anthelmic, particularly in Japan. It was in 
Japan that KA was first extracted from D. simplex (Murakami et al, 1953), its 
structure described (Nitta et al, 1958) and its excitotoxic effects on the mammalian 
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central nervous system (CNS) discovered. Twenty years later, two studies (Ben-Ari 
et al, 1978; Nadler et al, 1978) independently showed that intraamygdaloid or 
intraventricular injections of KA respectively, could induce repetitive seizures and a 
pattern of neuronal damage reminiscent of that associated with TLE in humans. 
 
Following the discoveries in 1978, KA has been widely used to induce seizures, 
particularly in rodents, providing useful models for both acute seizures and TLE. 
Local or systemic injections of kainate first activate CA3 pyramidal neurons via high-
affinity receptors present in mossy fiber synapses. The activation of CA3 recurrent 
collateral synapses generates synchronized network-driven glutamatergic currents 
that propagate to other hippocampal regions (Ben-Ari & Cossart, 2000). 
Grabenstatter et al (2005) describe three major stages for a KA-induced SE model of 
epilepsy: 1. A period of SE, typically lasting several hours, 2. A seizure free latent 
period, typically lasting several days or weeks and 3. the gradual emergence and 
progressive increase in the frequency of spontaneous recurrent seizures (SRS).  
 
For both ethical and scientific reasons it is often common practice to administer 
diazepam after inducing seizures with KA to reduce mortality and SE. Terminating 
SE with diazepam can allow for the experimental control over the duration of the 
insult, decreasing variability between animals. Diazepam and related compounds are 
routinely used in the treatment of epilepsy and are members of the benzodiazepine 
family (see section 1.6 of this chapter). The mechanism of action is via the 
potentiation of inhibitory drive via gamma-aminobutyric acid (GABA). 
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1.6 Pharmacological interventions in epilepsy  
 
1.6.1 Overview 
 
Because our understanding of the complex processes underlying the generation of 
both individual seizures and epileptogenesis is currently limited (Engel Jr, J, 2008), 
available treatments largely tackle the symptoms rather than underlying causes. 
Pharmacological agents that increase the threshold for seizures invariably have 
significant side-effects on normal brain activity, contributing to mood and cognitive 
disorders (Martin et al, 1999). Conditions that are well controlled often become 
refractory to treatment, while even when a treatment programme is effective, the 
reason for the success is often unclear. Antiepileptic drugs (AEDs) typically target 
ion channels, neurotransmitter transporters, neurotransmitter metabolic enzymes, 
modulate voltage-gated ion channels, enhance synaptic inhibition or inhibit synaptic 
excitation.  
 
Continued development of AEDs is driven by two main goals: the need to develop 
drugs for use in patients refractory to currently available pharmacological treatment 
and the development of drugs with better side-effects and pharmacokinetic profiles 
than currently available AEDs (Walker & Sander, 1996). Alternatives, or 
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complements to pharmacological intervention include the adoption of a ketogenic 
diet, implantable electroshock devices or the surgical removal of parts of the brain. 
although there is little understanding of how the ketogenic is effective. 
1.6.2 Phenobarbitol 
Following on from the use of bromide salts, which were the first drugs to legitimately 
claim success in seizure suppression (Tunnicliff, 1996), barbiturates, such as 
Phenobarbitol (PB) became popular treatments for grand mal epilepsy. The big 
drawback of this type of therapy is the pronounced ancillary sedative actions 
(Tunnicliff, 1996). It is mainly used in the clinic in emergencies for the control of SE 
rather than the control of chronic epilepsy conditions. PB, like all barbiturates is a 
GABA agonist, with a high affinity for the GABAA receptor. The binding site is distinct 
from the binding site of GABA itself and from the benzodiazepine binding site. 
Although Barbiturates can halt seizures, they are not suitable for chronic control of 
epilepsy because of their general somnolescent effect and the strong danger of 
overdose 
1.6.3 Diazepam  
Diazepam and other benzodiazapines are also GABA agonists and enhance 
inhibitory drive by binding to the GABAA receptor at a different site from barbiturates. 
They have largely replaced barbiturates because they are safer drugs with less risk 
of dangerous overdose. Like phenobarbitol, Diazepam is often administered in in the 
clinic to halt SE in emergency situations, rather than to control chronic epilepsy.  
1.6.4 Phenytion 
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Phenytoin, 5,5-diphenylhydantoin has been shown to be non-specific for sodium 
channels: it antagonises calcium dependent action potentials, calcium currents and 
calcium fluxes, delays or reduces  voltage gated K+ currents and augments post-
synaptic responses to GABA (Lees & Leach, 1993). The introduction of phenytoin 
was important because it was the first effective anticonvulsant not to possess 
significant sedative side effects (Tunnicliff, 1996). Despite the large numbers of 
AEDs subsequently developed, Phenytoin is still widely used to control all epilepsy 
types other than absence seizures. It can also be used as emergency treatment to 
halt SE. 
1.6.5 Carbamazepine  
Carbamazapine (CBZ) is a tricyclic iminostilbene derivative related structurally to the 
antidepressant imipramine (Marangos et al, 1983). The primary mechanism of action 
of CBZ is the blocking of voltage-gated Na+ channels and the subsequent decreased 
Na+ influx into neurons (Willow et al, 1985), however, it also has other effects in the 
CNS, including interactions with adenosine receptors (Marangos et al, 1983). While it 
can subdue secondarily generalized seizures, CBZ can exacerbate the symptoms of 
absence epilepsy. It has a short half-life and therefore must be administered 
regularly (4 times daily) or administered in a controlled release formulation (Bonneto 
et al, 1993).  
1.6.6 Oxcarbazepine 
Oxcarbazepine (OXC) is an analog of CBZ, but with a much less complex 
pharmacokinetic profile (Kalis & Huff, 2001). The mechanism of action is similar to 
that of CBZ, however, the blocking of Na+ channels occurs at much lower 
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concentrations (McLean, 2002) and there is a variation between the two drugs in 
their affinities for L-, N-, P-, R- and T-type Ca2+ channels (Schmidt & Elger, 2004). 
OXC can be more effectively combined with other AEDs than can CBZ and because 
of the difference in the way the drug is metabolised, OXC is associated with less 
adverse side effects. 
1.6.7 Felbamate  
Felbamate (FBM), 2-phenyl-1,3-propanediol dicarbamate is an orally active 
compound that exhibits anticonvulsant and neuroprotective properties (Faught et al, 
1992). Its mechanism of action is poorly understood, however, it seems to function 
both by enhancing GABAergic transmission and inhibiting the excitatory effects of 
aspartate (Rho et al, 1994). Because it has severe side effect in the liver and bone 
marrow, FBM is used as a therapy of last resort for patients exhibiting refractory 
partial epilepsy and to control the severe Lennox-Gestaut syndrome. FBM is more 
commonly used as a monotherapy, because of the side effects related to its 
interaction with other AEDs, such as vomiting, insomnia, nausea and headache 
(Leppik et al, 1991). Side effects are particularly severe when FBM is combined with 
CBZ. 
1.6.8 Gabapentin  
Gabapentin (GBP), 1-(aminoethyl)cyclohexaneactic acid, is widely used as an 
adjunctive therapy for refractory partial epilepsy (Heilbroner & Devinsky, 1997). 
Although it has structural similarities with GABA, it is not believed to function as a 
GABA agonist. Its mechanism of action is not fully understood, however it is believed 
that it plays a role in modulating the metabolism of GABA as well as excitatory amino 
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acids in the CNS (Errante et al, 2003). GBP is an effective treatment against partial 
and secondarily generalized seizures in many patients, however, it is ineffective in 
generalized seizures and absence seizures. The use of GBP in epilepsy therapy is 
associated with a low incidence of serious adverse effects and, unlike many 
alternative therapeutic options, has not been associated with toxicity in the liver or 
bone marrow (Ojemann et al, 1992). 
1.6.9 Lamotrigine  
Lamotrigine (LTG), 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine, is chemically 
unrelated to other AEDs, but has a pharmacological profile similar to phenytoin and 
CBZ (Leach et al, 1991). LTG acts by perturbing voltage-gated cation channels, with 
a higher affinity for Na+ channels than Ca2+ channels (Lees & Leach, 1993). When 
used as a monotherapy, LTG has a similar efficacy as CBZ or phenetoin against 
partial and generalised tonic-clonic seizures, however, it is generally much better 
tolerated and associated with fewer adversive side-effects, such as asthenia, 
dizziness and somnolence (Kaminow et al, 2003). It is also not associated with the 
weight-gain seen in patients taking valproate (Biton et al, 2001). Lamotrigine is 
effective against both partial and generalised seizures.  
1.6.10 Topiramate 
Topiramate (2,3;4,5-bis-O-(1-methylidene)-beta-D-fractopyranose sulphamate) is a 
sulphamate-substituted monosaccharide (Walker & Sander, 1996). It has a complex 
mechanism of action with five separate actions at the cellular level reported, 
including inhibition of kainate evoked currents, enhancement of GABA-evoked 
currents, blockage of voltage-gated N+ channels, blockage of voltage-gated Ca2+ 
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channels, and inhibition of carbonic anhydrase isoenzymes. It is used in as an 
adjunctive to monotherapy in patients with partial epilepsy who are refractory to other 
pharmacological treatment regimes (Bensalam & Fakhoury, 2003). The multiple 
mechanisms of action confer broad spectrum efficacy against different seizure types 
and make topiramate an attractive choice in the treatment of both partial and 
generalized status epilepticus (SE) (Bensalem Fakhoury, 2003). 
1.6.11 Tiagabine 
Tiagabine (TGB), (R)-N-[4,4-di-(3-methylthien-2-yl)but-3-enyl] nipecotic acid 
hydrochloride, is a GABA reuptake inhibitor (Giardina, 1994), which increases 
extracellular concentrations of GABA, increasing the seizure threshold (Fink-Jensen 
et al, 1992). TGB can be used to supplement treatments in patients aged over 12 
suffering recurrent partial seizures with or without secondary generalization which 
cannot be satisfactorily controlled with other antiepileptic drugs (Schmidt et al, 2000). 
TGB is effective in conjunction with other AEDs, such as CBZ and LTG (McKee, 
2004) and has limited adverse side effects, generally limited to the CNS. 
1.6.12 Levetiracetam 
Levetiracetam (LEV), (S)-α-ethyl-2-oxo-1-pyrrolidine acetamide is used as an 
adjunctive therapy for patients refractive to other therapeutic treatment regimes, 
suffering from partial seizures with or without secondary generalization (Betts et al, 
2000). The mechanism of action of LEV is not well understood. Unlike the majority of 
AEDs, it does not appear to function through the mediation of GABAergic inhibition, 
or by acting at voltage-gated Na+ or T-type Ca2+ channels (Rigo et al, 2002). 
However, there is some evidence to support the idea that it works by mediating 
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intacellular Ca2+ concentrations through effects at ryanodine and IP3 receptors 
(Nagarkatti et al, 2008) and at ROMK1 channels via the modulation of 
phosphorylation by protein kinase A (Lee et al, 2008). Adverse side-effects of LEV 
have been shown to lead to much lower levels of treatment discontinuity than in TPM 
(Bootsma et al, 2008). 
1.6.13 Valproic Acid 
Valproic Acid or valproate (VPA) is the most commonly used AED in the treatment of 
generalised epilepsy and also used against partial epilepsy absence seizures and 
myoclonic seizures (Johannessen, 2000). VPA has a pleiotropic mechanism of 
action, with a combination of effects of the drug in the CNS mediating its 
anticonvulsant function (Price, 1989). Similarly to GBP, it has a simultaneous effect 
of upregulating GABA synthesis, whilst downregulating the synthesis of asparate 
(Johannsessen, 2000), but it can also inhibit high-frequency firing of neurons by 
blocking voltage-gated Na+ channels and act by decreasing the potentiation of 
excitatory transmission at the NMDA receptor (Griffith & Taylor, 1988). Adverse 
effects of VPA include weight gain (Gidal et al, 1996) and relatively mild cognitive 
deficits which are reversible upon removal of the drug (Gallassi et al, 1990). 
1.6.14 Vigabatrin 
Vigabatrin (VGB), γ-vinyl GABA, is a selective inhibitor of GABA transaminase, 
having the effect of decreasing the enzymatic breakdown of GABA and increasing 
brain concentrations of the inhibitory neurotransmitter. VGB can be used to control a 
range of epilepsy conditions, though it has been found to be most effective against 
partial seizures (Mumford & Dam, 1989). Because of the severe adversive side 
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effects associated with it, such as the destruction of peripheral vision (Sergott et al, 
2010), it is used mainly as a therapy of last resort and is banned in several countries 
including the United States. It is however, a useful option, because of its unique 
mechanism of action, it can be effective where other, less aversive treatment 
regimens have failed.  
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1.7  Nitric oxide 
 
1.7.1  History of Nitric oxide research 
 
NO was first discovered by the English chemist, Joseph Priestly (1775) and 
described by him as ‘nitrous air’. The biological importance of NO is testified by its 
ubiquity across taxa and in the diversity of physiological functions in which it is 
involved. The ancient evolutionary heritage of nitric oxide synthase enzymes (NOS) 
suggest that control over its release conferred a strong advantage in early organisms 
(Kream & Stefano, 2009), but despite its importance, the biological role of the 
molecule was not recognized until the 1980s. Prior to this discovery, a molecule of 
unknown identity, referred to as Endothelial Derived Relaxation Factor (EDRF) 
(Furchgott & Zawadzki, 1980) was described in many reports, until Ignarro et al 
(1987) discovered that NO and EDRF were one and the same. 
 
NO does not have the features of a typical signalling molecule. It is a free radical and 
a highly reactive oxidizing agent capable of causing damage to the cellular 
machinery; indeed, in the concentrations typically studied by chemists, it is highly 
poisonous (Priestly, 1775). As a gaseous molecule, it freely crosses lipid bilayers 
and has a very short half-life meaning that it can therefore not be stored in vesicles, 
but diffuses from the site of synthesis according to the laws of Brownian motion. NO 
does not conform to any of the features of signalling molecules studied prior to its 
discovery.  
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Following the discovery of this important, ubiquitous signalling molecule, however, a 
number of gaseous molecules sharing similar features have been discovered to play 
important roles in mediating physiological processes, including carbon monoxide 
(CO) (Kim et al, 2006) and Hydrogen sulphide (H2S) (Lefer, 2007). It is now 
becoming clear that, far from disqualifying NO from a role in cell signalling, the very 
features of gaseous molecules that make them appear so unsuitable must confer 
advantages, however, this is currently poorly understood. 
 
1.7.2   Nitric oxide and Nitric oxide synthase 
 
Because of its ability to cross lipid bilayers, NO cannot be stored in vesicles and 
diffuses from the point of synthesis as an active molecule. It is produced by the 
conversion of L-arginine to L-citrulline by NOS enzymes, which exist in three 
isoforms: neuronal (nNOS), expressed mainly in neurons; endothelial (eNOS), 
expressed mainly in endothelial cells and inducible (iNOS), expressed mainly in 
immune cells, or microglia in the CNS. The isoforms are alternatively referred to as 
NOS-1, NOS-2 and NOS-3, respectively. A fourth isoform, mitochondrial NOS (Bates 
et al, 1995) has also been reported, however, it is currently unclear whether this 
molecule represents a novel isoform, or is simply nNOS with post-translational 
modifications (Finocchietto et al, 2009) and will not be further discussed here. 
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nNOS and eNOS are expressed constitutively and are activated by the binding of 
two NOS monomers with two calmodulin (CaM) molecules to form a tetramer 
(Knowles & Moncada, 1994) in the presence of Ca2+. In contrast, iNOS expression is 
induced in response to inflammation, under the control of the transcription factor NF-
κB, is permanently tightly bound to CaM and, thereby, synthesizes NO in a Ca2+-
independent manner. Each isoform is encoded by a separate gene and, while 
showing high levels of homology in the catalytic domains greater variability is found 
in their membrane anchor points (Meyer & Andrew, 1998). 
 
NO is an extremely simple molecule made up of a single nitrogen atom, with 5 
electrons in the outer shell and a single oxygen atom with 6 valence electrons. The 
two atoms form the simplest, stable ‘odd electron’ molecule possible (Stamler et al, 
1992), with the unpaired electron classifying NO as a free radical. NO is synthesised 
by NOS, in the presence of the co-factor nicotinamide diphosphonucleotide 
(NADPH) alongside L-cittruline, from the substrates L-arginine and molecular oxygen 
(02). NOS enzymes have a reductase domain at the C-terminal and an oxygenase 
domain at the N-terminal, with the reductase domain passing an electron via NADPH 
to the oxygenase domain of the opposing NOS molecule in the tetramer as shown in 
Figure 1.7.1. 
 
Oxygenase domain: L-arginine + O2  N
-OH-L-arginine  L-citrulline + NO 
Reductase domain: NADPH  NADP+ + H+ 
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Figure 1.7.1 Reaction catalysed by activated nitric oxide synthase 
 
1.7.3  Molecular targets of Nitric oxide 
 
Because of the highly diffusible nature of NO, the nature of the target is probably 
more important for defining the physiological function of NO signalling than the origin 
of the signal). The ‘classical’ target for NO signalling is soluble Guanyl cyclase 
(sGC), an enzyme which catalyses the production of the secondary messanger, 
cyclic guanosine monophosphate (cGMP) (Ignarro et al., 1991). cGMP production 
via activated sGC activates a wide array of signalling pathways which can involve 
translocation to the nucleus and the modulation in gene expression.  
 
Downstream effectors of cGMP include c-GMP-dependent protein kinase (PKG), 
which can activate AP-1 transcription factors, mitogen-activated protein (MAP) 
kinase p38 and p42/p44 extracellular signal -related kinase (Erk-1/2) (Lamas et al, 
2007). cGMP signalling can also exert an effect on physiological function 
independently of gene expression. cGMP-regulated phosphodiesterases such as 
can modulate intracellular signalling pathways and and cyclic nucleotide-gated 
(CNG) cation channels (Denninger and Marletta, 1999) can modulate 
neurotransmission.  
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Beyond the classical signalling via sGC, NO is involved in cellular signalling in a 
bewilderingly diverse number of ways. NO can exert post-translational modification 
of proteins via S-nitrosylation, altering their physiological function in a similar way to 
the addition of a phosphate by kinases (Stamler et al, 1992). Wink & Mitchell (1998) 
list mechanisms by which NO can interact with molecules in the cell: Interactions 
with metal-containing substrates such as haemoglobin, interactions with high energy 
radicals, such as peroxynitrite, nitration of tyrosine residues to form nitrotyrosine,  
and oxidation.  
 
 
1.7.4  Nitric oxide signalling in the central nervous system 
 
NO was first reported to have a role in the central nervous system by Garthwaite, et 
al (1989) and has since been ascribed a broad range of functions, including the 
modulation of synaptic plasticity (Yang, et al, 2007) and cerebral blood flow (CBF) 
(Pereira de Vasconcelos, 2005). In the vertebrate central nervous system (CNS), NO 
is associated with many different behaviours, including learning and memory 
formation, feeding, sleeping and male and female reproductive behaviour, as well as 
in sensory and motor function (Garthwaite, 2008).  
 
1.7.5 Nitric oxide in epilepsy 
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Using a broad range of models, general NOS antagonism has been shown to have a 
proconvulsive effect (Takei, 2001; Hagioka, 2005). Pereira de Vasconcelos, et al 
(2005) report a major role for eNOS in the modulation of local CBF during seizures 
and the restriction of this mechanism may account for the pro-convulsive effect of 
general NOS inhibition. Evidence for the role of nNOS in seizure generation is less 
clear, with questionable specificity of available drugs targeting nNOS, such as 7-
nitroindazole (7NI) and 3-bromo-7-nitroindazole (3-Br-7NI)  and conflicting reports on 
the extent of nNOS involvement in CBF regulation (Santizo, et al, 2000; Pereira de 
Vasconcelos, 2005). Recently, Kovacs, et al (2009) have reported an anticonvulsant 
affect of nNOS antagonism using an in vitro approach; however, this is yet to be 
replicated in vivo. 
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2. GENERAL MATERIALS AND METHODS 
 
2.1 Animals 
Experiments were performed in 10-12 week old male C57BL/6J mice. All animals 
were purchased from Charles River (UK) and maintained in the Biomedical Services 
Unit, University of Liverpool under controlled environmental conditions (19oC – 23oC, 
12h light: 12h dark), with food and water available ad libitum. All experiments were 
carried out according to Animals (Scientific Procedures) Act 1986 approved by the 
Secretary of State, Home Office, UK and University's Ethical Review Committee.  
 
2.2 Reagents 
KA (Ascent, UK) was prepared in distilled water (DW) at concentrations of 5mg/ml 
and (apart from in the incremental dosing protocol, described in chapter 5), 
administered at a dose of 20mg/kg via intraperitoneal injection. An equivalent volume 
of DW alone was used as a vehicle control. Rabbit anti-c-Fos (1:2000) was 
purchased from Calbiochem (UK), mouse anti-NeuN (1:400) from Chemicon (UK), 
and rabbit anti-synaptophysin (1:1000) was a gift from Dr P Greengard, Rockefeller 
University, USA. Mouse anti-GFAP (1:400) and biotinylated tomato lectin (1:500) 
were purchased from Sigma Aldrich (UK), CY3-conjugated streptavidin (1:300), 
donkey anti-rabbit IgG - CY3/FITC (1:200) and donkey anti-mouse IgG - CY3/FITC 
(1:200) were all purchased from Jackson ImmunoResearch Laboratories, UK. All 
antibodies were prepared in a diluting solution (PBS, 0.1% Triton X-100, 2.5% 
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donkey serum and 0.25% sodium azide). Streptavidin conjugates were diluted in 
PBS alone. 
 
2.3 Drug treatments 
Following initial pilot studies in our laboratory, A dose of 20mg/kg was considered 
suitable for inducing convulsive motor seizures without leading to high levels of 
mortality. While there was considerable inter-batch variation in response to KA, 
responses were largely consistent within batches. Batches were initially screened 
and were rejected if the behavioural response was either subconvulsive or fatal. 
Following the injection with KA, mice were monitored and their behaviour scored for 
a two hour time period. At the two hour point, mice were either sacrificed for 
immunohistochemical analysis of early markers of excitotoxicity, such as c-Fos, or 
seizures were terminated with diazepam (10mg/kg, i.m). 
 
2.4 Behavioural scoring 
The induced period of SE was videotaped and scored blind in 5 minute epochs for 
2h following KA administration, with the most severe behaviour in each five-minute 
epoch recorded using a modified Racine scale (Racine, 1972): Stage 1 – absence-
like immobility, Stage 2 – hunching with facial or manual automatisms, Stage 3 - 
rearing with facial or manual automatisms, Stage 4 – rearing with forelimb clonus 
and falling, and Stage 5 – generalised clonic convulsions with loss of the righting 
reflex. Scores 1 to 2 were defined as non-convulsive seizures (NCS) and scores 3 to 
5 as convulsive motor seizures (CMS) (Williams et al., 2009). Mann-Whitney U tests 
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were performed to compare the maximum severity score between treatment and 
vehicle treated animals.  
 
2.5 Tissue processing and immunohistochemical analysis 
Mice employed for immunohistochemistry were sacrificed at 2h, 24h 72h, 7d or 14d 
timepoints after KA administration by overdose of pentobarbitone (60mg/kg, i.p.). 
Animals were fixed by trans-cardial perfusion with 0.1M phosphate buffered saline 
(PBS), followed by 4% paraformaldehyde in PBS (PBS-PFA). Brains were dissected 
immediately, post-fixed for 4h in 4% PBS-PFA, then cryopreserved in 20% sucrose 
in PBS and stored at 4oC. Thereafter, brains were gelatin-embedded (15% porcine 
gelatin, 7.5% sucrose, 0.1% sodium azide in PBS), incubated for 3h at 38oC and 
chilled overnight at 4oC in Saran wrap to avoid desiccation. Tissue blocks were then 
mounted on 10 mm corks with optimum cutting temperature embedding medium 
(TissueTek, Qiagen, UK), rapidly frozen by immersion in liquid nitrogen-cooled 
isopentane, and stored at -80oC prior to sectioning. Coronal sections (15µm) were 
cut on a cryostat (Leica, UK) at an ambient temperature of -20oC and a block 
temperature of -23oC, thaw-mounted sequentially onto chrome-alum-gelatin coated 
slides as described previously for rat (Cosgrave et al., 2010), and stored at -20oC 
prior to immunohistochemical analysis. 
 
Brain sections were washed several times in PBS to remove traces of fixative. Non-
specific binding sites were blocked with 10% donkey serum in PBS for 1h at room 
temperature. Double-staining was performed on brain sections from vehicle or L-
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NPA treated and untreated animals simultaneously, using the same reagents and 
antibodies. All antibodies were prepared in a diluting solution (PBS, 0.1% Triton X-
100, 2.5% donkey serum and 0.25% sodium azide). Sections were incubated at 4oC 
overnight with primary antibodies. Primary antibody omission was used as a 
negative control, while other brain regions served as known positive controls (e.g. 
thalamic nuclei for c-Fos). After overnight incubation, sections were again washed in 
PBS before being incubated with appropriate secondary antibodies (CY3/FITC 
conjugated) for 1h at room temperature. Following further washes, sections that had 
been incubated with biotinylated anti-species were subsequently treated with 
streptavidin-FITC (1:80, Vector Laboratories, UK) for 1h, washed thoroughly in PBS, 
rinsed in DW and cover-slipped with Vectashield® (Vector Laboratories, UK). 
 
2.6 Microscopy and cell counting 
Immunostained brain sections representing three different cortical regions [septal 
(cranial/rostral), middle and temporal (caudal)] were used for cell counts as 
described previously (Cosgrave et al., 2008, 2010). Sections were viewed using a 
Nikon inverted microscope (Eclipse TE2000, Nikon, UK), photographed (Hamamatsu 
C-4742-95) and handled using IPL software (Nikon, UK).  All photographs were 
taken following a 2 second exposure. ImageJ software (Rasband, 1997-2011) was 
used to measure the counting area (mm2) and performed blind cell counts. Bilateral 
counts were made from a minimum of three sections per animal, each representing a 
different cortical region (15 sections per treatment group). NeuN was used to mark 
neurons.  
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Microglia and astrocytes, stained with Biotinylated tomato lectin and GFAP 
respectively were counterstained with 4',6-diamidino-2-phenylindole (DAPI) and only 
those cells positive for either tomato lectin or GFAP and with a visible nucleus were 
counted. An Abercrombie correction was used (Abercrombie et al., 1946), based on 
the width of the mean of 20 randomly selected DAPI-stained nuclei in each section, 
with the formula: P = A x [M ÷ (L+M)], where P = corrected cell count, A = crude cell 
count, M = section thickness (µm) and L = average width of nuclei (µm). This 
correction allows for a closer approximation of the number of cells in a section, 
correcting for the overcounting bias caused by the counting of fractions of cells as 
whole cells. Synaptophysin immunoreactivity was analysed by measuring the mean 
intensity of a given area using ImageJ and normalizing against unstained regions. c-
Fos+ cell counts were analysed using a Student’s t-test, while synaptophysin and 
glial immunoreactivity were analysed using a one-way ANOVA with post-hoc tests.  
 
2.7 Surgical procedure – transmitter implant 
In each study, a number of mice were implanted with a telemetry device (Physiotel® 
transmitter TA10ETA-F20, 3.8 g, 1.75cc, Data Science International, Amsterdam, 
The Netherlands) for remote EEG recording. Pre-operative antibiotics (Baytril®, 
Bayer Health group, Germany, 5mg/kg, s.c) and buprenorphine (Vetergesic, Reckitt 
Benckiser Healthcare, UK, 0.3mg/kg, i.m) were administered prior to anaesthetisia 
with gaseous isoflourane. The surgical site was shaved and Videne® surgical scrub 
applied. Mice were placed on a sterile drape on a heating pad and surgery was 
performed in sterile conditions. An incision was made through the skin, muscle and 
connective tissue over the skull. Bilateral burr holes (0.7 mm) were drilled, 
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approximately 5 mm cranial to lambda and 2 mm lateral to midline over each 
hemisphere.  
 
A subcutaneous pocket was created over the spine and flank, irrigated with sterile 
saline solution and the telemetry device inserted. Insulation was removed from the 
electrode tips, a ‘V-shape’ bend was made and inserted into the burr holes, in 
contact with the dura mater. Electrodes were secured using dental cement (Alphacryl 
Rapid Repair, National Dental Supplies, UK), taking care to insulate electrode 
terminals from surrounding tissues in order to eliminate signal interference. The 
incision was sutured using size 4.0 absorbable sutures and reinforced with 
VetbondTM Tissue adhesive (3M Animal Care Products, USA). Claws were trimmed 
to prevent scratching and removal of stitches. Animals were given soft food, and 
their eating, drinking, behaviour and bodyweight monitored for 10 days post-surgery. 
After post-operative recovery, animals were subjected to experiments, as described 
in the methods sections of individual research chapters.  
 
2.8 EEG recording 
EEG recording commenced 2h prior to the first drug treatment. In animals receiving 
a pre-treatment, this meant 2h 30m prior to the KA administration. Recording 
continued for 7 days throughout SE and the subsequent early epileptogenic phase. 
Data was transmitted to a RPC-1 receiver pad (Data Science International, 
Amsterdam, The Netherlands) placed under each cage, forwarded to a data 
exchange matrix, and from there to a PC via a Micro1401-3 data acquisition unit. 
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Electrographic data was captured using Spike2 software (Cambridge Electronic 
Design, UK). Distinctive patterns in the EEG trace were described qualitatively and 
quantitative analysis was performed offline in Matlab 7 (Mathworks, UK) as 
described below.  
 
2.9 Quantification of electrographic status epilepticus and electrographic 
changes during ‘latent period’ 
Two independent methods were used to quantify electrographic SE; spike-frequency 
analysis and quantification of power in the γ-frequency band. In order to count spike 
events, raw EEG data was band-pass filtered between 1 and 100Hz. Artifacts were 
removed manually. A standard deviation was calculated from the baseline EEG (i.e., 
prior to any treatment) for each animal in order to produce a threshold at mean +/- 3 
x SD. These thresholds were applied to the post-KA data and each threshold-
crossing event was counted. Total counts were halved in order to calculate a spike 
rate. Spike rate was calculated from the time of KA injection for 7 days. The temporal 
change of spike rate was displayed graphically and Student’s t-tests were performed, 
with a Bonferroni correction for multiple samples, to compare mean spike rates 
between treatment and vehicle mice for the time periods 0-30mins, 30 – 60 mins, 60 
– 90 mins and 90 – 120 mins. A similar method was applied to the EEG trace 
following the termination of SE with diazepam. The temporal progression of spike 
frequency was displayed graphically and the frequency of spikes was binned into 
wider time periods for statistical analysis, including: 3 – 12h post-SE, 12 – 48h post-
SE and 48 – 168h post-SE. 
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The power distributed in the γ-frequency band is a reliable indicator of the severity of 
electrographic SE (Lehmuke et al., 2008). In order to quantify the power in the 
gamma band, raw data was band-pass filtered between 20 and 70 Hz. Power was 
calculated in 5 minute epochs and normalised to artifact-free epochs of baseline 
data. The temporal change in the power distributed in the γ-frequency band and 
mean γ-band power was presented for each 30 minutes of SE.  
 
2.10 Statistical analysis 
All statistical analysis was carried out using SPSS v16 (IBM, USA). Student’s t-tests 
were performed to analyse the effect of treatment versus vehicle on γ-frequency 
band power, with a Bonferroni correction for multiple samples. c-Fos+ cell counts 
were analysed using a Student’s t-test, while synaptophysin and glial 
immunoreactivity were analysed using a one-way ANOVA with post-hoc tests. A 
Student’s t-test was applied for the latency to the onset of CMS (Racine score ≥ 3) 
and duration of CMS i.e., summation of epochs in which epileptic behaviour (Racine 
score ≥ 3) was observed. The median maximum seizure severity was compared 
between treatment groups using Mann-Whitney U tests.  
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Chapter 3. Neurobiological, electrographic and behavioural 
characterisation of a kainic acid-induced status epilepticus 
model of epileptogenesis in the C57BL/6J mouse 
 
3.1 ABSTRACT 
 
In this chapter, the anatomical distribution of GABAergic, GAD-67 immunopositive 
interneurons in the hippocampal formations of two strains of mice was compared: an 
outbred strain, CD-1 and an inbred strain: C57BL/6J. The anatomical distribution of 
neurons expressing a neuropeptide, somatostatin, an enzyme, nNOS and a calcium 
binding protein, Calbindin-D28K, was also compared; all considered important 
modulators of hippocampal network dynamics. A period of status epilepticus was 
induced in both strains using intraperitoneal injections of the excitotoxic glutamate 
analog, kainic acid and quantified the emergence of epileptiform behaviour and 
analysed the anatomical distribution of c-Fos expression in the hippocampal 
formation 2 hours post KA. 
 
In C57BL/6J mice, the emergence of electrographic changes during the period of 
status epilepticus and in the 7 days was investigated following the termination of 
seizures with diazepam, using implantable electrodes to record directly from the 
surface of the brain. Indicators of epileptogenesis, including reactive gliosis and 
synaptogenesis were investigated using immunohistochemistry at 24 and 72 hours.  
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We report that C57BL/6J mice generally have a lower tolerance to kainic acid than 
CD-1, however c-Fos expression in the CD-1 mice is more widespread in the 
hippocampal formation following status epilepticus. 4 patterns of EEG associated 
with status epilepepticus in the C57BL/6J mouse are described and he frequency of 
epileptiform discharges quantified. The power distributed in the gamma frequency 
band is quantified, following the methods described in Lehmuke et al (2009). Further, 
it is reported that epileptiform spiking continues for at least 7 days following kainic 
acid injection, in the absence of any behavioural indicators and that reactive gliosis 
in the CA3 region and reactive synaptogenesis in the outer molecular layer of the 
dentate gyrus occur 72 hours after induction of SE with diazepam.  
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3.2 INTRODUCTION 
 
Kainic acid has been used as an agent for modelling seizures and the development 
of chronic epilepsy for many years (Ben-Ari & Cossart, 2000) (See introduction for 
more information on the development of Kainic acid as a research tool). A wide 
variety of approaches have been used, including in vitro models investigating 
excitotoxicity in culture (Rothman, 1985), acute (Alici et al, 1996) and organotypic 
hippocampal slices (Gahwiler, 1981, Bruce et al, 1995) and in vivo studies, where 
the drug is administred via intracerebral (Cavalheiro et al, 1982) or systemic 
(Lothman et al, 1981) injections. For a review of the contribution kainic acid models 
to the understanding of epilepsy, see Laursen (1984).   
 
Studies performed in the 1980s have shown that systemic or intracerebral injections 
of kainic acid produce epileptiform seizures in the CA3 region of the hippocampus. 
These seizures propagate to other limbic structures and are followed by a pattern of 
cell loss that is similar to that seen in patients suffering TLE (Nadler, 1981). The 
induction of a period of SE in rodents has served as a useful model for investigating 
the progression of epileptogenesis and the emergence of chronic epilepsy and 
spontaneous seizures. SE models of TLE have offered insights into molecular and 
cellular changes underlying epileptogenesis, such as neuroinflammation (Vezzani, 
2008) gliosis (Riban et al, 2002), selective neuronal loss (Sperk et al, 1983) and 
mossy fibre sprouting (Tauck & Nadler, 1985). 
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For a number of reasons historically, the majority of in vivo studies have been 
performed in rats. Rats show a consistent response to KA and a spatiotemporal 
pattern of neurobiological changes that closely replicates that seen in human TLE 
(Sperk, 1994). With the development of transgenic technology, however, the use of 
mice has quickly outstripped rats as the priniciple animal model for the majority of 
neurological conditions. The reduced cost of housing and quicker breeding speed 
make mice a preferable species for developing techniques in genetic manipulation. 
As a result, an understanding of the genetics and developmental biology of mice is 
far more advanced than in rats, however, neurobiological and electrophysiological 
changes in models of disease requires greater characterisation in this species.   
 
Both outbred and inbred strains of mice are commonly used to model neurological 
diseases, including TLE. While inbred strains offer the advantage of isogenicity, 
especially valuable to geneticists, they also often exhibit strong strain-specific 
behaviour, physiology or responses to pharmacological treatment (Crawley, 2008). 
The CD-1 outbred strain is widely used in biomedical research, particularly in studies 
of drug toxicology, whereas the C57BL/6J is the most widely used background strain 
for the generation of mutants and is therefore of particular interest for the 
development of genetic studies in epilepsy.  
 
While outbred strains, such as CD-1 show significant neuronal loss and spontaneous 
seizures comparable to rats following a period of drug-induced SE, the hallmarks of 
TLE have proven harder to model in inbred strains. C57BL/6J mice have proved to 
be particularly resistant to induced TLE. C57/BL6J mice have widely been reported 
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as having a high tolerance for kainic acid (Engstrom & Woodbury, 1986; 1988) and a 
resistance to neuronal loss and the development of spontaneous seizures following 
temporal lobe epilepsy (McKhann et al, 2003).  
 
Other studies, however have found that C57BL/6J mice are not as resistant to kainic 
acid-induce epileptogenesis as widely reported. A variety of studies have reported 
that sensitive methods for the detection of neuronal cell loss, such as a Flourojade B 
stain indicate that a period of KA-induced SE does indeed cause lasting and 
progressive damage to neurons in the hippocampal formation in this strain (Hu et al, 
1998; Shikhanov et al, 2005) comparable to the cell loss found in TLE. The 
emergence of spontaneous seizures in C57BL/6J mice, however, is yet to be 
reported. 
 
Neurons in the hippocampal formation can be roughly divided into excitatory, 
principal cells and inhibitory interneurons. Excitatory cells are largely restricted to the 
granule cell layer of the dentate gyrus and pyramidal cell layer of the hippocampus, 
however, small numbers of specialised excitatory neurons, such as mossy cells exist 
in other lamina (Anderson et al, 2006). Inhibitory interneurons represent 
approximately 10% of the neurons in the hippocampal formation, are heterogenous 
and express varieties of neuropeptides and calcium binding proteins, however it is 
assumed that the majority of them are GABAergic (Freund & Buzsaki, 1996).  
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Despite their low numbers, GABAergic interneurons play an important role in 
keeping the hippocampal network in balance. Differences in the anatomical 
distribution of particular populations of interneurons is likely to have an effect on the 
network response to excitotoxins, such as kainic acid. GABA is synthesised by the 
enzyme glutamic acid decarboxylase (GAD), of which there are 2 varieties: GAD-65 
and GAD-67. A study by Jinno et al (1998) showed that markers of GABA and 
markers of GAD-67 co-expressed to such an extent that GAD-67 can be cautiously 
used as a marker for all GABAergic neurons in the hippocampus. The anatomical 
distribution of GAD-67 immunopositive cells in the hippocampal formation of CD-1 
and C57BL/6J mice is investigated and the distribution of  the neuropeptide 
somatostatin (SST), the enzyme nNOS and the calcium binding protein, calbindin 
D28K (CB).  
 
Activator protein 1 (AP-1) is a heterodimeric transcription factor composed of 
proteins which can include both c-Fos and c-Jun. The exact composition of the 
transcription factor determines the nature of transcription catalysed. Transcription of 
AP-1 subunits is regulated in a given cell by a broad range of physiological and 
pathological stimuli, including cytokines, growth factors and excitotoxic stress (Karin 
et al, 1995). The expression of c-Fos in particular is rapidly elevated in response to 
neuronal firing, which has meant that this subunit is often used in studies of the CNS, 
as a marker of neurons undergoing high levels of activity (Dragunow & Faull, 1989). 
The distribution of a range of markers of distinct populations of inhibitory 
interneurons in the hippocampus between CD-1 and C57BL/6J mice is compared, 
and characterised the progression of epileptiform behaviour during a 2 hour period of 
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KA-induced SE. Further, the spatiotemporal expression of c-Fos in the hippocampal 
formation in both strains from 2 – 12h following the induction of SE is analysed.  
 
Despite the consistent presence of gliosis in post-mortem sections from TLE 
patients, the likely importance of gliosis to the progression of the disease and 
potential opportunity afforded for treatment of the latent period, time-course studies 
of the onset of gliosis in mouse SE-models are fairly limited in number and suffer 
from a lack of temporal resolution. The development of electrographic status 
epilepticus and electrographic activity for 7 days following seizure in C57BL/6J mice 
is characterised using implantable electrodes and analysed glial activation and 
reactive synaptogenesis at 24 and 72 hours following KA in this strain. 
 
During seizure, higher frequency oscillations show an increase in power, 
representing the combined effect of hyperactivity and hypersynchronisation. 
Lehmuke et al (2009) demonstrated that the dynamic power of oscillations in the 
gamma frequency (20 – 70Hz) was a good correlate of seizure severity during a 
period of KA-induced SE in rats. Following seizure, the frequency of IED’s is a good 
indicator of the progression of epileptogenesis. In C57BL/6J mice only, EEG was 
recorded during a period of KA-induced SE and for 7 subsequent days and 
described qualitatively and quantitatively the changes observed in the trace 
associated with seizure and epileptogenesis.  
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3.3 MATERIALS AND METHODS 
 
3.3.1 Overview 
 
Information regarding materials and methods described in this chapter refer only to 
that which is specific to this particular study. For general materials and methods, see 
chapter 2 where detailed protocols of methods performed throughout all chapters are 
described, including: KA administration and behavioural scoring of SE, basic 
protocols used for immunohistochemistry, microscopy and quantification of 
immunohistochemistry, surgical procedures for the implantation of electrodes and 
transmitters and EEG data collection and analysis. For ease of understanding, 
however, some information is duplicated. 
 
3.3.2 Animals 
 
Experiments were performed in 10-12 week old male C57BL/6J and CD-1 mice. All 
animals were purchased from Charles River (UK) and maintained in the Biomedical 
Services Unit, University of Liverpool under controlled environmental conditions 
(19oC – 23oC, 12h light: 12h dark), with food and water available ad libitum. All 
experiments were carried out according to Animals (Scientific Procedures) Act 1986 
approved by the Secretary of State, Home Office, UK and University's Ethical 
Review Committee.  
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A total of 54 mice were used for studies reported in this chapter, including 18 CD-1 
and 36 C57BL/6J. 5 mice from each strain were used as control animals for free-
floating immunohistochemistry, while SE was induced with KA (20mg/kg, i.p) in 13 
CD-1 mice and 11 C57BL/6J mice. Behavioural seizures in these mice were scored 
for 2 hours. Of these mice, 5 CD-1 and 4 C57BL/6J were perfused 2 hours after KA 
injection for the analysis of c-Fos in the hippocampal formation in free floating 
sections. Of the remaining mice, seizures were terminated with an intramuscular 
(i.m) injection with diazepam (10mg/kg) and these mice were perfused at 6 hours 
(CD-1: n = 4, C57BL/6J: n = 4) and 12 hours (CD-1: n = 3, C57BL/6J: n = 3). 1 CD-1 
mouse died during SE. 
 
Following this comparison between strains, a further study was performed 
investigating histological and electrographic changes in the hippocampus of 
C57BL/6J mice only. Of the remaining 20 C57BL/6J mice, 5 were used as controls 
for thaw mounted immunohistochemistry, while SE was induced in 10 mice using KA 
(20mg/kg). In these mice, seizures were terminated 2 hours following injection with 
KA (diazepam, i.m, 10mg/kg) and these mice were perfused at 24 (n = 5) and 72 (n 
= 5) hours. A further 5 mice were implanted with telemetry device for the recording 
and transmitting of EEG. Following post-operative recovery, SE was induced in 
these mice with KA (20mg/kg, i.p), terminated with diazepam at 2 hours (10mg/kg, 
i.m) and EEG was recorded for 7 days post-SE. 
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3.3.3 Drugs, Reagents and antibodies   
 
Mouse anti-GAD-67 (1:1000) was purchased from Chemicon (UK) and visualised 
using an FITC-conjugated donkey anti-mouse secondary antibody (1:200). Sheep 
anti-nNOS (1:2000) was a gift from Dr P.C. Emerson and visualised using a CY3-
conjugated donkey anti-sheep antibody (1:200). Rabbit anti-CB D28K (1:2000) was 
purchase from Millipore (UK) and visualised using a CY3-conjugated donkey anti-
rabbit antibody (1:200). Rabbit anti-SST (1:1000) was purchased from Chemicon 
(UK) and visualised using a CY3-conjugated donkey anti-rabbit antibody (1:200). 
Rabbit anti-c-Fos (1:2000) was purchased from Calbiochem (UK) and visualised 
using a CY3-conjugated donkey anti rabbit secondary antibody (1:200). Mouse anti-
NeuN (1:400) was purchased from Chemicon (UK) and visualised using an FITC 
donkey anti-mouse secondary antibody (1:200). Rabbit anti-synaptophysin (1:1000) 
was a gift from Dr P Greengard, Rockefeller University, USA and visualised using a 
CY3-conjugated donkey anti-rabbit antibody (1:200). Mouse anti-GFAP (1:400) was 
purchased from Sigma Aldrich (UK) and visualised using an FITC-conjugated 
donkey anti-mouse secondary antibody (1:200) Biotinylated tomato lectin (1:500) 
was purchased from Sigma Aldrich (UK) and visualised using CY3-conjugated 
streptavidin (1:100). All flourochrome-conjugated secondary antibodies and 
streptavadin were purchased from Jackson Immunoresearch laboratories (UK). DAPI 
used for visualizing cell nuclei was in the Vectashield ® mounting medium (Vector 
Laboratories, UK). 
 
3.3.4 Free-floating sections 
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Following transcardial perfusion with 4% PFA (as described in chapter 2), brains 
were put soaked in 4% PFA for 4 hours, before being transferred to a 20% sucrose 
(in PBS) solution for cryopreservation. Brains remained in the sucrose solution for at 
least 24 hours before being sectioned as soon as possible (brains remained in 
sucrose for no longer than 2 weeks). 80μm thick free floating sections were cut using 
a freeze-plate microtome, directly into PBS. Sections were washed several times in 
PBS to remove any traces of PFA, before incubation in 5% donkey serum  for 1.5 
hours to block non-specific binding. Following incubation in donkey serum, sections 
were incubated in primary antibodies for at least 12 hours. Sections were again 
washed in PBS several times, prior to incubation in secondary antibodies for 3 hours. 
Sections were again thoroughly washed in PBS, placed into distilled water to reduce 
the salt content and mounted on CAG-coated slides using a fine paintbrush. Finally, 
sections were mounted using a Vectashield ® wet mount medium (Vector 
Laboratories, UK). 
 
3.3.5 Semi-quantitative analysis of c-Fos expression 
 
Because c-Fos expression in the hippocampal formation was too dense for accurate 
cell counting in 80μm sections following KA-induced SE, a semi-quantitative method 
was employed to score the extent of c-Fos expression in different regions. This 
involved a scoring system from 0 – 5, as follows: 0: no c-Fos expression. 1: A 
minimum of 1 cell immunopositive for c-Fos, up to 10% of cells 2: between 10 and 
20% of cells immunopositive 3: between 20 and 50% of cells immunopositive 4: 
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majority of neurons c-Fos immunopositive, but not expressed in all neurons5: c-Fos 
expressed in all neurons. 
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3.4 RESULTS 
 
3.4.1 Inhibitory interneurons 
 
GAD-47 immunopositve cell bodies were found in the highest density in the CA1 
region, with a slightly higher density in the stratum oriens (around 16 immunopositive 
cells/section) than in the stratum radiatum (around 14 immunopositive cells/section) 
(Figure 3.1a - d). A dense band of fibre tracts were clearly marked in the deep layers 
of Stratum radiatum of CA1 and CA3. GAD-47 distribution in the hippocampal 
formation varied little between strains, however, C57BL/6J mice did show higher 
numbers of GAD-47 immunopositive cell bodies in the Stratum Oriens region of CA1 
(t8 = 2.7386, p = 0.026, Fig 3.1a – d). 
 
In both strains of mice, the highest density of SST-positive somata were found in in 
the polymorphic layer of the dentate gyrus, with far fewer found in the molecular 
layer of either strain (Figure 3.1a, 3.1d). CD-1 mice showed higher concentrations of 
SST-positive cells in both Stratum radiatum (t8 = 2.8415, p = 0.022) and Stratum 
oriens (t8 = 2.5175, p = 0.036) of the CA3 region of the hippocampus (Figure 3.1a, 
d), while C57BL/6J mice had a higher distribution in the same layers of the CA1 
region (Stratum radiatum: t8 = 3.901, p = 0.005) Stratum oriens: : t8 = 4.1712, p = 
0.003, Figure 3.1a, d). In all mice, some SST-;like immunoreactivity was observerd in 
the pyramidal cell layer throughout the hippocampus, however this staining was of a 
much lower intensity than in other layers and cells with this lower intensity of staining 
 
92 
 
were not counted as SST-positive. This lower intensity staining may be an artefact, 
or evidence of some SST-staining in pyramidal neurons. The intensity of this staining 
was much higher in CD-1 mice (Figure 3.1a). SST-immunopositive fibres were found 
in the highest density in the polymorphic and molecular layers of the dentate gyrus. 
 
In both strains, nNOS-immunopositive neuronal somata were found in high densities 
in the polymorphic layer of the dentate gyrus, with 30 – 40 neurons observed in each 
section and a heavy density of fibres was observed in the inner molecular layer, 
particularly in CD-1 mice (Figure 3.1b, 3.1d). nNOS-immunopositive somata were 
also observed at lower densities (5 – 15 cells/section) throughout the dentate gyrus 
molecular layer and the stratum radiatum and oriens throughout CA3 and CA1, 
however, no nNOS immunopositive neurons were observed in the dentate gyrus 
granule cell layer or the pyramidal layer of the hippocampus in any sections. 
C57BL/6J mice showed a slightly higher density of nNOS-immunopositive cell bodies 
throughout the hippocampal formation, however, this was most pronounced in the 
molecular layer of the dentate gyrus (t8 = 2.5976, p = 0.0317) and Stratum oriens of 
the CA3 region (t8 = 2.400, p = 0.043). 
 
CB-immunopositive cells were found in the highest denstity in thin band in the 
Stratum lacunosum-moleculare and were also dispersed in the stratum radiatum of 
the CA3 region (Figure 3.1c, d). Although cell bodies were found at a lower density 
than GAD-47, SST or nNOS, a very high intensity staining of fibre tracts was 
observed throughout the dentate gyrus and a distinctive high density  band of CBD-
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postive fibres could be clearly seen in every section in the stratum lucidum of CA3 
(Figure 3.1c). 
 
3.4.2 Behavioural scoring 
 
C57BL/6J mice could be divided into three distinct populations based on their 
response to KA. While the majority of mice (approximately 80%) showed tonic-clonic 
seizures between 30 minutes and one hour following KA administration, followed by 
recovery, some mice exhibited either an enhanced resistance or an enhanced 
sensitivity to KA. Animals in the resistant group failed to show CMS in response to 
20mg/kg KA, while animals in the hypersensitive group showed full tonic clonic 
seizures within 10 minutes of KA administration, which were lethal. This variability 
was at the level of the batch, with relatively consistent responses seen between 
individuals from the same home cage. Consequently, when an animal was found to 
show an ‘aberrant’ response to KA, the entire batch was excluded. From here in, 
only C57BL/6J mice from ‘normal’ batches are considered. 
 
Shortly after KA administration, all mice (excluding aberrant C57BL/6J populations 
showed similar behaviour, with pronounced hypoactivity (Racine stage 1, lasted 
approximately 5 to 10 minutes), CD-1 mice showed a greater tolerance to KA than 
C57BL/6J mice (Figure 3.2). CD-1 mice reached a lower maximum severity, with a 
median of Racine 4, compared with Racine 5 in C57BL/6J mice (Mann Whitney U 
test: U = 1915, p< 0.001, Figure 3.2b). The latency to complex motor seizures 
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(≥Racine 3) was approximately 20% longer than in C57BL/6J mice (t22 = 2.212, p = 
0.019, Figure 3.2c), whilst the duration was approximately 30% lower in the outbred 
strain (t22 = 2.632, p = 0.008, Figure 3.2d).  
 
3.4.3 Expression of immediate early gene products in the hippocampal 
formation 
 
In control mice of both strains, c-Fos expression was completely absent from the the 
principal excitatory neurons, including both granule cells in the granule cell layer of 
the dentate gyrus and pyramidal cells in the pyramidal cell layer of the CA1, CA2 and 
CA3 regions of the hippocampus. In both strains, cFos was constitutively expressed 
in a number of neurons in the polymorphic zone of the dentate gyrus. In C57BL./6J 
mice, this constitutive expression extended into the stratum radiatum and stratum 
oriens regions of areas CA1, CA2 and CA3(Figure 3.3a, e). 
 
2 hours following KA administration, c-Fos expression was strongly elevated in in the 
granule cell layer of the dentate gyrus in both strains (Figure 3.3b, e). This elevated 
expression was also found throughout the pyramidal cell layer of the all hippocampal 
regions in CD-1 mice, however, in C57/BL6 mice, although there was some c-Fos 
expression in pyramidal cells of all mice investigated, expression was generally 
lower, sporadic, with greater variation between animals (U = , p = 0.032, Figure 3.3b, 
e). c-Fos expression was also elevated more strongly in neurons found in the 
dentate hilus of CD-1 mice than the C57/BL6 strain (Figure 3b, e). 
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At 6 hours following KA administration, there is a greater variability in c-Fos 
expression between individual animals than between strains. c-Fos is observed 
throughout the dentate gyrus and hippocampus, both in the main excitatory circuitry 
(dentate granule cells and pyramidal cells) and in interneurons in the hilus, dentate 
gyrus molecular layer, stratum radiatum and stratum oriens (Figure 3.3c, e). at this 
timepoint, c-Fos expression was found in higher densities in the granule cell layer of 
C57BL/6J mice than in CD-1 mice. 12 hours following KA administration, c-Fos 
expression is largely indistinguishable from naive controls. In some CD-1 mice, some 
low density c-Fos immunoreactivity can be observed in the granule cell layer, 
however, this was completely absent in all sections taken from C57BL/6J mice 
(Figure 3.3d, e).  
 
In both strains of mice, there was high-intensity c-Jun immunoreactivity in the 
granule cell layer of the dentate gyrus, suggesting that this protein is constitutively 
expressed (Figure 3.3f). c-Jun is absent in the pyramidal cell layer throughout the 
hippocampus and was not found to be induced in any region following KA-induced 
Status epilepticus, suggesting that it was not  suitable as an indicator of seizure 
severity. 
 
3.4.4 Electrographic status epilepticus 
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C57/BL6J mice implanted with telemetry devices exhibited normal behavioral 
patterns following post-operative recovery period, with no obvious effect on eating, 
drinking, activity levels, alertness, aggression or signs of discomfort. Baseline EEG 
activity was also normal, with occasional changes in amplitude and frequency that 
correlated with activity levels and state of alertness (Figure 3.4a, b). SE began with 
discrete electrographic seizures (figure 3.4c), correlating with hypoactivity (Racine 
Class I) As these electrographic seizures become more regular, they began to 
merged into each other, evolving into continuous, high amplitude spiking (figure 
3.4e) with intervening flat periods. The spiking interrupted by flat periods gradually 
became more regular (figure 3.4f) until the pattern observed resembled regular high-
amplitude discharges (figure 3.4d). 
 
Following the administration of KA, the rate of epileptiform spikes increased over the 
initial 20 minutes to a peak of approximately 65 spikes min-1 (Figure 3.5a), and from 
this point, decreased to around 30 spikes min-1 by approximately 35 minutes. Over 
the period from 20 minutes to 80 minutes, the spike rate fluctuated in regular cycles 
of approximately 25 minutes duration, with a general trend downwards. By 80 
minutes, the spike rate had decreased to approximately 50 spikes min-1. From 
around 100 minutes, the spike rate decreased towards the 2 hour point to 
approximately 40 spikes min-1. In contrast to the spike rate, the power distributed in 
the γ-band increased steadily from the point of KA administration to a peak of 5dB 
around 90 minutes post injection. From this point, it gradually declined to 
approximately 3.5 at 120 minutes.  
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3.4.5 Gliosis 
 
24h after KA administration, there were no qualitative differences in morphology, 
distribution, or quantitative differences in cell numbers in either astrocytes or 
microglia than seen in sections taken from control mice (Figure 3.6e, f). In region 
CA3, astroglial distribution was largely restricted to stratum radiatum and stratum 
oriens and this pattern was largely replicated by microglia (Figure 3.6a, b). By 72h, 
however, there was an approximately two-fold increase in GFAP immunopositive 
astrocytes and a three-fold increase in microglia in the CA3 region compared to 
control mice. A one-way analysis of variance with a Tukey’s honestly significant 
difference criterion was performed and found that this was significant (Astroctyes: F12 
= 122.0, p < 0.001 Microglia: F12 = 53.77, p < 0.001).  
 
Qualitative analysis revealed  evidence of significant invasion of stratum lucidum and 
the pyramidal cell layer by both cell types (Figure 3.6a, b, d, e) and an increased 
number of microglial cells and GFAP immunopositive astrocytes possessing an 
‘activated’ phenotype with hypertrophic cell bodies and thick processes (Figure 3.6c). 
 
3.4.6 Reactive synaptogenesis 
High levels of Synaptophysin immunoreactivity was constitutively expressed in the 
dentate hilus and stratum lucidum of the CA3 region C57BL/6J mice (Figure 3.7a). 
Initial changes in the spatial distribution of synaptophysin following KA induced 
status epilepticus were witnessed at 72h. At this timepoint, synaptophysin 
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immunoreactivity was elevated in the outer molecular layer of the dentate gyrus (F12 
= 92.55 = , p < 0.001 . Figure 3.7a, b), suggesting an increase in synaptogenesis in 
this region.  
 
3.4.7 EEG analysis for 7 days following kainic acid administration 
 
Following termination of SE with diazepam and subsequent recovery, no behavioural 
seizures were observed in any animals during the first 7 days. However, despite 
diazepam treatment and the absence of behavioural seizures, epileptiform activity 
was still evident in all animals throughout the post-SE or early epileptogenic period. 
This was dominated by the regular epileptiform spikes (Figure 3.4d) Spike frequency 
was initially high (>5 spikes per minute), declining to close to 1 spike/minute at 52h, 
before re-emerging and remaining at approximately 4-5 spikes per minute for the 
remainder of the 7 day recording period (Figure 3.8).  
 
 
 
Figure 3.1a. GAD-47 and Somatostatin expression in the hippocampal formation: comparison between CD-1 and 
C57BL/6J mice. Magnification: x20. Scale bar = 100μm. 
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Figure 3.1b. GAD-47 and nNOS expression in the hippocampal formation: comparison between CD-1 and C57BL/6J 
mice. Magnification: x20. Scale bar = 100μm. 
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Figure 3.1c. GAD-47 and Calbindin expression in the hippocampal formation: comparison between CD-1 and C57BL/6J 
mice. Magnification: x20. Scale bar = 100μm. 
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Figure 3.1d. Cell counts of GAD-47, Somatostatin, nNOS and Calbindin in hippocampal formation of CD-1 and C57BL/6J 
mice. GCL: granule cell layer; PL: polymorphic layer; ML: molecular layer; PCL: pyramidal cell layer; SO: stratum oriens; 
SR: stratum radiatum; SL: stratum Lucidum; SL-M: stratum lacunosum-moleculare (* p < 0.05). 
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Figure 3.2. CD-1 mice have a higher tolerance for kainic acid than C57BL/6J. (a) Timecourse of seizure severity over 120 
minutes following  injection with 20 mg/kg KA. (b) Maximum seizure severity reached (Median +/- IQ range) *p <0.001. 
(c) Latency to onset of CMS ( ≥Racine 3) seizures. **p = 0.019. (d) Duration of CMS . ***p = 0.008. 
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Figure 3.3a. c-Fos expression in hippocampal formation of CD-1 and C57BL/6J control mice. Magnification: x20. Scale 
bar = 100μm. *p = 0.032 (CD-1, n = 5, C57BL/6J, n = 4). 
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Figure 3.3b. c-Fos in hippocampal formation of CD-1 and C57BL/6J mice 2h following injection with Kainic acid. 
Magnification: x20. Scale bar = 100μm. *p = 0.032 (CD-1, n = 5, C57BL/6J, n = 4). 
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Figure 3.3c. c-Fos in hippocampal formation of CD-1 and C57BL/6J mice 6h following injection with Kainic acid. 
Magnification: x20. Scale bar = 100μm.  
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Figure 3.3d. c-Fos expression in hippocampal formation of CD-1 and C57BL/6J mice 12h following injection with Kainic 
acid. Magnification: x20. Scale bar = 100μm.  
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Figure 3.3e. c-Fos expression in dentate gyrus of CD-1 and C57BL/6J mice up to 12 hours following kainic acid 
administration. c-Fos intensity score: score 0 – 5, described in 3.35 materials and methods.  GCL: granule cell layer, PL: 
polymorphic layer, ML: molecular layer 
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Figure 3.2e. c-Fos expression in CA3 region of hippocampus up to 12h following kainic acid administration. c-Fos 
intensity score: score 0 – 5, described in 3.35 materials and methods . PCL: pyramidal cell layer, SO: Stratum oriens, SR: 
Stratum radiatum. * U = 10.5, p = 0.032 
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Figure 3.3e. c-Fos expression in CA1 and CA2 region of hippocampus up to 12 hours following kainic acid 
administration. c-Fos intensity score: score 0 – 5, described in 3.35 materials and methods . PCL: pyramidal cell layer, 
SO: Stratum oriens, SR: Stratum radiatum.   
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Figure 3.4. Typical EEG patterns associated with Kainic acid-induced Status epilepticus in C57BL/6J mouse. (a & b) 
Typical EEG pattern from control mice. (c) irregular high amplitude epileptiform discharges. (d) regular high amplitude 
spikes. (e) High frequency epileptiform discharges. (f) Burst firing. 
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Figure 3.5. Timecourse of status epilepticus in C57BL/6J mice over 2 hour period from injection with kainic acid. (a) 
Spike rate (spikes min-1) with resolution of 5 minutes. (b) Power distributed in Gamma-band (dB). n = 5. 
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Figure 3.6. Gliosis in CA3 at 1 – 3 
days post Kainic acid-
administration. (a) GFAP-positive 
cells in CA3 (b) Tomato lectin 
positive cells in CA3 region of 
hippocampus (c) Close up images of 
Tomato lectin-positive microglia 
demonstrating morphological 
changes during activation. (d) Close 
up image of activated astrocyte 
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Figure 3.6c. Gliosis in CA3 region of hippocampus during latent period following KA-induced status 
epilepticus. (d) Corrected astrocyte cell numbers in CA3 region . *F12 = 122.0, p < 0.001 (e) Corrected 
microglia cell numbers in CA3 region. **F12 = 53.22, p < 0.001  
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Figure 3.7. Kainic acid-induced status 
epilepticus increases Synpatophysin 
immunoreactivity in molecular layer of 
Dentate gyrus 3 days following 
injection. (a) photomicrographs. 
Magnification: x20, scale bar: 100 μm. 
DG: Dentate gyrus 
 (b) Quantitative analysis of staining 
intensity. *F12 = 92.55, p < 0.001.  
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Figure 3.8. Interictal spike frequency for 7 days following injection with kainic acid. Inset: 48h – 168h at higher 
spike rate resolution. 
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3.5 DISCUSSION 
 
3.5.1 Overview 
 
Minor differences were found between strains in the anatomical distribution of GAD-
67, SST, nNOS and CB. C57BL/6J mice generally have a lower tolerance to kainic 
acid than CD-1, however c-Fos expression in CD-1 mice is more widespread in the 
hippocampal formation following status epilepticus. 4 patterns of EEG associated 
with status epilepepticus in the C57BL/6J mouse are described and the frequency of 
epileptiform discharges and power distributed in the gamma frequency band 
quantified. Further, epileptiform spiking continues for at least 7 days following kainic 
acid injection, in the absence of any behavioural indicators and that reactive gliosis 
in the CA3 region and reactive synaptogenesis in the outer molecular layer of the 
dentate gyrus occur 72 hours after induction of SE with diazepam.  
 
3.5.2 Inhibitory interneurons in the hippocampus 
 
The distribution of GAD-67 immunopositive neurons in the hippocampal formation of 
C57BL/6J mice largely corresponded to the numerical densities found by Jinno et al 
(1998) using optical dissection with a confocal laser scanning microscope. Reduced 
numbers of neurons immunopositive for GAD-67 have been linked with an increased 
susceptability to seizures in a number of animal models, including in hyperbaric 
oxygen exposure, where a reduction in GAD-67 content occured shortly prior to 
convulsions (Li et al, 2008), cathepsin-D deficient mice, where a reduction of GAD-
67 increased disinhibition (Shimizu et al, 2005) and the use of an antisense GAD 
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oligodeoxynucleotide (Wang et al, 2002) to expirmentally decrease expression of 
GAD67 protein. A small but sigificant difference between strains in the number of 
GAD-67 immunopositive neurons in the stratum oriens of the CA1 region of the 
hippocampus was found. However, the C57BL/6J strain which showed a slightly 
higher density of GAD-67 neurons in this region was also slightly more sensitive to 
kainic acid, suggesting that this difference was not of principal importance. 
 
It has been reported that SST suppresses epiletiform activity in the CA1 and CA3 
subfields of the hippocampus, is released in greater concentrations during seizures 
and that the selective loss of SST neurons may contribute to the neurobiological 
causes of epileptogenesis (Tallent & Siggins, 1999). A crude analysis of this 
information would suggest that seizure susceptability may be considered inversely 
proportional to SST expression in the hippocampal formation. Because SST 
expression was not found to be uniformly higher in either strain, but, rather, showed 
a slightly different anatomical distribution, with CD-1 mice showing higher numbers 
of SST-immunopositive neurons in the CA3 region and C57BL/6J mice showing 
higher numbers in CA1, it is difficult to interpret whether this is likely to have 
contributed to the sensitivity to kainic acid.  
 
The anatomical distribution of nNOS in the hippocampal formation is consistent with 
that found by other authors in mice (Cork et al, 1998; Kovacs et al, 2009) and other 
mammalian species (Chung et al, 2004), with the highest density of nNOS-positive 
cells, with immunoreactivity in both soma and neurites, is found in the polymorphic 
layer of the dentate gyrus. nNOS expression has been tentatively linked to an 
increased susceptibility to seizures, for example Kovacs et al (2009) have reported 
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that nNOS inhibition reduces seizure-like events in an in vitro hippocampal slice 
model and Kim (2010) reported that an up-regulation of nNOS in the rat 
hippocampus in response to early-life seizures was followed by an nNOS-dependent 
elevation in seizure susceptibility in adulthood (Kim, 2010). It is likely that large 
differences between strains in hippocampal nNOS expression would lead to similar 
difference is sensitivity to kainic acid. Our study showed a slightly increased number 
of nNOS-immunopositive neurons in C57BL/6J mice, particularly in the stratum 
oriens of the CA3 region. This could be considered a potential contributor to the 
increased sensitivity to kainic acid in this strain. 
 
Data for the distribution of CB largely concurred with that reported in C57BL/6J mice 
by Maskey et al (2012). Decreased CB immunoreactivity in the hippocampal 
formation has been linked with temporal lobe epilepsy in humans (Magloczky et al, 
1997) and in genetically epilepsy-prone rats (Montpied et al, 1995) and there is 
evidence to suggest that alterations in hippocampal expression of CB may be one 
potential mechanism for the mechanism for seizure control exerted by the ketogenic 
diet (Kim & Rho, 2008). No significant difference was found however, in the 
anatomical distribution of CB-immunopositive neuronal cell bodies. Neither were any 
qualitative differences in the distribution of fibres observed, suggesting that CB 
expression was unlikely to be an important difference between the two strains. 
 
Although minor differences in the anatomical distributions of neuropeptides in the 
hippocampal formation were found between the two strains and the clear importance 
of the network dynamics of inhibitory interneurons in modulating susceptability to 
seizures, it is not possible, from our data to make any strong connection between 
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differences in interneuron distribution and seizure susceptabiilty. Differences that 
were found were small and did not always correlate with seizure severity in the way 
predicted from the literature. From intraperitoneal injection to the expression of 
status epilepticus, there are myriad variables, such as the rate of adsorption of the 
drug into the blood stream, the permeability to the drug of the BBB, fine network 
dynamics in the hippocampus, or expression of glutamate receptors and ion 
channels which went untested, but may differ between strains. 
 
3.5.3 Behaviour comparison between strains 
 
The outbred CD-1 strain is not widely used in studies of seizure and epilepsy and so 
little data exists regarding sensitivity to kainic acid. The C57BL/6J strain, however, 
as the principal background strain for genetic studies, has been widely investigated. 
Comparisons between the strains in response to convulsant drugs are limited, 
however, Shibley & Smith (2002) report an increased latency to seizure in C57BL/6J 
mice in comparison with CD-1 mice, induced with pilocarpine, contrasting with our 
findings with KA-induced status epilepticus. 
 
The dose of kainic acid administered via i.p injection necessary for inducing 
convulsive motor seizures in mice varies considerably across strains. More 
surprisingly, however, it also varies within the same strain across studies. Hu et al 
(1998) report only 2 out of 6 mice displaying manual automatisms at a dose of 
20mg/kg, with 4 out of 6 mice not even showing any rearing behaviour. Indeed, at 
40mg/kg, there was still no mortality. Ferraro et al (1995) report that 25mg/kg KA 
was sufficient to induce tonic-clonic seizures in only 25% of C57BL/6J mice. 
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Schauewecker & Steward (1997), in a study investigating response to KA across a 
range of inbred strains report a dose of 25mg/kg as being sufficient for inducing 
tonic-clonic seizures whilst limiting mortality in C57BL/6J and this dose seems to be 
fairly standard in other studies.  
 
C57/Bl6 mice have often been contrasted with DBA strains as seizure resistent vs. 
seizure-prone, respectively (Engstrom & Woodbury, 1986; 1988; Wang & Chow, 
1994; Kurschner et al, 1998). In contrast, our studies indicated that 20mg/kg was 
sufficient a dose to induce tonic-clonic seizures in  of C57BL/6J mice, while 
increasing the dose to 25mg/kg induced mortality in almost 50% of animals (data not 
shown), suggesting a higher sensitivity to KA in C57BL/6J mice than previously 
reported.  
 
While a fairly consistent response between animals caged together was found, 
between cages, there was greater variation. It is possible that this is due to an 
increased sensitivity to environmental factors resulting from isogenicity. Subtle 
differences between laboratory can manifest themselves in different behavioural 
responses in inbred mouse strains. It may be that the same is true for responses to 
KA, perhaps accounting for the variation in responses reported across laboratories 
and between studies. While no similar issues are typically reported in the literature, 
Benkovic et al (2004) report a biphasic response to systemic KA in C57BL/6J mice, 
with a hypersensitive population showing high mortality in response to KA 
administration. 
 
3.5.4 Immediate early gene expression in hippocampus between strains 
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Expression of c-Fos is triggered by excessive levels of intracellular Ca2+ and has 
been widely used as a marker for excitotoxic glutamatergic neurotransmission (Gall 
et al., 1998). c-Fos immunoreactivity is considered a hallmark of neuronal network 
activation and the spatiotemporal pattern of expression in the hippocampal formation 
is a reliable and sensitive indicator of seizure severity (Samoriski et al., 1997; 
Willoughby et al., 1997; Vezzani et al., 2000). In mice, c-Fos is expressed in dentate 
granule cells within 30 to 90 minutes of a seizure and in pyramidal cells of CA1, CA3 
and the subiculum at between 2 to 6 hours.  
 
Our data indicates that at 2 hours following KA administration, in C57/BL6J mice, c-
Fos in excitatory circuits is largely restricted to dentate granule cells, whereas in CD-
1 mice, c-Fos expression extends in the pyramidal cell layers of CA3, CA2 and CA1 
of the hippocampus. This is indicative of neurons in these regions being exposed to 
high levels of excitotoxic stress. However, it may not be entirely appropriate to infer 
information about the spatial evolution of epileptiform activity from c-Fos distribution. 
Rather, the anatomical distribution of c-Fos proceeds according to the severity of the 
seizure and the time interval. Rather than an anatomical distinction between the two 
strains in epileptiform activity, this is more likely to represent an increased severity of 
epileptiform activity per se in the hippocampi in CD-1 mice in comparison with 
C57BL/6J, in contrast to behavioural observations of motor seizures. 
 
3.5.5 Electrographic status epilepticus in C57BL/6J mice 
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For various reasons, the vast majority of electrographic data recorded in 
experimental seizure models has come from rats. With the increasing use of mice as 
a model organism and the development of microtechnology, however, an increasing 
number of studies are being performed in mice. Data that is consistent between 
species and strains and has correlates in human patients is of greatest significance. 
Typically, in animal models of TLE, the actual period of SE has attacted less interest 
for analysis than subsequent electrographic changes. This is partly because of the 
challenge of making meaningful interpretations of such chaotic data and because SE 
has been generally considered merely as a method of induction. Our qualitative 
observations of epileptiform activity in the EEG trace corresponds strongly with that 
observed by Treiman et al (1990) and Medvedev et al (2000) following KA-induced 
SE in rats. The gradually increasing power of γ-frequency over the 2 hour period of 
analysis conforms to the findings of Lehmuke et al (2009) using a similar model and 
method of analysis in rats.  
 
3.5.6 Gliosis during ‘latent period’ in C57BL/6J mice 
 
Reactive gliosis in the hippocampal formation has long been considered a hallmark 
of TLE. Evidence of gliosis associated with neuronal loss in resected hippocami from 
TLE patients has been reported numourous times (e.g. Crespel et al, 2002; Cohen-
Gadol et al, 2006), however the role that gliosis plays in disease progression is 
impossible to dissect from correlations with disease state in human sections alone. 
Evidence from animal studies indicates that the effect of gliosis on neuronal loss or 
survival and in modulating network dynamics is strongly dependent on the extent 
and duration of the gliosis and on tissue specific microenvironmental factors.  
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While low levels of astrocyte proliferation may contribute to protecting neurons with 
the release of trophic factors and reduce the excitability of neuronal assemblies by 
taking up glutamate from the extracellular space, higher levels of gliosis are 
associated with molecular changes in astrocytes, including the suppressed 
expression of glutamate transporter-1 (Tanaka et al, 1997) and glutamate-aspartate 
transporter  (Watanabe et al, 1999) and enzymes involved in glutamate metabolism, 
such as glutamine synthatase and glutamate dehydrogenase (Eid et al, 2004). 
These changes reduce the capacity of astrocytes to manage extracellular levels of 
glutamate in the extracellular space (Coulter & Eid, 2012) and may contribute to the 
increased excitability of neuronal networks.  
 
Reactive astrocytes may also provide a source of glutamate. Because they release 
glutamate through a regulated Ca2+-dependent mechanisms, high densities of 
reactive astrocytes may play a causal role in synchronous firing of large populations 
of neurons. Ortinski et al (2010), however found an alternative mechanism for the 
increased excitability of neuronal circuits in the hippocampus following reactive 
gliosis. By virally inducing astrogliosis, this grou found a reduction in inhibitory drive, 
while excitatory neurotransmission remained intact.  
 
Regardless of the extent to which gliosis plays a pro- or anti- epileptogenic role, the 
activation and proliferation of glial cells is a well characterised feature of the early 
stages of epileptogenesis and strongly predictive of neuronal loss and the 
development of spontaneous seizures (Vezzani et al., 2000; 2009; Foresti et al., 
2009). The increased number of both astrocytes and microglia, the morphological 
 125 
 
changes described and the invasion of these cells into stratum lucidum and the 
pyramidal cell layer of CA3 at 72 hours (figure 3.6) is predictive of both neuronal loss 
in this region and a decreased threshold for seizure generation.  
 
Other authors have found similar results in different models. Do Nascimento et al 
(2012) report a slight increase reactive astrogliosis in the CA3 region of the mouse 
hippocamus at 24 hours and a peak in astrogliosis in this region one week following 
the induction of status epilepticus in a pilocarpine induced SE model, however, they 
did not investigate intervening timepoints. A greater number of these studies have 
been performed in rats. Hendrikson et al (2001) report extensive gliosis in the 
hippocampus, with upregulation of markers for both microglia and astrocytes 8 days 
following the induction of SE in rats, however, again, their study offers no data 
regarding the latency to onset of gliosis as earlier timepoints were not  investigated. 
Our data suggest that, in the case of KA-induced SE in mice at least, the initiation of 
reactive gliosis occurs far earlier than 1 week. Strong evidence was found of astro- 
and microgliosis in areas CA3 and CA1 from 72h onwards, correlating with the sites 
where neuronal loss has been reported in the hippocampus, both of TLE patients 
(Wieser, 2004) and in rodents following a period of status epilepticus (Nitecka et al, 
1984).  
 
The extent to which the increase in GFAP+ve astrocytes and microglia in the CA3 
region of the hippocampus post seizure is the result of cell proliferation or migration 
of existing cells into the site of insult from other anatomical regions is unclear. Work 
done in culture has shown that astrocytes both proliferate and migrate to the site of 
injury when challenged. Under these experiments, it is easier to track cell fate by 
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tagging cells, or using BrdU to mark newly formed cells. This is more difficult to study 
in vivo and the methods that we have used do not tackle this issue. 
 
3.5.7 Synaptophysin 
 
SYN is effectively a marker of activity-dependent synaptogenesis, rather than of 
synapse density per se. The high density of SYN immunoreactivity constitutively 
expressed in the stratum lucidum of CA3 and dentate hilus is indicative of a high 
turnover of synapses in these regions, possibly relating to their role in the 
consolidation of spatial memory.  Our studies show that at 72h post KA, these areas 
of high SYN immunoreactivity remain unchanged, while a modest increase in SYN 
immunoreactivity occurs in the OML of the dentate hilus within 72h of KA 
administration, indicating reactive synaptogenesis in this region (figure 3.7).   
 
Neosynapse formation in the molecular layers of the dentate gyrus is strongly 
predictive of the emergence of chronic epilepsy (Wenzel et al, 2000) and is usually 
associated with the aberrant sprouting of mossy fibres, creating recurrent 
connections between dentate granule cells. In SE rodent models, however, while 
varying depending on species, strain and method of induction, mossy fibre sprouting 
is typically reported no sooner than from around 4 - 8 weeks following SE 
(Cantallops & Routtenberg, 2000). Our data suggests the formation of new synapses 
precedes this by a significant time margin.  
 
Hendrikson et al (2001) also found evidence of neosynapse formation in the 
molecular layer of the dentate gyrus 8 days following the induction of SE in rats, 
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however, the progression of epileptogenesis is more rapid in mice and the authors 
did not investigate earlier timepoints. Both our data and that of the Hendrikson group 
indicates that reactive synaptogenesis in the molecular layer of the dentate gyrus 
long precedes the sprouting of mossy fibres. The vast majority of inputs to the outer 
molecular layer are from by neurons originating in layer II of the entorhinal cortex via 
the perforant path, suggesting that the increase in synaptophysin immunoreactivity 
may indicate a strengthening of this perforant path input. It may be that the molecular 
cues involved in synaptogenesis in the early ‘latent phase’ are also involved in the 
formation of aberrant synapses formed between dentate granule cells in later stages 
of the development of chronic epilepsy.  
 
3.5.8 EEG recorded during ‘latent period’ 
 
The causative role of IEDs in the progression of epilepsy is not at all clear (Gotman, 
1991; Janszky et al, 2001). While it was previously assumed that a seizure 
developed from an IED (Ralston, 1958), more recent research has revealed that the 
two phenomena are characterised by different EEG patterns are are, in part 
mediated by different neuronal mechanisms. Katz et al (1991) demonstrated a 
decrease in IED activity prior to seizures, while numerous studies have suggested 
that IED activity actually inhibits seizures (Engel & Ackermann, 1980; Barbarosie & 
Avoli, 1997).  
 
Long-term potentiation (LTP) induced by spikes in vitro can increase the strength of 
recurrent collateral synapses in a network, thereby increasing positive feedback and 
the propensity for synchronous activity (Staley et al 2001). Staley et al (2011) 
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suggest that IEDs play the role of maintaining and expanding recurrent networks by 
inducing synaptic changes, and thereby drive epileptogenesis. Regardless of the 
causative role of IEDs, however, they are strongly predictive for the development of 
chronic epilepsy. In a SE model in rats, Chauviere et al (2012) report that IEDs 
preceed spontaneous seizures by several days and that shortly before spontaneous 
seizures, IED with a spike and wave shape lose the wave.  
 
3.5.9 Conclusions 
 
C57BL/6J were more sensitive to KA-induced SE, however, this was unlikely to be 
related to the minor differences between the two strains in the distribution of  GAD-
67, SST, nNOS and CB in the hippocampal formation. Interestingly, despite their 
greater tolerance of KA, c-Fos expression in CD-1 mice was more widespread in the 
hippocampal formation following status epilepticus, suggesting that our 
understanding of the mechanisms underlying the expression of immediate early 
genes in response to excitotoxicity is insufficient. The patterns of EEG observed 
during status epilepticus the C57BL/6J mouse had correlates with observations in 
rats and in human patients. Epileptiform spiking continues for at least 7 days 
following kainic acid injection, in the absence of any behavioural indicators. Reactive 
gliosis occured in the CA3 region of the hippocampus at an earlier timepoint 
following SE than has previously been reported and that reactive synaptogenesis in 
the molecular layer of the dentate gyrus precedes mossy fibre sprouting by a 
significant period of time.  
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Chapter 4. Effects of an NR2B antagonist, [R-(R,S)]-α-(4-
hydroxyphenyl)-β-methyl-4-phenyl-methyl)-1-piperidine-
propanol (Ro 25-6981), and an nNOS inhibitor, N
w
-propyl-L-
arginine (L-NPA), on acute KA-induced status epilepticus 
and neurobiological and electrographic changes in the 
early latent period in C57BL/6J mice.  
 
4.1 ABSTRACT 
 
In this chapter, the anticonvulsant effects of a specific antagonist of the NR2B 
subunit of the NMDA receptor, Ro 25-6981 and a highly selective neuronal nitric 
oxide synthase inhibitor, L-NPA, was investigated on kainic acid induced status 
epilepticus using behavioural scoring and analysis of c-Fos distribution in the dentate 
gyrus 2 hours following injection with kainic acid. Further, the effect of L-NPA on 
modulating electrographic status epilepticus and electrographic changes during the 
‘latent period’ was investigated, using an implantable telemetry device for the 
recording and transmission of EEG signals. Neurobiological changes, such as gliosis 
and reactive synaptogenesis during the ‘latent period’ were also investigated 
 
Status epilepticus was induced with 20mg/kg kainic acid and seizures terminated 
after 2h with diazepam (10mg/kg, i.m). Pharmacological interventions, or appropriate 
vehicles were delivered 30 minutes prior to kainic acid. Behavioural seizure severity 
was scored using a modified Racine score and c-Fos immunoreactivity in the dentate 
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gyrus was investigated using immunohistochemistry. Reactive gliosis and 
synaptogenesis were investigated using astrocyte and microglial markers and a 
marker of activity dependent synaptogenesis, synaptophysin, respectively. R 25-
6981 was found to have little effect on status epilepticus or c-Fos expression, 
however, L-NPA treatment reduced the severity and duration of convulsive motor 
seizures, the power of EEG in the gamma band, and the frequency of epileptiform 
IEDs during status epilepticus, reduced c-Fos expression in dentate granule cells 2h 
post kainic acid injection. Furthermore, L-NPA pretreatment reduced electrographic 
indicators of epileptogenesis during the ‘latent period’, including the frequency of 
epileptiform discharges over the first 7 days and reactive gliosis and synaptogenesis 
at 3 days following status epilepticus. These results suggest that nNOS facilitates 
seizure generation during SE and may be important for the neurobiological changes 
associated with the development of chronic epilepsy, especially in the early stages of 
epileptogenesis. As such, it might represent a novel target for disease modification in 
epilepsy.  
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4.2 INTRODUCTION 
 
4.2.1 Overview of NMDA receptor and NMDAR-mediated excitotoxicity 
 
The NMDAR acts as a coincidence detector, activated only when the membrane is 
simultaneously depolarized and activated by glutamate, allowing it to reinforce 
signals that are close in space or time. NMDAR, in the open state allows for the 
influx of Ca2+ into the neuron, which can activate numerous downstream targets, 
modulating ion channel kinetics (Derkach et al, 1999), transcription (Malenka & Bear, 
2004) or the trafficking of AMPA receptors to the cell surface (Bredt & Nicoll, 2003). 
The NMDA receptor is a powerful modulator of synaptic plasticity, underlying 
mechanisms of memory. Under pathophysiological conditions however, Ca2+ influx 
through the NMDA receptor has been heavily implicated in mediating excitotoxic cell 
death (Duchen, 2000). NMDAR kinetics can also be modulated by a ligand binding 
site for the amino acid neurotransmitter, glycine, which can act as a co-agonist 
(Danysz & Parsons, 1998) 
 
High levels of glutamate signalling associated with seizures, and particularly, the 
excessive stimulation of NMDA receptors, can lead to a series of potentially 
neurotoxic events (Hellier et al, 2009). The Ca2+ influx, vital to normal signalling, 
when in excessive quantities, can lead to neurodegeneration, the perturbation of 
neural networks, leading to a chronic state of seizure susceptibility (Mody & 
Macdonald, 1995). The clinical utility of general NMDA antagonists, however, is 
reduced by the severe associated side-effects, including psychotropic effects, similar 
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to schizophrenia (Newcomer et al, 1999). Any neuroprotective strategy of potential 
clinical importance must leave physiological NMDA signalling largely intact.  
Although general NMDA receptor antagonists, such as ketamine and MK801 have 
proven extremely problematic in the clinic, the increasing understanding of the extent 
of NMDA receptor heterogeneity has reinvigorated research into potential methods 
for restricting its pathophysiological role. The NR2 subunit content of the NMDA 
receptor defines the receptors’ location on the cell membrane and its 
pharmacological and functional properties (Moyner et al, 1992). Antagonists which 
are subunit selective have been developed and their efficacy in suppressing disease 
progression in a range of CNS pathologies is being explored.  
 
An alternative approach is to target downstream effectors of Ca2+ influx through the 
NMDA receptor. In neurons, Ca2+ influx through NMDARs promotes cell death more 
efficiently than through other Ca2+ channels (Aarts et al, 2002), suggesting that the 
most important proteins responsible for Ca2+-dependent excitotoxicity reside within 
the NMDAR signaling complex (NSC) (Soriano et al, 2008). Two potential 
pharmacological interventions following KA-induced SE in C57BL/6J mice were 
investigated, targetting NMDA receptors containing the NR2B subunit with a 
selective antagonist, (αR,βs)-α-(4-Hydroxyphenyl)-β-methyl-4-(phenylmethyl)–1-
piperidinepropanol maleate (Ro25-6981) and use a selective inhibitor of nNOS, Nw-
propyl-L-arginine to reduce Ca2+ induced NO signalling at excitatory synapses.. 
 
4.2.2 NMDAR subunits 
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NMDARs are tetrameric (some reports have indicated pentomeric) complexes made 
up of a combination of subunits from the groups NR1, NR2 and NR3 (Malherbe et al, 
2003). Of these different groups, there are eight different NR1 subunits, four NR2 
and 2 NR3 subunits. Whereas all NR1 subunits are encoded in a single gene, with 
the diversity stemming from alternative splicing, each NR2 and NR3 subunit is 
independently encoded in the DNA.  The rules of subunit composition in functioning 
NMDARs is incompletely understood, however, it seems that at least one NR1 and 
one NR2 subunit is required. The NR1 subunit provides the glycine binding site and 
the NR2 subunit provides the site for glutamate binding. Data regarding NR3 is 
limited, however, Nishi et al (2001) reported that it can act in a dominant negative 
fashion, while it has also been demonstrated that it can form excitatory channels with 
NR1, activated by glycine (Chatterton et al, 2002). 
 
NMDAR subunits all share a common membrane topology, characterized by a large 
extracellular N-terminus, three transmembrane segments (TM1, 3 and 4), a re-
entrant pore loop (M2), an extracellular loop between TM3 and TM4 and a 
cytoplasmic C-terminus. While the extracellular loop determines the affinity for 
neurotransmitters, the C-terminal is the site of the majority of variation between 
subunits, conferring differences between differently composed receptors in 
distribution, kinetics, interaction with intracellular proteins and physiological function 
(Danysz & Parsons, 1998). The NR1 subunit forms a substrate for the folding of 
other subunits for the formation of the complete receptor, however little is known 
regarding functional differences in NR1 subunit diversity. Of the three subunit 
families, the most completely understood is the NR2 subunit. 
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4.2.3 NR2B and Ro 25-6981 
 
NMDA receptors modulate a wide array of physiological processes through Ca2+ 
signalling. In order for a single molecule to modulate such a diversity of signalling 
pathways within the cell, requires spatiotemporal division. At excitatory synapses, a 
collection of Ca2+-sensitive effector molecules are held in close apposition to the 
NMDAR Ca2+ channel (Soriano et al, 2008) where highly localized Ca2+ IEDs exert 
physiological effects dependent on the identity of effector molecules in the 
microdomain. Ca2+ influx through other routes, such as extrasynaptic NMDA 
receptors effects an entirely different set of signalling pathways with divergent 
physiological functions (Dumas, 2005). 
 
The pharmacology, functionality and location of NMDA receptors is largely 
determined by their NR2 subunit content. NMDA receptors containing NR2B 
subunits are expressed extrasynaptically in adults (Kudryashova, 2007), where they 
mediate neuronal responses to excessive glutamate in the extracellular space as a 
result of ‘spill over’ from the synaptic cleft or release from astrocytes (Pasti et al, 
2001). A role for NR2B-containing extrasynaptic NMDA receptors in mediating 
neuronal death has been reported (Poddar et al, 2010) and NR2B subunit specific 
antagonists have been developed in order to intervene in this pathway without 
disrupting the normal functioning of synaptic NMDA receptors. 
 
Ro25-6981 is a moderate-affinity, uncompetitive and NR2B-selective NMDAR 
antagonist that shared a structural similarity with ifenprodil (Lynch et al, 2001), and 
binds to the allosteric modulatory site on the NR2B leucine/isoleucine/valine binding 
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site (LIVBP) (Malberbe et al, 2003). Positive outcomes have been reported when 
used in animal models of, amongst others migraine (Peeters et al, 2007), 
Alzheimer’s disease  and ischemic brain injury (Wang & Schaib, 2005). The efficacy 
of Ro 25-6981 in modulating the severity of a period of epileptiform behaviour was 
investigated when administered prior to the induction of KA-induced SE. The severity 
of epileptiform behaviour was scored using the Racine scale and the anatomical 
distribution of c-Fos was quantified in the dentate gyrus 2 hours following injection 
with KA. 
 
4.2.4 nNOS and L-NPA 
 
Nitric oxide (NO), a gaseous signaling molecule, was first reported to have a role in 
neurotransmission in the central nervous system (CNS) by Garthwaite et al (1989). It 
has since been ascribed a wide range of neurophysiological functions, including the 
modulation of synaptic plasticity (Yang & Cox, 2007). Importantly, NO is also 
implicated in the pathogenesis of a variety of CNS disorders, including epilepsy 
(Takei, et al., 2001; Pereira de Vasconcelos et al., 2005; Hagioka et al., 2005; 
Kovacs et al., 2009; Kim, 2010; Arhan et al., 2011). NO is catalysed by three 
isoforms of NO synthase (NOS); endothelial (eNOS), inducible (iNOS) and neuronal 
(nNOS), and plays a pleiotropic role in the nervous system which is determined by 
the site of catalysis, NOS isoform and cell type involved. NO, produced by nNOS 
associated with the NSC may mediate much of the neurotoxic effects of excessive 
NMDAR signalling (Bonfoco, et al, 1995). As discussed in Chapter 1, high levels of 
NO production, coupled with the generation of the superoxide anion, O2-, can react 
to form peroxynitrite, (ONOO-) resulting in neuronal damage (Heales et al, 1999).  
 136 
 
 
Using a broad range of in vivo and in vitro models, non-specific NOS inhibition has 
been shown to have a pro-convulsive effect (Takei, 2001; Hagioka, 2005), which 
may be largely attributed to the inhibition of eNOS modulation of local cerebral blood 
flow (CBF) (Pereira de Vasconcelos et al., 2005). Evidence for the role of nNOS in 
seizure generation and/or modulation is less clear, with questionable specificity of 
available inhibitors, (such as 7-nitroindazole and 3-bromo-7-nitroindazole) and 
conflicting reports on the extent of nNOS involvement in CBF regulation (Santizo et 
al., 2000; Pereira de Vasconcelos, 2005).  
 
A recent study has reported an up-regulation of nNOS in the rat hippocampus in 
response to early-life seizures, followed by an nNOS-dependent elevation in seizure 
susceptibility in adulthood (Kim, 2010). This suggests a role for nNOS in the 
epileptogenic process. Kovacs et al (2009) have reported that nNOS inhibition 
reduces seizure-like events in an in vitro hippocampal slice model, although this is 
yet to be tested in vivo. A highly selective nNOS inhibitor would offer an opportunity 
to address this issue. Nw-propyl-L-arginine (L-NPA) has been reported by Zhang et 
al (1997) to have a149- and 3,158-fold greater selectivity (Zhang et al., 1997) over 
eNOS and iNOS, respectively. While various studies have suggested a more modest 
level of selectivity (Boer et al, 2000), used at the correct dose, it nevertheless offers 
a promising method for dissecting the contribution of neuronal NO from other 
sources. This has been exploited in a wide-range of studies of nitric oxide signaling 
pathways (e.g. Romero et al, 2012), but, to our knowledge has not yet been applied 
to an in vivo model of SE.  
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Using a period of KA-induced SE, the effects of L-NPA pre-treatment on epileptiform 
activity in C57BL/6J mice was investigated, in order to elucidate the role of nNOS 
signalling in modulating seizures. Three complementary approaches were employed 
to characterise the severity of SE. Behavioural seizures during SE were scored using 
a modified Racine score (Racine, 1972) and electrographic seizures detected using 
electroencephalography (EEG) recorded with an implanted telemetry device. In 
addition, neuronal activity, activity-dependent synaptogenesis and hippocampal 
gliosis were investigated immunohistochemically, using c-Fos (Samoriski et al., 
1997), synaptophysin, tomato lectin (microglia marker) and glial fibrillary acidic 
protein (GFAP, astrocyte marker) and analysed both qualitatively and semi-
quantitatively. 
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4.3 MATERIALS AND METHODS 
 
4.3.1 Overview 
Information regarding materials and methods described in this chapter refer only to 
that which is specific to this particular study. For general materials and methods, see 
chapter 2 where detailed protocols of methods performed throughout all chapters are 
described, including:  KA administration and behavioural scoring of SE, basic 
protocols used for immunohistochemistry, microscopy and quantification of 
immunohistochemistry, surgical procedures for the implantation of electrodes and 
transmitters and EEG data collection and analysis. For ease of understanding, 
however, some information is duplicated. 
 
4.3.2 Animals 
 
Experiments were performed in 10-12 week old male C57BL/6J mice. All animals 
were purchased from Charles River (UK) and maintained in the Biomedical Services 
Unit, University of Liverpool under controlled environmental conditions (19oC – 23oC, 
12h light: 12h dark), with food and water available ad libitum. All experiments were 
carried out according to Animals (Scientific Procedures) Act 1986 approved by the 
Secretary of State, Home Office, UK and University's Ethical Review Committee. 
 
A total of 60 mice were used in this study. 15 mice were used to test the effects of 
RO 25-6981, in the following treatment groups: dimethyl sulphide (DMSO) only 
(control, n = 5), DMSO + KA (vehicle, n = 5), RO-25 6981 + KA (n = 5) (see below for 
a more detailed description of this protocol). In these mice, epileptiform behaviour 
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was scored using a modified Racine scale for 2 hours after KA injection, before they 
transcardial perfusion for immunohistological analysis of c-Fos expression in the 
dentate gyrus. 
 
Of the remaining 45 mice, 5 mice were used as naïve control animals and 30 mice 
were used for behavioural and immunohistological analysis. In all of these animals, 
pre-treatment of either 20mg/kg L-NPA or an equivalent volume of distilled water 
(DW, vehicle) was administered via i.p injection 30 minutes prior to 20mg/kg KA. 
Mice were perfused at 2 hours post-KA (Vehicle, n = 5, L-NPA, n = 5) or SE was 
terminated with diazepam and mice perfused at 24 (Vehicle, n = 5, L-NPA, n = 5) or 
72 (Vehicle, n = 5, L-NPA, n = 5) hours following KA injection. Of the 10 remaining 
mice, telemetry devices were implanted (as described in chapter 2) and following 
post-operative recovery, were treated in the following groups: L-NPA + KA (n = 5), 
vehicle + KA (n= 5). In implanted mice, seizures were terminated with diazepam 2 
hours following KA injection and EEG was recorded for 7 days. 
 
4.3.3 Drugs, reagents and antibodies  
 
L-NPA (Tocris, UK) was prepared in distilled water (DW) at a concentration of 
5mg/ml and administered i.p at a dose of 20mg/kg. An equivalent volume of DW 
alone was used as a vehicle control. RO 25-6981 (Tocris, UK) was prepared in 
DMSO at a concentration of 2.5mg/ml and administered i.p at a dose of 10mg/kg. An 
equivalent volume of DMSO was used as a vehicle control. 
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Rabbit anti-c-Fos (1:2000) was purchased from Calbiochem (UK) and visualised 
using a CY3-conjugated donkey anti rabbit secondary antibody (1:200). Mouse anti-
NeuN (1:400) was purchased from Chemicon (UK) and visualised using an FITC 
donkey anti-mouse secondary antibody (1:200). Rabbit anti-synaptophysin (1:1000) 
was a gift from Dr P Greengard, Rockefeller University, USA and visualised using a 
CY3-conjugated donkey anti-rabbit antibody (1:200). Mouse anti-GFAP (1:400) was 
purchased from Sigma Aldrich (UK) and visualised using an FITC-conjugated 
donkey anti-mouse secondary antibody (1:200) Biotinylated tomato lectin (1:500) 
was purchased from Sigma Aldrich (UK) and visualised using CY3-conjugated 
streptavidin (1:100). All flourochrome-conjugated secondary antibodies and 
streptavadin were purchased from Jackson Immunoresearch laboratories (UK). DAPI 
used for visualizing cell nuclei was in the Vectashield ® mounting medium (Vector 
Laboratories, UK). 
 
4.3.4 Drug treatment and experimental groups 
 
In the RO 25-6981 study, 10mg/kg RO 25-6981 diluted in DMSO (n = 5) or an 
equivalent volume of DMSO vehicle control (n = 5) was administered, i.p 30 minutes 
prior to i.p injection with KA. Behavioural seizures were scored for 2 hours and mice 
were sacrificed at this timepoint and perfused for immunohistochemical analysis. In 
the L-NPA study, 20mg/kg L-NPA or an equivalent volume of DW was administered 
30 minutes prior to induction of SE with 20mg/kg KA. Again, seizures were scored 
for 2 hours and mice were either sacrificed at 2 hours (vehicle, n = 5; L-NPA, n = 5), 
or seizures were terminated with diazepam (i.m, 10mg/kg) and mice sacrificed at 24 
(vehicle, n = 5; L-NPA, n = 5) or 72 (vehicle, n = 5; L-NPA, n = 5) hours post KA. 
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Mice implanted with telemetry devices for the recording of EEG (vehicle, n = 5; L-
NPA, n = 5) were treated in the same way. Behaviour was assessed in all animals 
(vehicle, n = 20; L-NPA, n = 20). 
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4.4 RESULTS 
 
4.4.1 Ro 25-6981 effect on kainic acid induced epileptiform behaviour 
 
Ro 25-6981 administration prior to KA injection had little discernible effect on the 
severity of KA-induced status epilepticus when compared with mice treated with 
vehicle DMSO (Figure 4.1). The median peak seizure severity in both treatment 
groups was Racine 5 (Figure 4.1a, b), the latency to CMS was slightly reduced with 
Ro 25-6981 treatment, from 45 to 35 minutes (Figure 4.1c), while the duration of 
CMS was slightly increased, from 70 to 90 minutes, suggesting that, if anything, Ro 
25-6981 had a facilitatory effect on seizures. Neither of these effects, however, was 
statistically significant.  
 
4.4.2 Ro 25-6981 effect on SE-induced c-Fos expression 
 
As with behaviour, Ro 25-6981 administration had little or no effect on SE-induced c-
Fos expression in the dentate gyrus (Figure 4.2). c-Fos was expressed in between 
60 and 75% of neurons in the granule cell layer of the dentate gyrus in both 
treatment groups and between 40 and 50% of neurons in the polymorphic and 
molecular layers. Ro 25-6981 treated animals showed a trend towards a decrease in 
c-Fos expression in granule cells and an increase in expression in neurons of the 
polymorphic and molecular layers, however this effect was small and insignificant. 
 
4.4.3 L-NPA has anticonvulsant effect on kainic acid-induced epileptiform 
behaviour 
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Pre-treatment with L-NPA 30 minutes prior to KA-induced SE delayed and reduced 
the severity and duration of epileptiform behaviour (Figure 4.3). The peak severity 
score reached during the two hour period of observation was significantly reduced by 
L-NPA pre-treatment (U = 294.0 p<0.001, Figure 4.3a, b), the latency to onset of 
CMS was increased (t38 = 2.130, p = 0.040, Figure 4.3a, c) and the duration of CMS 
was decreased (t38 = 4.303, p < 0.001, Fig 4.3a, d).   
 
4.4.4 L-NPA pretreatment suppresses SE-induced c-Fos immunoreactivity 
 
In both groups, c-Fos immunoreactivity was largely restricted to dentate granule 
cells, however there was also lower levels of expression in neurons of the 
polymorphic and molecular layers (Figure 4.4a). Expression in the hippocampus, 
subiculum or entorhinal cortex was minimal (data not shown). L-NPA pre-treatment 
reduced the percentage of neurons expressing c-Fos in the DG as a whole by 
approximately 65% (t8 = 10.653, p < 0.001, Fig. 4.4c) at 2h post-KA. This reduction 
was most pronounced in dentate granule cells (~70%) (t8 = 9.273, p < 0.001), 
however, expression was also suppressed in the molecular layer, although no effect 
of L-NPA was found on c-Fos expression in the polymorphic layer. c-Fos expression 
was entirely restricted to neuronal nuclei at this timepoint, with no expression in the 
cytoplasm of either cell bodies, axons or dentrites (Figure 4.4c). 
 
4.4.5 L-NPA reduces the severity of electrographic status epilepticus. 
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Following post-operative recovery, mice behaved normally, with no obvious effect on 
eating, drinking, activity levels, alertness, aggression or signs of discomfort. EEG 
activity was regular, with some changes in amplitude and frequency dependent on 
activity levels (Figure 3.4). L-NPA alone had a mild behavioural effect, with mice 
showing increased alertness, aggression and resistance to handling, in comparison 
with vehicle treated animals; however, this was not accompanied by any discernible 
effect in the EEG (data not shown).  
 
Following the administration of KA, the frequencies of epileptiform discharges in 
vehicle pre-treated mice increased over the initial 20 minutes to a peak of 
approximately 65 epileptiform discharges min-1. In L-NPA pre-treated mice, this 
slope was shallower, with an initial peak reached at approximately 25 minutes, of just 
below 35 epileptiform discharges min-1 (Figure 4.5a). Throughout the entire duration 
of the 2 hour period of induced status epilepticus, L-NPA pre-treated animals had a 
reduced frequency of epileptiform discharges in comparison with animals in the 
vehicle pre-treated group (Figure 4.5a). When split into 30 minute bins, the 
frequency of epileptiform discharges was significantly reduced by L-NPA pre-
treatment for all time points (0 – 30 mins: t8 = 5.946, p < 0.001, 30 – 60 mins: t8 = 
4.480, p = 0.002, 60 – 90 mins: t8 = 5.420, p < 0.001, 90 – 120 mins: t8 = 7.400, p < 
0.001, Figure 4.5b).  
 
From the initial peak, 20 minutes following KA injection, spike frequency in vehicle 
pre-treated animals followed a cyclical pattern, with peaks ranging between 50 and 
70 epileptiform discharges min-1, troughs ranging between 30 and 40 epileptiform 
discharges min-1 and a cycle length of approximately 20 minutes (Figure 4.5a).  The 
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frequency of epileptiform discharges in L-NPA pre-treated animals followed a similar 
cyclical pattern, however, the difference between peaks and troughs was smaller 
(peaks: 30 – 40 epileptiform discharges min-1, troughs: 20 – 30 epileptiform 
discharges min-1) and the cycle lengths were shorter (~10 mins) (Figure 4.6a). While 
in vehicle pre-treated animals, the frequency of epileptiform discharges began to 
decline from around 100 minutes, in L-NPA pre-treated animals, this occurred 
approximately 15 minutes earlier.  
 
In contrast to the frequency of epileptiform dischages, the power distributed in the γ-
band increased steadily in vehicle pre-treated animals from the point of KA 
administration to a peak of 5dB around 90 minutes post injection (Figure 4.6a). In L-
NPA pre-treated animals, a similar pattern was seen, with a peak in γ-band also 
around 90 minutes, however, the peak was considerably lower at around 2dB and 
throughout the entire the 2 hour period, γ-band power was less than 50% of that 
seen in the vehicle pre-treated group. When divided into 30 minute bins, the power 
distributed in the γ-band was significantly lower in L-NPA pre-treated animals for 
every timepoint apart from the first 30 minutes (30 – 60 mins: t8 = 3.135, p = 0.014, 
60 – 90 mins: t8 = 3.664, p = 0.006, 90 – 120 mins, t8 = 4.540, p = 0.002, Figure 
4.6b). 
 
4.4.1 The effects of L-NPA pre-treatment on electrographic seizures during 
early latent period 
 
Following the termination of SE with diazepam and subsequent recovery, no 
epileptic behaviour was observed in any animals during the first 7 days. Diazepam 
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administration 2 hours following KA injection, terminated behavioural indicators of 
epileptic activity, however, although epileptiform spiking was dramatically reduced, it 
was not completely stopped, but reached a nadir of approximately 8 IEDs min-1 in 
vehicle pre-treated mice and 6 IEDs min-1 in L-NPA pre-treated mice (Figure 4.7a, 
b). In both treatment groups, following the initial diazepam-induced sharp decline in 
IED frequency, the IED rate increased approximately 6 hours following diazepam 
injection, presumably as an effect of the reduction in the concentration of the drug 
(Figure 4.7a, black arrow) to approximately 17 IEDs min-1 in vehicle pre-treated 
animals and 12 IEDs min-1 in L-NPA pretreated animals. 
 
During the period from 6 – 12 hours, the frequency of epileptiform spiking was 
between two and three-fold higher in vehicle pre-treated animals than in animals pre-
treated with L-NPA (Figure 4.7a). From 12 hours, the IED frequency in the two 
treatment groups diverged, with Vehicle pre-treated animals showing a steady, or 
slightly increasing rate of firing between 5 and 10 IEDs min-1 between 12 and 40 
hours before declining, while IED frequency in L-NPA pretreated animals continued 
to decline steadily from 12 hours onwards. This period showed the most marked 
difference between the treatment groups throughout the entire 7 day period 
observed following the termination of seizures with diazepam (Figure 5.1a, black 
horizontal line). 
 
IED frequency was lowest in Vehicle pre-treated animals by around 52h post KA 
injection. In L-NPA pretreated animals, this low point occurred around 36h. From 
between 50 and 65h, the IED frequency in both treatment groups began to increase 
again, with a local peak in vehicle pre-treated animals at approximately 5 IEDs min-1 
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and in L-NPA pre-treated animals at approximately 3 IEDs min-1 (Figure 4.7a). From 
approximately 80h post KA until the termination of the experiment at 7d, IED 
frequency remained relatively consistent, with Vehicle pre-treated animals showing 
between 4 and 5 IEDs min-1 and L-NPA pre-treatment suppressing this by 
approximately 2 - 2.5 fold. No obvious circadian effects were observed in the IED 
rate of either treatment group (Figure 4.7a). For all time periods quantified, L-NPA 
reduced the frequency of IEDs (3 – 12 h: t8 = 6.788, p < 0.001. 12 – 48h: t8 = 14.45, 
p < 0.001. 48 – 168h: t8 = 3.907, p = .0045, figure 4.7a). 
 
In summary, L-NPA treatment, prior to KA administration, increased the 
effectiveness of diazepam at reducing the IED rate more quickly in comparison with 
vehicle pre-treated mice (Figure 5.1a). It reduced the subsequent increase in IEDs 
around 6h following the reduced control of epileptiform activity by diazepam (Figure 
5.1b). It decreased the latency for the IED frequency to reduce below 5 IEDs min-1 
by approximately 16 hours (Figure 5.1a) Most importantly, in comparison with 
Vehicle pre-treated mice, L-NPA pre-treatment reduced the IED frequency between 
3 and 7 days post KA injection by 2 – 2.5 fold.  
 
4.4.2 L-NPA pre-treatment reduces gliosis during early latent period.  
 
In view of assertaining L-NPA’s effect beyond acute SE period and to understand 
whether seizure modulation by L-NPA during SE will have an effect on epileptogenic 
events during the early latent period, glial cells and synaptophysin immunostaining 
was examined. At 24h post-KA period, there was no significant difference in 
microglia or astrocyte cell counts in any treatment groups (Figure 4.8f – i), nor was 
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there any qualitative differences in astrocyte or microglial morphology that would 
associate them with an activated state. This suggests, that in the kainic acid model, 
24h is too early to see changes in glial activation associated with seizures. 
 
By 72h, however, qualitative changes in morphology of both astrocytes and microglia 
could be observed in sections from animals of both treatment groups. Astrocytes 
expressed higher densities of GFAP and were hypertrophic (Figure 4.8b, c) and 
many microglia were observed to assume the rod-like ‘activated’ morphology (Figure 
4.8d, e) as described by Kreutzburg (1996). These changes could be seen in stratum 
radiatum and stratum oriens throughout the hippocampus, however the activated 
morphology was not increased in any region of the dentate gyrus (Figure 4.8a). L-
NPA pre-treatment had the effect of suppressing these morphological changes, with 
fewer cells showing an activated morphology (Figure 4.8b, c, d, e). As well as 
qualitative changed in morphology, changes in cell numbers and distribution, 
associated with reactive gliosis were also observed. 
 
72h after KA injection, both astrocytes (Figure 4.8b) and microglia (Figure 4.8d) 
showed a propensity to invade the stratum lucidum and pyramidal cell layer of the 
CA3 region. Further to this, the density of both types of glial cells increased 
throughout the CA3 region, with GFAP-immunopositive cell numbers increasing 
approximately 2-fold (Figure 4.8b, f) and tomato lectin-immunopositive cell numbers 
increasing approximately 3-fold (Figure 4.8d, i). The number of tomato lectin 
immunopositive cells in the CA1 region also increased by approximately 2-fold. L-
NPA pre-treatment suppressed both the tendancy for cell migration to stratum 
lucidum and the pyramidal cell layer of CA3 and the increased number of glia in this 
 149 
 
region, with astrocyte proliferation reduced by close to 50% (t8  = 6.534, p < 0.001 . 
Figure 4.8b, f) and microglial proliferation reduced by approximately 30% (t8 = 5.674, 
p < 0.001 . Figure 4.8d, i). L-NPA had only a minor suppressing effect on microglia 
proliferation in the CA1 region at this timepoint, which was not found to be significant 
with a 95% confidence interval. 
 
4.4.3 Synaptogenesis 
 
High levels of SYN immunoreactivity was constitutively expressed in the polymorphic 
layer of the dentate gyrus and stratum lucidum of the CA3 region of C57BL/6J mice 
(figure 4.9a). 24h following KA administration, no changes in SYN immunoreactivity 
were observed (figure 4.9b). Initial changes in the spatial distribution of SYN 
following KA induced status epilepticus were witnessed at the 72h timepoint. At this 
timepoint, SYN immunoreactivity was elevated in the outer molecular layer of the 
dentate gyrus (t8 = 3.748, p = 0.006. Figure 4.9a, c), suggesting an increase in 
synaptogenesis in this region. This increase was suppressed in animals pre-treated 
with L-NPA. No change in synaptophysin immunoreactivity was observed in the 
stratum lucidum of CA3 or the polymorphic layer of the dentate gyrus in any 
treatment group at this timepoint.   
 
Figure 4.1. NR2B antagonist, Ro 25-6981 shows no effect on severity of Kainic acid-induced status epilepticus. (a) 
Timecourse of behavioural seizure progression over 120 minutes  following kainic acid injection (b) Maximum seizure 
severity reached (Median +/- IQ range . (c) Latency to onset of CMS (≥Racine 3) (d) Duration of CMS.  
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Figure 4.2. NR2B antagonist, Ro 25-6981 has 
no effect on c-Fos expression in the Dentate 
gyrus 2 hours following systemic 
administration of Kainic acid. (a) 
Photomicrographs displaying c-Fos expression 
in Dentate gyrus 2h post KA administration 
with pre-treatment of DMSO vehicle control 
or Ro 25-6981. Magnification: x20. Scale bar: 
(b) Counts of c-Fos immunopositive neurons 
in dentate gyrus displayed as neurons/10 (+/- 
S.E.M). GCL: Granule cell layer; PL: 
Polymorphic layer; ML: Molecular layer. 
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Figure 4.3. L-NPA reduces severity of kainic acid-induced Status epilepticus in C57BL/6J mice (a) Timecourse of 
behavioural seizure progression over 120 minutes  following kainic acid injection (b) Maximum seizure severity reached 
(Median +/- IQ range . *p <0.001 (c) Latency to onset of CMS. **p = 0.040. (d) Duration of CMS. ***p = 0.008 
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Figure 4.4. L-NPA reduces seizure-induced c-Fos expression in dentate granule cells. (a) DAPI and c-Fos in Dentate gyrus. 
Magnification: x20. Scale bar: (b) c-Fos clearly restricted to neuronal nuclei. Number of cells +ve for c-Fos/10. 
Magnification: x 63. Scale bar:  (c) cell counts. *t8 = 10.653, p < 0.001,  **t8 = 9.273, p < 0.001. 
DGG DGG 
Vehicle + KA L-NPA + KA 
DAPI + c-Fos 
(a) (a) 
(b) 
0
1
2
3
4
5
6
7
8
9
10
Total GCL PL ML
Vehicle + KA (n = 5)
L-NPA + KA (n = 5)
N
eu
ro
n
s/
1
0
 c
-F
o
s 
+v
e 
Region of dentate gyrus 
 * ** 
154 
010
20
30
40
50
60
70
80
90
0 10 20 30 40 50 60 70 80 90 100 110 120
Vehicle + KA (n = 5) L-NPA + KA (n = 5)
0
10
20
30
40
50
60
70
80
90
0 - 30 30-60 60-90 90-120
Figure 4.5 L-NPA reduces frequency of epileptiform discharges in C57BL/6J mice during 2 hour period of Status 
epilepticus following injection with kainic acid. (a) Spikes min-1 over initial 2 hours with resolution of 5 minutes. (b) 
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Figure 4.6. L-NPA decreases power (dB) in γ –frequency band during status epilepticus. (a) Timecourse over 2 hours (b) 
Quantified data in 30 minute bins. *t8 = 3.135, p = 0.014. **t8 = 3.664, p = 0.006., ***t8 = 4.540, p = 0.002 
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Figure 4.7. L-NPA pre-treatment reduces 
frequency of IEDs recorded during first 7 
days post kainic acid injection. (a) 
Timecourse of IED frequency for 7 days 
following KA injection. Inset: 48 – 168h at 
higher spike frequency resolution (b) 
Quantified data for. *t8 = 6.788, p < 0.001. 
**t8 = 14.45, p < 0.001. ***t8 = 3.907, p = 
.0045. 
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Figure 4.8. L-NPA supresses gliosis in CA3 region of hippocampus. (a) Astrocytes and microglia in dentate gyrus. 
Magnification 10X, scale bar: 100μm  (b) Astrocytes in CA3 region of the hippocampus .Magnification 10X (scale bar: 
100μm), Magnification 20X (scale bar: μm), Magnification 40X (scale bar: μm)(c) Astrocytes in CA1 region of hippocampus. 
Magnification 10X (scale bar: 100μm), Magnification 20X (scale bar: μm), Magnification 40X (scale bar: μm) (d) Microglia in 
CA3 region of the hippocampus . Magnification 10X (scale bar: 100μm), Magnification 20X (scale bar: μm), Magnification 
40X (scale bar: μm)(e) Microglia in CA1 region of the hippocampus. Magnification 10X (scale bar: 100μm), Magnification 
20X (scale bar: μm), Magnification 40X (scale bar: μm) (f) Astrocyte cell counts in dentate gyrus, CA3 and CA1, 24h post-KA. 
(g) Astrocyte cell counts in dentate gyrus, CA3 and CA1 72h post-KA. *t8  = 6.534, p < 0.001.  (h) Microglia cell counts in 
dentate gyrus, CA3 and CA1, 24h post-KA. (i) Microglia cell counts in dentate gyrus, CA3 and CA1, 72h post-KA. **t8 = 
5.674, p < 0.001. 
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Figure 4.9 L-NPA supresses reactive synaptogenesis in molecular layer of dentate gyrus 72h post KA. (a) 
Photomicrographs of dentate gyrus at 3 levels of magnification: Dentate gyrus 10X (scale bar = 100μm), 20X (scale 
bar = ) and molecular layer of dentate gyrus 40X (scale bar = ) Boxes indicate regions viewed at increased 
magnification  (b) Quantification of SYN staining intensity 24h post-KA (c) Quantification of SYN staining intensity 
72h post-KA. *t8 = 3.748, p = 0.006. 
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4.5 DISCUSSION 
 
4.5.1 Overview 
 
In this chapter, the effects of an NR2B specific antagonist, Ro 25-6981 and a highly 
selective nNOS inhibitor, L-NPA were tested on SE and the effects of L-NPA on 
early neurobiological and electrographic indicators of early epileptogenesis. 
Targetting the NR2B subunit with the antagonist Ro 25-6981 had no effect, or 
perhaps even a slightly pro-convulsive effect on behavioural SE (figure 4.1) and had 
no effect on the anatomical distribution of c-Fos expression in the dentate gyrus 
(figure 4.2) post SE. L-NPA treatment, meanwhile, delayed the onset and reduced 
the severity of KA-induced SE (figure 4.3), suppressed c-Fos expression in the 
dentate gyrus (figure 4.4), reduced electrographic indicators of severe SE (figures 
4.5, 4.6) and reduced the extent of electrographic and neurobiological indicators of 
epileptogenesis in the hippocampus during the ‘latent period’ following KA-induced 
SE (figures 4.7 – 4.9). 
 
The acute effects of L-NPA on SE were characterised by a reduction in; the duration 
of CMS (figure 4.3), the power of the γ-frequency band (20 - 70Hz) EEG (figure 4.6) 
associated with seizure severity, the frequency of epileptiform discharges (figure 
4.5), and a decrease in the expression of c-Fos (figure 4.4), suggesting that nNOS is 
involved in seizure susceptibility and in the manifestation of CMS in the KA model. In 
the early epileptogenic period, L-NPA treatment reduced the frequency of IEDs 
(figure 4.7), suppressed reactive gliosis in the CA3 region (figure 4.8) and reactive 
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synaptogenesis in the OML and MML of the dentate gyrus (figure 4.9) These 
observations might suggest a potential disease-modifying action of L-NPA on the 
epileptogenic process by modulation of the initiating event. 
 
4.5.2 Effect of specific NR2B antagonist, Ro 25-6981 on SE 
 
Pharmacological agents targetting the NMDA receptor have been widely tested for 
their role in controlling seizures and processes underlying epileptogenesis. Although 
numerous agents have proved effective as anticonvulsants, their aberrant side 
effects are too severe for the drugs to be clinically useful (Newcomer et al, 1999). 
Targetting pathophysiological NMDAR signalling, while not disrupting normal 
function could be the key to addressing numerous CNS disorders that involve 
excitotoxicity and neuronal death, such as ischemic or traumatic brain injury and 
temporal lobe epilepsy.  
 
While RO 25-6981 has previously been reported to have a protective effect against 
spontaneous seizures in animal models after a period of epileptogenesis (Wang et 
al, 2004), no effect of the drug was found on epileptiform behaviour during a period 
of KA-induced SE, nor on the subsequent expression of c-Fos in the dentate gyrus. 
NMDA receptors with NR2B subunits have been heavily implicated in excitotoxic cell 
death, making them potential key players in progressive diseases, involving neuronal 
loss, such as chronic epilepsy (Moddel et al, 2005), however, the role of NR2B in 
mediating network excitation directly is not so straight forward. This means that while 
targetting the NR2B subunit may be effective in chronic models of epilepsy, the 
effect prior to an acutely induced seizure is negligible. 
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4.5.3 Hippocampal nNOS and seizures 
 
NO production in the hippocampus increases during seizures as a result of Ca2+-
dependent activation of nNOS in neurons and eNOS in the vascular endothelium (Al-
Ghoul et al., 1995; Kaneko et al., 2002; Cosgrave et al., 2008; Kovacs et al., 2009). 
Conflicting roles for NO in the generation of seizures have been reported, with both 
pro- and anti-convulsant effects described. Periera de Vasconcelos et al (2005) 
reported a reduction in seizure susceptibility due to eNOS-mediated effects on blood 
flow to the epileptic focus, whereas Kovacs et al (2009) reported an exacerbation of 
seizure-like events through nNOS-mediated modulation of synaptic plasticity in a 
hippocampal slice model.  
 
It has been widely reported that membrane-associated nNOS plays a significant role 
in the signal transduction through glutamate receptors (Garthwaite, 1985; Garthwaite 
et al., 1988). Hopper and Garthwaite (2006) showed that phasic NO-signalling 
mediated by nNOS is necessary, in conjunction with a tonic, paracrine NO signal 
from eNOS, for long-term potentiation, a phenomenon that is largely dependent on 
NMDA-receptors. Kovacs et al (2009), eliminating the role of CBF changes by using 
organotypic slices, showed that the same mechanism is involved in the initiation of 
seizure-like events in the hippocampus. 
 
The scaffolding protein, PSD95, associates nNOS with glutamate receptors via PDZ 
domains (Burette et al, 2002) coupling glutamatergic neuronal activity and Ca2+-
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dependent NO formation, allowing transient, autocrine and synaptic NO signaling 
(Namiki et al, 2005). This is important in modulating synaptic transmission, excitatory 
post-synaptic potentials (EPSPs) and LTP. (Hopper & Garthwaite, 2006; Kovacs, et 
al, 2009). Wang et al (2002) reported that NMDA receptors on dentate granule cells 
are involved in regulating synaptic plasticity via perforant path inputs from the 
entorhinal cortex, suggesting the DG granule cell layer as a possible site of action for 
the NMDA-PSD95-nNOS complex.  
 
nNOS, activated during seizures by high levels of Ca2+ influx, may influence seizure 
severity through paracrine, autocrine and synaptic signaling from nNOS anchored at 
the PSD, or all three mechanisms. These results support the findings of Rajesekaran 
(2005), who suggested abnormal nNOS activity as a major trigger for seizure 
generation. Recently, an increase in nNOS expression following early-life seizures 
has been reported (Kim, 2010), which increased susceptibility to spontaneous 
seizures later in life in an nNOS-dependent manner, giving further evidence for how 
nNOS may play a role in the development of chronic epilepsy from a precipitating 
event.  
Robust in vivo evidence to support the proconvulsant effect of nNOS-derived NO, 
however, is lacking. In vivo studies reported thus far have been undermined by the 
use of nNOS inhibitors of questionable specificity, such as 7-nitroindazole, 3-bromo-
7-nitroindazole and 1-[2-(trifluoromethyl)phenyl] imidazole (kaneko et al., 2002). The 
use of L-NPA, which has 149- and 3,158-fold greater selectivity (Zhang et al., 1997) 
for nNOS over eNOS and iNOS, respectively, has allowed us to undertake a more 
reliable characterization of the role of nNOS in both icto- and epilepto- genesis. 
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4.5.4 L-NPA suppresses KA-induced SE reduces epileptogenic changes 
 
Triggered by excessive intracellular Ca2+ and widely used as a marker for excitotoxic 
glutamatergic neurotransmission (Gall et al, 1998), c-Fos expression is considered a 
hallmark of neuronal network activation. The spatiotemporal pattern of expression in 
the hippocampal formation is a reliable and sensitive indicator of seizure severity 
(Samoriski et al., 1997; Willoughby et al., 1997; Vezzani et al., 2000). Our data 
indicates that, in the C57BL/6J strain, c-Fos expression in excitatory circuits is 
largely restricted to dentate granule cells 2h post-SE. The significant reduction of c-
Fos expression in this region associated with L-NPA treatment is consistent with the 
view that our intervention reduced the severity of SE and profoundly reduced the 
exposure of neurons in the region to excitotoxic stress.  
 
Electrographic markers of epileptogenesis include the re-emergence of IEDs 
following an initial post-SE decline in IED frequency (Williams et al., 2009). The 
reduced frequency of IEDs in L-NPA pretreated mice, when compared with vehicle 
pre-treated controls provides evidence that the suppression of neurobiological 
changes associated with epileptogenesis is accompanied by changes in the pattern 
of neuronal network activity. Further work is necessary in order to establish the 
extent to which IED frequency in the first week following KA administration is 
predictive of the onset and pattern of spontaneous recurrent seizures.  
 
Reactive gliosis is a well characterised feature of the early stages of epileptogenesis 
and strongly predictive of neuronal loss and the development of spontaneous 
seizures (Vezzani et al., 2000; 2009; Foresti et al., 2009). The suppression of gliosis 
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in L-NPA treated animals provides strong evidence that the seizure-modulating effect 
is sufficient to prevent pathological neurobiological changes associated with 
neuronal loss and the development of chronic epilepsy. SYN was used as a marker 
of activity-dependent synaptic formation to explore synaptic events occurring in the 
hippocampus and dentate gyrus during the early epileptogenic period. As described 
in the previous chapter; following a period of KA-induced SE, C57BL/6J mice show 
signs of reactive synaptogenesis in the molecular layer of the dentate gyrus. This 
appears to long precede the aberrant sprouting of mossy fibres and presumably 
indicates a strengthening of inputs from the perforant path. The suppression of early 
synaptogenesis in this region in L-NPA pretreated animals is further evidence of the 
drug’s considerable disease-modifying effect.  
 
4.5.5 Conclusions 
 
We present data demonstrating a strong disease modifying effect of L-NPA when 
administered as a pre-treatment prior to KA-induced SE. To our knowledge, this is 
the first study to have investigated the effect of an nNOS inhibitor on ictogenesis and 
charted the subsequent effect of the initial intervention on neurobiological and 
neurophysiological indicators of subsequent disease progression. The severity of SE 
was dramatically reduced, leading, in turn, to a reduced expression of a wide range 
of biomarkers of epileptogenesis at 2h, 24h, 72h and for the first 7 days following KA 
administration. Our data support the hypothesis that nNOS plays a facilitatory role in 
seizure generation and may represent a target for novel disease-modifying 
therapies. 
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Chapter 5. Incremental dosing of kainic acid and 
pharmacological interventions in the post-synaptic density 
and iNOS 
 
5.1 ABSTRACT 
 
In this chapter, the development of an incremental dosing regimen for kainic acid 
administration is reported in order to induce status epilepticus with a greater inter-
animal uniformity and increase the duration of severe status epilepticus without 
increasing the mortality rate. By comparing the effects on status epilepticus and the 
early ‘latent period’ this method was found to be preferable to the administration of a 
single dose of KA for modeling TLE in inbred mouse strains commonly used as 
background for genetic manipulations. In particular, C57BL/6J. 
 
We then used this incremental dosing regimen to carry out pilot studies to investigate 
the value of two separate potential interventions of the progression of 
epileptogenesis and the development of chronic epilepsy, using indicators of disease 
progression during the ‘latent period’. A cell permeable peptide, Tat-NR2B9c was 
injected intravenously directly after the termination of status epilepticus with 
diazepam and the effects on gliosis at 3 days post-status epilepticus were 
investigated. 1400W, a specific inhibitor of the inducible isoform of nitric oxide 
synthase was administered and neuronal cell loss and the anatomical distribution of 
nNOS were investigated at 7 and 14 days post-status epilepticus. In both studies, 
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the frequency of epileptiform discharges was also analysed for 7 days following the 
induction of status epilepticus.  
 
We report that Tat-NR2B9c reduced the frequency of epileptiform discharges during 
the ‘latent period’, possibly as a result of modulating network activity directly 
following the termination of behavioural seizures with diazepam. Tat-NR2B9c also 
had a minor effect of reducing gliosis at 3 days post-SE. 1400W slightly reduced the 
frequency of epileptiform discharges between 3 and 7 days post-SE and reduced the 
proliferation of nNOS immunopositive neurons 14 days post-SE.  
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5.2 INTRODUCTION 
 
5.2.1 Incremental dosing regimen 
 
The presence of a latent period between the first manifestations of seizures and the 
emergence of chronic epilepsy offers a potential window for therapy. While it is 
informative to investigate the effects of potential disease-modifying pharmacological 
agents administered prior to the induction of SE, treatments that are effective in 
suppressing disease progression when administered after an IPI could be of far 
greater clinical value. The control of epilepsy in the clinic suffers from a shortage of 
tools for suppressing disease progression, with the majority of effective interventions 
targeted the symptoms of epilepsy, rather than disease progression (see chapter 
1.6). 
 
In order to investigate the efficacy of treatments administered post-seizure, 
pharmacological agents used in animal models must be shown to be effective in 
controlling the progression of epileptogenesis when administered after an IPI. In 
order to achieve this, the variability in the severity of epileptiform behaviour must be 
reduced as much as possible in SE models. Further, the severity of the initial insult 
should be maximized in order to increase the potential for suppression without 
increasing mortality. While the dose of kainic acid, per se, may be important in 
determining the outcome, it is likely that the severity and duration of the period of 
status epilepticus is of greater importance.  
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For this reason, an incremental dosing regimen was developed in order to titrate the 
dose of kainic acid by behavioural response. In this way, the severity of seizure can 
be standardised, maximized, while at the same time the mortality of animals can be 
minimized. The effects on behavioural indicators of seizure severity were compared, 
hippocampal c-Fos expression post-SE and EEG both during the period of KA-
induced SE and for a 7-day period following. This model was then used in two pilot 
studies to test the efficacy of pharmacological agents administered following the 
termination of status epilepticus with diazepam. Two separate molecular signalling 
pathways that may be involved in mediating epileptogenesis were investigated.  
 
5.2.2 PSD-95 and Tat-NR2B9c 
 
The NMDA receptor is heavily implicated in mediating excitotoxic and inflammatory 
processes post-seizure and though treatments that target this molecule have proven 
effective at suppressing seizures, the side effects associated with NMDA antagonism 
have meant that the drugs are largely unsuitable for disease control (Newcomer et 
al, 1999). A range of pharmacological therapies that target specific subunits of the 
NMDA receptor (see chapter 4) or signalling pathways downstream of the NMDA 
receptor have been investigated (Koponen et al, 2000). The NMDA receptor exists 
within a multiprotein signalling complex known as the post synaptic density (PSD). 
There is considerable interest in elucidating the molecular mechanisms that controls 
synaptic targeting and trafficking of glutamate receptors, particularly because of their 
role in the induction and expression of various forms of synaptic plasticity underlying 
myriad functions in the CNS, including memory formation and also important in the 
pathogenesis of epilepsy (Malenka & Nicholl, 1999).  
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Most populous amongst the myriad proteins involved with organising the structure of 
the PSD is the post-synaptic density protein 95 (PSD-95), with between 200 and 300 
molecules of PSD-95 present at in an average PSD (Chen et al, 2005). Alternatively 
referred to as synapse-associated protein-90, PSD-95 is a member of the 
membrane-associated guanlylate kinase (MAGUK) family (Oliva et al, 2012), 
encoded by the disks large homolog 4 (DLG4) gene (Cho, et al, 1992). PSD-95 
couples the NMDA receptor to intracellular proteins and signaling enzymes, including 
nNOS. This spatial coupling is a vital component of signalling cascades, but is also 
important for the signalling pathways underlying excitotoxicity. It therefore represents 
an opportunity to disrupt potentially pathophysiological aspects of NMDAR-signalling. 
 
NMDARs are anchored in the PSD by interactions between the cytoplasmic C-
terminal tails of their NR2 subunits and the PDZ domains of PSD-95, an abundant 
PSD protein that forms a two-dimensional lattice immediately under the postsynaptic 
membrane. The PDZ domains of PSD-95 bind to other postsynaptic membrane 
proteins, including potassium channels, tyrosine kinases, cell adhesion molecules, 
stargazin, which is involved in AMPAR trafficking (Tomita et al, 2005), shank, which 
forms a polymeric network structure with homer and regulates the maturation of 
dendritic spines (Hayashi et al, 2009), nNOS, as discussed in previous chapters,  
and many other proteins involved in both the maintenance of structural integrity of 
the synapse, trafficking receptors to and from the post-synaptic membrane and 
transducing signals from the synapse into the cell body. PSD-95 functions as a 
scaffold to assemble a specific set of signaling proteins around the NMDAR, with 
multiple domains that bind to a variety of cytoplasmic proteins.  
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PSD-95 forms multimers, mediated by N-terminal interactions (Hsueh & Sheng, 
1999). The multimerization of the PDZ scaffolds enhances clustering of specific 
assemblies of proteins in the PSD. The role that PSD-95 plays in clustering 
scaffolding and signalling proteins in the PSD is important in the maturation and 
strengthening of excitatory synapses (Kim et al, 2007). Of particular importance to 
epilepsy is the role that PSD-95 plays in facilitating the function of various proteins 
involved in transducing the molecular signalling pathways from Ca2+ influx through 
the NMDAR. Of particular note, PSD-95 holds nNOS in close apposition to the 
NMDAR pore, coupling NMDAR activation with NO production. Further, PSD-95 
plays an important role in recruiting AMPA receptors to the synapse. 
 
The use of pharmacological antagonsits is of limited clinical benefit because of the 
severity of side effects, while PSD-95 knockout mice show a severe phenotype, due 
to the disordered nature of excitatory synapses (Chen et al, 2011), specifically 
targetting subsets of NMDARs selected by subunit composition has proved to have 
greater potential. Another route to tackling NMDAR-mediated excitotoxicity 
associated with TLE is by disrupting the interaction between NMDARs and PSD-95, 
and thereby weakening the cellular response to Ca2+ influx though the NMDAR 
channel.  
 
Aarts et al (2002) developed a cell permeable peptide that targets the PDZ domain 
of PSD-95 and dissociates it from NR2 subunits of the NMDA receptor, thereby 
decoupling signalling pathways that link Ca2+ influx through the receptor with 
enactors of neuronal death, whilst largely preserving other functionalities of the 
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NMDA receptor in modulating synaptic plasticity. This cell permeable peptide, Tat-
NR2B9c has been used by Aarts et al (2002) and other authors (Cook et al, 2012) in 
models of neurodegenerative diseases and has proven to be strongly 
neuroprotective in a range of animal models of CNS pathology without exhibiting the 
aversive side effects associated with NMDA antagonists. In this study, the effects of 
post-SE administration with Tat-NR2B9c on epileptogenesis was investigated, 
investigating the frequency of IEDs during the ‘latent period’ (0 – 7 days post-SE) 
and on gliosis at three days post-SE. 
 
 
5.2.3 iNOS and 1400W 
 
NO acts via multiple downstream signalling mechanisms, depending on the 
concentration, with low concentrations being neuroprotective and mediating 
physiological signalling (e.g., neurotransmission or vasodilatation), whereas higher 
concentrations mediate immune/inflammatory actions and are neurotoxic. 
Nanomolar concentrations of NO are generated by eNOS and nNOS, whereas iNOS 
can produce micromolar levels in response to proinflammatory stimuli. Because 
iNOS production of NO is more clearly correlated with the progression of 
neuroinflammatory diseases and its expression is delayed following insult, the 
specific targetting of this isoform represents an attractive target for therapeutic 
intervention in the disease progression of chronic epilepsy. 
 
While the role of Ca2+/Calmodulin-dependent nitric oxide signalling has been 
extensively studied in epilepsy (Takei, et al., 2001; Pereira de Vasconcelos et al., 
2005; Hagioka et al., 2005; Kovacs et al., 2009; Kim, 2010; Arhan et al., 2011), the 
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inducible isoform has been largely neglected. Strong evidence exists for a huge 
upregulation of iNOS expression following seizures (Zheng, et al, 2010). There is 
also strong evidence that iNOS inhibition can significantly improve the pathological 
outcomes in animal models of a range of CNS pathologies (Parmentier et al, 1999; 
Sennlaub et al, 2002; Jafarian-Tehrani et al, 2005; Montezuma et al, 2012).  
Most NOS inhibitors described to date have been analogs of the NOS substrate, L-
arginine (Garvey, 1997), such as N-(G)-L-arginine methyl ester (L-NAME), L-NG-
Nitro arginine (L-NOARG) (Moore et al, 1990) or L-NPA, as already discussed in 
previous chapters. iNOS specific inhibitors also include L-arginine analogs such as 
N6-(1-iminoethyl)-L-lysine (L-NIL) (Moore et al, 1994). Other specific iNOS inhibitors 
include S- substituted isothioureas, such as S-methylisothiourea (SMT) (Southan et 
al, 1995), cyclic amidine derivatives, such as (1S,5S,6R,7R)-7-Chloro-3-imino-5-
methyl-2-azabicyclo[4.1.0]heptane hydrochloride (ONO-1714) (Naka et al, 2000), 
aminoguanidine (AG) (Griffiths et al, 1993) and 2-amino-5,6-dihydro-6-methyl-4H-
1,3-thiazine (AMT) (Nakane et al, 1995). 
N-[3-(aminomethyl)benzyl]acetamide (1400W) dihydrochloride is a potent, slow, 
tight-binding, inhibitor of inducible isoform of NOS and is described by Garvey, et al 
(1997) as the most selective discovered, with 5000- and 200- fold selectivity over 
endothelial and neuronal isoforms, respectively. 1400W is the iNOS inhibitor most 
widely used as an experimental tool and has previously been shown to ameliorate 
the pathogenesis associated with traumatic brain injury (Jafarian-Tehrani, et al, 
2005), ischaemic brain injury (Parmentier, et al, 1999), depression (Montezuma, et 
al, 2012) and ischaemic proliferative retinopathy (Sennlaub, et al, 2002) in in vivo 
animal models.  
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Despite the promise of this potential intervention, to our knowledge, no similar 
studies have been carried out using a kainic acid model of epileptogenesis in mice. 
1400W was administered after the termination of SE with diazepam, with regular 
treatments given over the first three days post-SE. The effect of inhibiting iNOS on 
electrographic indicators of epileptogenesis over the first 7 days post-SE was 
investigated and on neuronal loss and nNOS proliferation at 7 and 14 days.  
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5.3 MATERIALS AND METHODS 
 
5.3.1 Overview 
 
Information regarding materials and methods described in this chapter refer only to 
that which is specific to this particular study. For general materials and methods, see 
chapter 2 where detailed protocols of methods performed throughout all chapters are 
described, including:  KA administration and behavioural scoring of SE, basic 
protocols used for immunohistochemistry, microscopy and quantification of 
immunohistochemistry, surgical procedures for the implantation of electrodes and 
transmitters and EEG data collection and analysis. For ease of understanding, 
however, some information is duplicated. 
 
5.3.2 Animals 
 
Experiments were performed in 10-12 week old male C57BL/6J mice. All animals 
were purchased from Charles River (UK) and maintained in the Biomedical Services 
Unit, University of Liverpool under controlled environmental conditions (19oC – 23oC, 
12h light: 12h dark), with food and water available ad libitum. All experiments were 
carried out according to Animals (Scientific Procedures) Act 1986 approved by the 
Secretary of State, Home Office, UK and University's Ethical Review Committee. 
 
A total of 47 mice were used for studies reported in this chapter. 20 mice were 
implanted with telemetry devices for the recording and transmitting of EEG from 
electrodes placed below the skull. Of these, 5 were given a single dose of 20mg/kg 
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KA and the remaining 15 subjected to an incremental KA dosing schedule, titrated 
according to behaviour and described below. Following the termination of seizures 
with diazepam, the 15 incrementally dosed mice were put into one of four treatment 
groups: Tat-NR2B9c (n = 4), Tat-NR2B9c placebo (n = 3), 1400W (n = 4) or DW 
vehicle (n = 4). Specifics of the treatment regimen for these mice is described below. 
 
The remaining 27 mice were used for immunohistochemistry. Of these, 5 were used 
as naïve controls, and did not receive KA. The other 22 mice were given incremental 
doses of KA according to the protocol described below, and then treated accordingly: 
Tat-NR2B9c, sacrificed at 3 days (n = 4), Tat-NR2B9c-placebo, sacrificed at 3 days 
(n = 4), 1400W, sacrificed at 7 days (n = 3), DW vehicle sacrificed at 7 days (n = 3), 
1400W, sacrificed at 14 days (n = 4), DW vehicle sacrificed at 14 days (n = 4). 
 
5.3.3 Drugs, reagents and antibodies 
 
Tat-NR2B9c (gift from Dr M. Tymianski, University of Toronto) was prepared in 
saline at a concentration of 5mg/ml and delivered by intravenous injection into a tail 
vein at a dose of 7.8mg/kg. An inert peptide with structural similarities was 
administered via the same route and employed as a vehicle control. 1400W (Tocris, 
UK) was diluted in distilled water at a concentration of 20mg/ml and administered via 
i.p injection at a dose of 50mg/kg. 
 
Sheep anti-nNOS (1:2000) was a gift from Dr P.C. Emerson and visualised using a 
CY3-conjugated donkey anti-sheep antibody (1:200). Mouse anti-NeuN (1:400) was 
purchased from Chemicon (UK) and visualised using an FITC donkey anti-mouse 
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secondary antibody (1:200). Mouse anti-GFAP (1:400) was purchased from Sigma 
Aldrich (UK) and visualised using an FITC-conjugated donkey anti-mouse secondary 
antibody (1:200) Biotinylated tomato lectin (1:500) was purchased from Sigma 
Aldrich (UK) and visualised using CY3-conjugated streptavidin (1:100). All 
flourochrome-conjugated secondary antibodies and streptavadin were purchased 
from Jackson Immunoresearch laboratories (UK). DAPI used for visualizing cell 
nuclei was in the Vectashield ® mounting medium (Vector Laboratories, UK). 
 
5.3.4 Incremental dosing protocol 
 
Mice were given repeated doses of KA and behaviour closely monitored. An initial 
dose of 10mg/kg KA was administered. 30 minutes later, a further 5mg/ml was given. 
This dose was repeated at 30 minute intervals until the first class II seizure. 
Behaviour was scored for a 2 hour period from this point. 2 hours from the first class 
III seizure, SE was terminated with diazepam (10mg/kg, i.m).  
 
5.3.5 Tat-NR2B9c & 1400W administration 
 
Tat-NR2B9c is a peptide comprising the nine COOH-terminal residues of NR2B  
(Lys-Leu-Ser-Ser-Ile- Glu-Ser-Asp-Val, fused to the cell-membrane transduction 
domain of the human immunodifficiency virus-type 1 (HIV-1) Tat protein (Tyr- Gly-
Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg- Arg) (Aarts et al, 2002). Tat-NR2B9c (or Tat-
NR2B9c-placebo) was administered in our studies immediately following the 
termination of SE with diazepam, with a dose of 7.8mg/kg being injected directly into 
the tail vein. 50mg/kg 1400W (or equivalent volume of DW in vehicle controls) was 
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administered immediately following the termination of SE with diazepam. A further 
dose of 50mg/kg was administered every 24 hours for 3 days.  
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5.4 RESULTS 
 
5.4.1 Behaviour following incremental dosing of kainic acid 
 
Mice were given a dose of 10mg/kg KA, followed by a further 5mg/kg every 30 
minutes until convulsive motor seizures were observed (Racine 3), at which point 
treatment did not continue. Of all the mice given this treatment, 100% showed full 
tonic-clonic seizures, while there was 0% mortality. The median dose given was 
25mg/kg, with a range between 15 and 35mg/kg, meaning that, while all animals had 
an identical duration of complex motor seizures, the duration from the administration 
of the initial dose of KA to the termination of status epilepticus with diazepam ranged 
from 150 minutes to 240 minutes.  
  
5.4.2 c-Fos expression following status epilepticus induced by incremental 
doses of kainic acid 
 
In both animals treated with 20mg/kg KA and animals given an incremental dosing 
regimen to titrate dose according to behaviour, c-Fos expression was highest in the 
granule cell layer of the dentate gyrus. Expression in this region was moderately 
higher in animals given a single dose (figure 5.1a, b), however, the most notable 
difference in the distribution of c-Fos between the two treatment groups was in the 
excitatory circuitry of the hippocampus. While animals given a single injection 
showed low and variable expression of c-Fos in the pyramidal cell layer of CA3 and 
CA1, with between 5 and 10% of pyramidal neurons c-Fos positive in CA3 and 
around 10% in CA1, animals undergoing an incremental dosing regimen showed c-
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Fos expression in between 30 and 35% of pyramidal neurons in CA3 and between 
35 and 40% in CA1 (pyramidal cells in CA3: t8 = 5.782, p < 0.001, pyramidal cells in 
CA1: t8 = 5.431, p < 0.001, figure 6.1a, c, d). In the stratum radiatum and stratum 
oriens of the CA1 region of both treatment groups, c-Fos expression was observed 
in around 10% of neurons, while in the CA3 region, incrementally dosed animals 
showed an approximately 25% increase in the percentage of neurons expressing c-
Fos in stratum oriens and a 75% increase in stratum radiatum (Figure 6.1a, d). 
 
5.4.3 Comparison between electrographic status epilepticus induced with 
bolus injection and incremental dosing regimen of kainic acid 
 
In animals given an incremental dosing regimen, the analysis of status epilepticus 
began at the point at which complex motor seizures were first observed. Spike 
frequency was initially around 40 spikes min-1, increasing to a peak of between 65 
and 75 spikes min-1, which was similar to the initial peak observed in animals given a 
single injection (figure 5.2a). While the spike frequency during status epilepticus in 
mice given a single injection followed a cyclical pattern with peaks and troughs, 
incrementally dosed animals showed a steadier spike rate, remaining between 50 
and 70 spikes min-1 from around the 20 minute mark to 80 minutes when the spike 
rate began to decrease (figure 5.2a). In each 30 minute bin for the first 90 minutes 
post-KA, incrementally dosed mice showed a spike frequency significantly higher 
than mice receiving a single injection (0 – 30mins: t18 = 3.811, p = 0.005; 30 – 60 
mins: t18 = 2.525, p = 0.035; 60 – 90 mins: t18 = 3.144, p = 0.014, figure 5.2b). 
 
189 
 
While mice receiving a single injection of kainic acid showed a steadily increasing 
power distributed in the γ-frequency band, reaching a peak at around 90 minutes, 
incrementally dosed animals showed a greater level of power in the γ-frequency 
band power throughout the two first 90 minutes of observation (0 – 30 mins: t18 = 
10.889, p < 0.001; 30 – 60 mins: t18 = 7.769, p < 0.001, 60 – 90 mins: t18 = 4.237, p < 
0.001). This variation suggests that γ-frequency power is more strongly related to the 
time since the initial dose of kainic acid, rather than the severity of seizures, as these 
animals showed a fairly pattern of behaviour (figure 1.1a). 
 
5.4.4 Comparison of EEG during latent phase between animals receiving 
bolus injection and incremental dosing regimen of kainic acid 
 
Following termination of SE with diazepam, no behavioural seizures were observed 
either in animals receiving a single dose of kainic acid or in animals given an 
incremental dosing regimen over the first 7 days. Animals undergoing an incremental 
dosing regimen had a higher frequency of epileptiform spikes throughout the first 36 
hours of recording post KA injection and from around 3 days to the end of the 7th 
day period of recording. Between 36 and 72 hours, the frequency of epileptiform 
spiking between the two treatment groups converged (figure 5.3a).   
 
The timecourse of spike frequency over the first 7 days in mice treated with a single 
dose of kainic acid has been described in previous chapters. In incrementally dosed 
animals, the spike frequency at the point of diazepam administration was 
approximately 2-fold higher (figure 5.3a), and the suppression of epileptiform spikes 
by diazepam was less effective. While in mice treated with a single dose, 
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epileptiform spikes had decreased to around 10 spikes min-1, 2 hours after diazepam 
injection, in incrementally dosed animals, the spike rate was still around 80 spikes 
min-1 at this timepoint (figure 5.3a).  
 
While at around 6 hours following diazepam injection, mice treated with a single 
dose of kainic acid showed an increase in spike rate, up to around 15 spikes min-1, 
(presumably as a consequence of decreasing brain concentrations of diazepam), at 
this timepoint, the frequency of epileptiform spiking in incrementally dosed mice 
plateaued at around 60 spikes min-1. From around 8 hours post injection, the spike 
rate continued to decline steeply before plateauing again at around 20-25 spikes 
min-1 at approximately 15 hours post kainic acid injection (figure 5.3a). From 
approximately 20 hours post injection, the spike rate in incrementally dosed mice 
decreased steadily and the spike rate of mice from both treatment groups converged 
at around 40 hours at approximately 10 spikes min-1. 
 
The frequency of epileptiform spikes both decreased from 40 hours post injection to 
approximately 58 hours post injection, where it dropped to around 1 spike min-1 in 
both treatment regimen. At this timepoint, the frequency of epileptiform spikes in 
incrementally dosed animals increased sharply to approximately 6 spikes min-1 at 60 
hours, dropped to around 4 spikes min-1 at around 60 hours, before increasing again 
reaching approximately 8 spikes min-1 at around 72 hours. In contrast, in animals 
receiving a single dose of kainic acid, the spike frequency gradually increased from 
around 1 spike min-1 at 60 hours to approximately 4 spikes min-1 at 72 hours.  
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In both treatment groups, the spike frequency between 72 hours and 7 days 
remained relatively constant, at approximately 8 spikes min-1 in incrementally dosed 
animals and 4 spikes min-1 in animals receiving a single dose of kainic acid (figure 
5.3a). When the 7 day period of recording was split into bins of 3 – 12 hours, 12 – 48 
hours and 48 – 168 hours, incrementally dosed animals showed a higher spike 
frequency than animals receiving a single dose at between 3 and 48 hours (3 – 12h: 
t7 = 7.109, p 0.002, 12 – 48h: t7 = 3.614, p = 0.009, figure 5.3a), however, though 
spike frequency was higher in incrementally dosed animals from 48h – 168h, the 
difference was not statistically significant at the 0.05 level. 
 
5.4.5 Effect of Tat-NR2B9c treatment on epileptiform spike frequency in 7 day 
period following kainic acid induced status epilepticus 
 
Following the termination of status epilepticus with diazepam and the administration 
of either placebo or Tat-NR2B9c, mice in both treatment groups showed no 
behavioural seizures for the first 7 days. In animals treated with Tat-NR2B9c, the 
decline in spike frequency associated with diazepam administration was steeper, 
suggesting that Tat-NR2B9c had a facilitatory or complementary effect on the action 
of diazepam (figure 5.4a). While in placebo treated animals, Rather than sharp 
reduction in spike rate, followed by an increase as the drug concentration reduced, 
as seen in animals given a single dose, incrementally dosed animals showed a 
shallow decline in spike frequency, followed by a plateauing from around 6 hours at 
approximately 60 spikes min-1 (figure 5.4b).  
 
192 
 
From around 12 hours post-KA, spike frequency again decreased sharply to 
approximately 30 spikes min-1 by the 24 hour point. Spike frequency continued to 
steadily decline until it reached around 15 spikes min-1 at around 36 hours post-KA, 
from where it remained at approximately this frequency for remainder of the 7 day 
recording period (Figure 6.4b, c).Throughout the entire 7 day period recorded, Tat-
NR2B9c treated mice had a reduced frequency of epileptiform spikes, in comparison 
with placebo-treated controls, however, this difference was only statistically 
significant at the level of 0.05 for the first 12 hours post KA: 3 – 12 hours: t5 = 3.438, 
p = 0.019 (figure 5.5b, e). 
 
5.4.6 Effect of Tat-NR2B9c treatment on gliosis in hippocampal formation 
during latent phase 
 
In view of assertaining L-NPA’s effect beyond acute SE period and to understand 
whether seizure modulation by L-NPA during SE will have an effect on epileptogenic 
events during the early latent period, glial cells and synaptophysin immunostaining 
was examined. At 24h post-KA period, there was no significant difference in 
microglia or astrocyte cell counts in any treatment groups (Figure 5.5f – i), nor was 
there any qualitative differences in astrocyte or microglial morphology that would 
associate them with an activated state. This suggests, that in the kainic acid model, 
24h is too early to see changes in glial activation associated with seizures. 
 
By 72h, however, qualitative changes in morphology of both astrocytes and microglia 
could be observed in sections from animals of both treatment groups. Astrocytes 
expressed higher densities of GFAP and were hypertrophic (Figure 5.5a) and many 
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microglia were observed to assume the rod-like ‘activated’ morphology (Figure 5.5b) 
as described by Kreutzburg (1996). These changes could be seen in stratum 
radiatum and stratum oriens throughout the hippocampus, however the activated 
morphology was not increased in any region of the dentate gyrus (Figure 5.5a). L-
NPA pre-treatment had the effect of suppressing these morphological changes, with 
fewer cells showing an activated morphology (Figure 5.5b, c, d, e). As well as 
qualitative changed in morphology, changes in cell numbers and distribution, 
associated with reactive gliosis were also observed. 
 
72h after KA injection, both astrocytes (Figure 5.5b) and microglia (Figure 5.5d) 
showed a propensity to invade the stratum lucidum and pyramidal cell layer of the 
CA3 region. Further to this, the density of both types of glial cells increased 
throughout the CA3 region, with GFAP-immunopositive cell numbers increasing 
approximately 2-fold (Figure 5.5b, f) and tomato lectin-immunopositive cell numbers 
increasing approximately 3-fold (Figure 5.5d, i). The number of tomato lectin 
immunopositive cells in the CA1 region also increased by approximately 2-fold. Tat-
NR2B9c had a small effect towards suppressing the proliferation of astrocytes and 
microglia, however, this effect was not significant in any region of the hippocampal 
formation investigated. 
 
5.4.7 Effect of 1400W treatment on EEG recorded during latent phase 
 
Following the termination of status epilepticus with diazepam and the administration 
of either DW or 1400W, mice in both treatment groups showed no behavioural 
seizures for the first 7 days. 1400W had no effect on the frequency of IEDs for the 
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first 48 hours following SE. When the spike rate increased again between the second 
and third day post-SE, 1400W appeared to suppress epileptiform spiking, reducing 
the frequency by approximately 50%, however this was not statistically significant at 
the 0.05 level. 
5.4.7 Neurodegeneration at 7 and 14 days post-seizure 
 
At 7 days post-seizure, no evidence of neuronal loss was found, however after 14 
days, neurons in the pyramidal cell layer of the hippocampal CA3 region were 
sparser (figure 5.7a – c). Cell counts revealed a small drop in numbers of neurons 
stained with NeuN (figure 5.7d) and cresyl violet (figure 5.7e). 1400W administration, 
however, had no detectable neuroprotective properties in this model.  
 
5.4.8 Distribution of nNOS immunopositive neurons at 7 and 14 days post-
seizure 
 
7 days following KA-induced SE, no detectable changes in the anatomical 
distribution of nNOS immunopositive neurons were found in the hippocampal 
formation. By 14 days post-SE, however, a notable proliferation of nNOS 
immunopositive neurons was observed (figure 5.8). nNOS positive neurons 
increased in numbers most strikingly in the polymorphic layer of the dentate gyrus 
(F10 = 7.0094, p = 0.0125, figure 5.8a, d) and the stratum radiatum of CA3 (figure 
5.8a, d). Control regions of the brain with high densities of nNOS were 
photographed, including the thalamus and the arcuate nucleus. In these regions, no 
changes in nNOS distribution were witnessed, suggesting that the SE-induced 
increase is local and specific. 
Figure 5.1.  c-Fos expression is more 
widespread in hippocampal formation 
following incremtal dosing of KA (a) 
Photomicrographs. Magnification: 10X, scale 
bar: 100μm (b) Quantification of c-Fos 
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5.5 DISCUSSION 
 
5.5.1 Overview 
 
In this chapter a dosing regimen has been developed for the administration of KA 
to induce SE in mice, injecting the drug in incremental doses, titrated according 
to the development of epileptic behaviour and terminating SE with diazepam two 
hours after the first expression of class III seizures. This method was assessed 
by quantifying behavioural and electrographic indicators of SE severity and 
analyzing the distribution of hippocampal c-Fos expression. It is reported that the 
method could reliably induce SE with a prolonged period of repeated class IV and 
class V seizures, accompanied with an increased frequency of epileptiform 
spiking and an increased power of γ-frequency recorded by electrodes placed 
under the skull. Hippocampal c-Fos expression was also more widespread in the 
excitatory circuitry of the hippocampal formation than in seizures induced with a 
single dose of KA. The method was also associated with a zero mortality rate in 
the animals tested.  
 
Analysis of electrographic and neurobiological changes post-SE revealed that 
this method of induction could more reliably induce indicators of epileptogenesis, 
including reactive gliosis, synaptogenesis, neurodegeneration and nNOS 
proliferation and could prove to be a superior model of temporal lobe epilepsy in 
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inbred mouse strains, such as C57BL/6J, which have previously been reported 
as being largely resistant to epileptogenesis.   
 
Further, the incremental dosing regimen has been employed to perform pilot 
studies with low numbers of animals to investigate the potential of two 
pharmacological agents in suppressing disease progression, when administered 
after the period of KA-induced SE. A peptide, Tat-NR2B9c, targeted at the PDZ 
domains of PSD-95 and an iNOS inhibitor, 1400W were used to inhibit two 
signalling pathways thought to be key modulators of the inflammatory response. 
Tat-NR2B9c offered some limited suppression of gliosis at three days post-SE 
and suppressed the frequency of IEDs during the first 7 days post SE. 1400W, 
meanwhile, had little effect on either  neuronal loss at 7 or 14 days, or on the 
distribution of nNOS at 14 days post SE.  
 
5.5.2 Incremental dosing regimen  
 
Two main reasons exist for developing an incremental dosing regimen for KA 
administration in favour of a single injection. Firstly, it affords the ability to 
maximize the severity of SE in animals, whilst simultaneously limiting associated 
mortality (Hellier et al, 1998; Glien et al, 2001). Secondly, the incremental dosing 
regimen, titrated according to behavioural response, allows for a reduction in 
variation between individuals in the severity of the SE, reducing error and the 
number of animals necessary for studies of the latent phase and of chronic 
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epilepsy; particularly important in highly invasive procedure that are expensive in 
cost and time, such as the implanting of electrodes for recording EEG. Similar 
approaches have previously been used in rats (Hellier et al, 1998; Glien, 2001) 
and while incremental dosing regimens have been used to induce SE in mice 
(McKhann et al, 2003), they have not been directly compared with animals 
receiving a single dose and the characterization of the development of SE and 
subsequent indicators of epileptogenesis have been limited.  
 
We present evidence that by administering KA in incremental doses, titrated 
according to behaviour, a highly consistent period of SE, with a prolonged period 
of repeated class V tonic-clonic seizures can be achieved in C57BL/6J mice. 
These findings are similar to those reported using a repeated low-dose of KA in 
rats by Hellier et al (1998).  This group administered systemic injections of KA at 
a concentration of 5mg/kg per hour until animals showed class IV Racine 
seizures, increasing the consistency of post-SE events and reducing the mortality 
observed in a single dose model. Glien et al (2001) also found similar results with  
a repeated low dose induction method using pilocarpine. Incremental KA dosing 
regimens have also been reported in mice. McKhann et al (2003) gave 
subcutaneous injections of 6 – 12mg/kg KA every 30 – 90 minutes until Class II 
seizures were observed. In all these studies, an increase in severity and inter-
individual uniformity was reported along with a decrease in mortality. 
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We also provide evidence that the effect of prolonging the period of severe SE 
extends to an effect during the ‘latent period’. It is reported that, following an 
incremental dosing regimen approximately doubles the frequency of IEDs 
between 3 and 7 days post-SE. The frequency of IEDs is a strong predictor of 
chronic epilepsy (Staley et al, 2001). Longitudinal studies investigating neuronal 
loss, mossy fibre sprouting and spontaneous seizures would offer confirmation of 
whether this method has the potential to offer a useful model of TLE in the 
C57BL/6J strain, in which current methods induce only mild epileptogenic 
indicators. Because this strain is the most popular background for genetic 
manipulations, the development of a more useful model of chronic epilepsy would 
be a major step forward. 
 
A potential criticism of our approach is the variation between animals in the dose 
of KA received and duration in which animals have subconvulsive concentrations 
of KA in the brain. Although these concerns are valid, evidence suggests that the 
principal predictors of epileptogenesis are the duration and severity of 
epileptogenic activity, rather than specifics of the inducing agent per se and 
therefore, controlling these variables is of greatest concern. Many studies, using 
intracerebral administration of KA have indicated that neurobiological damage 
occurs distally to the site of injection, indicating that the induction of 
hyperexcitable networks is of greater significance than direct kainate toxicity 
(Schwob et al, 1980). 
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The effect of subconvulsive doses of KA prior to seizures is highly complex and 
likely to depend on drug concentrations and the exact timecourse. There is 
evidence that exposure to subconvulsive excitotoxic challenges can precondition 
the brain and increase the threshold for seizures and reduce neurobiological 
damage post-SE (Jiminez-Mateos & Henshall, 2009). There is, however, much 
evidence for the reverse effect, with the kindling model of seizure based on the 
premise that repeated sub-threshold stimulations eventually lead to a convulsion 
(Morimoto et al, 2004).  
 
Currently the pharmacokinetics of KA are poorly understood (and likely to vary 
considerably across species and strain). In order to better understand exactly 
what is happening during the period of incremental dosing, data on KA 
concentrations in the brain with a high temporal resolution would be extremely 
useful. The best method for achieving this would be through intracerebral 
microdialysis. A better understanding of the pharmacological induction of SE 
would aid the interpretation of subsequent neurobiological and electrographic 
changes. Evidence is provided, however, that regardless of the mechanisms 
involved, the administration of KA in regular low doses in mice, as already 
reported in rats (Hellier et al, 1998) can maximize the severity of SE, whilst 
limiting associated mortality.  
 
5.5.4 Tat-NR2B9a effect on electrographic and neurobiological changes 
during ‘latent period’ 
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We report that administration of Tat-NR2B9c post-SE reduces the frequency of 
IEDs during the ‘latent period’ in comparison with placebo treated controls and 
slightly reduces reactive gliosis, involving both astrocytes and microglia, in the 
CA3 region of the hippocampus associated with epileptogenesis three days after 
the induction of SE with an incremental dosing regimen of KA. This adds to the 
work of Dykstra et al (2009) who reported that Tat-NR2B9c administration could 
reduce neuronal loss in the rat hippocampus following a period of pilocarpine-
induced SE and suggests that perturbing NMDA receptor-PSD-95 protein 
interactions can retard disease progression in animal models of TLE. 
 
High levels of glutamate signalling associated with seizures, and particularly, the 
excessive stimulation of NMDA receptors, can lead to a series of potentially 
neurotoxic events (Hellier et al, 2009). The Ca2+ influx, vital to normal signalling, 
when in excessive quantities, can lead to neurodegeneration and the perturbation 
of neural networks, leading to a chronic state of seizure susceptibility (Mody & 
Macdonald, 1995). The clinical utility of general NMDA antagonists, however, is 
reduced by the severe associated side-effects, including psychotropic effects, 
similar to schizophrenia (Newcomer et al, 1999). Any antiepileptogenic strategy 
of potential clinical utility must leave physiological NMDA signalling largely intact.  
 
Aarts, et al (2002) were the first group to target the PDZ domains of PSD-95, 
using Tat-NR2B9c in an effort to alleviate excitotoxic damage. They administered 
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the cell permeable peptide following transient middle cerebral artery occlusion in 
rats and found that when applied before or 1 hour following insult Tat-NR2B9c 
could reduce focal ischemic brain damage and improve neurological function. In 
our study, Tat-NR2B9c is administered directly following the termination of 
behavioural seizures with diazepam and was found to facilitate the effect of 
diazepam in reducing the frequency of IEDs. Our data suggest that targetting 
PSD-95 directly after a seizure or period of status epilepticus can potentially have 
an effect on the disease progression of TLE, with the frequency of IEDs reduced 
throughout the first 7 days post-SE and indicators of reactive gliosis in the CA3 
region of the hippocampus reduced three days post SE. 
 
By dissociating PSD-95 from the NR2B subunit of the NMDA receptor, the 
neurotoxic effects of Ca2+ influx can be reduced whilst largely retaining the 
normal functioning of the synapse. PSD-95 is linked to the C-terminal PDZ ligand 
of NR2B, and also binds to nNOS. When the interaction of NR2B and PSD-95 is 
disrupted, the NMDAR becomes uncoupled from nNOS activation. As reported in 
chapter 4, nNOS signalling is involved in modulating the severity of seizures. By 
uncoupling NMDAR signalling from nNOS, NMDAR-dependent excitotoxicity can 
be reduced (Doucet et al, 2012). 
 
While targetting the NMDAR with a general antagonist, such as ketamine or 
MK801 creates severe side effects, it may be possible to reduce the excitotoxic 
effects of NMDA signalling, without disrupting the receptors general activity, 
217 
 
through the more specific targetting of receptors including the NR2B subunit. 
Alternatively, dissociating NMDAR from PSD-95 and, thereby, disrupting its close 
association with nNOS, may reduce the deleterious effects of excessive local NO 
production. NMDAR activity has been shown to be unaffected by the genetic 
disruption of PSD-95, or by the suppression of its expression in vitro (Lim et al, 
2003). These approaches do, however, dissociate NMDAR activity from nNOS 
and suppress excitotoxicity (Cui et al, 2007).   
 
5.5.5 1400W effect on electrographic changes during ‘latent period’ and 
neurobiological changes from 7 – 14 days 
 
Post insult iNOS expression is one part of the complex inflammatory response 
which has a role to play in almost all CNS pathologies (discussed at length in the 
context of seizures and epilepsy in chapter 1). While this response is usually 
protective; removing debris and promoting tissue repair (Brown & Bal-Price, 
2003), an inappropriately high or prolonged inflammatory response can 
contribute to disease progression. While inflammation is seldom the ‘root cause’ 
of pathology (something must initially induce the inflammation) the contributions 
to cell death, excitability and cerebral blood flow may often turn a relatively 
benign pathology into a dangerous one (Brown & Bal-Price, 2003).  
Unlike neuronal and endothelial NOS, which are constitutively expressed in the 
CNS at relatively high levels, are Ca2+/Calmodulin-dependent and are heavily 
involved in a wide array of physiological functions (such as synaptic transmission, 
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regulation of cerebral blood flow and development), the inducible isoform (iNOS) 
is constitutively expressed at very low levels, is thought to be largely uninvolved 
in physiological brain activeity and is regulated largely at the transcriptional level. 
iNOS expression is characteristic of the ‘activated’ state of microglia and 
astrocytes. As has been described, high levels of microglia activation are 
observed in our model from 72 hours (figure 5.4) and iNOS expression in similar 
models of epilepsy have been reported at similar time points (Zheng, et al, 2010).  
 
The capability to generate NO at micromolar levels provides potent pathological 
potential. NO from iNOS can lead to the release of Ca2+ from intracellular stores 
in astrocytes, stimulating the exocytosis of vesicular glutamate. In this way, 
different cell types can combine to increase the excitatory potential of neuronal 
networks. High levels of NO can also induce glutamate release and cell death in 
neurons directly by inhibiting mitochondrial cytochrome C oxidase (Antunes et al, 
2007).  
 
Inhibition of iNOS has been reported to have positive outcome in rodent models 
of neurological disease including traumatic brain injury (Jafarian-Tehrani et al, 
2005) and cerebral ischemia (Wang et al, 2004), however, to our knowledge, the 
effects of this drug on the progression of epileptogenesis following the induction 
of SE has not been investigated. It is found that systemic administration with 
1400W decreased the frequency of IEDs between three and seven days post-SE, 
suggesting that the drug has some ability to modulate disease progression. 
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However, no effect was found on neuronal cell loss at either 7 or 14 days post 
SE, nor did 1400W administration have any effect on the epileptogenic 
proliferation in nNOS expression. 
 
Almost everything that has been accepted about iNOS function in the CNS has 
been challenged. While it had been thought that it was not constitutively 
expressed, evidence has shown that low levels are expressed in the healthy 
brain (Chan et al. 2001; Starkey et al. 2001; Buskila, 2005). While it had been 
thought that its activity was controlled exclusively at the transcriptional level, 
Ratovitski, et al (1999) demonstrated that Kalarin could exert post-translational 
regulation by preventing the formation of functional dimers. 
 
The view that there is no functional role for iNOS in the healthy brain has also 
been challenged. Kalinchuk, et al (2006) demonstrate an important role for iNOS 
in the basal forebrain for inducing non-REM ‘recovery’ sleep. Ikeda & Murase 
(2004) report a role for astrocytic iNOS in regulating synaptic LTP in the spinal 
cord and more recently, Buskila & Amitai (2010) have demonstrated that a similar 
function is performed by iNOS released by astrocytes in the neocortex. The 
importance of these physiological functions remains unclear, however, despite 
the ever emerging complexity, the general view of iNOS as an induced (as 
opposed to constitutive) actor, regulated largely at the transcriptional level and of 
particular importance in pathological brain states is still largely intact. 
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5.5.6 Conclusions 
 
In this study, an alternative method of KA administration has been used in order 
to standardise the period of status epilepticus and have found that it increases 
the severity and inter-individual uniformity of SE. By inducing SE using this 
method, indicators of epileptogenesis, such as neuronal cell loss could be 
detected using fairly crude methods. The incremental dosing regimen is a 
promising model of TLE for inbred mouse strains that have proven relatively 
resistant to epileptogenesis. Of the two pharmacological agents tested, Tat-
NR2B9c seems the most promising, however, it is not clear whether the effect of 
this drug is in mediating the duration of post-diazepam electrographic SE, which 
could be considered a part of the initiating event, or on processes involved in 
disease progression. In order to get a better picture of the effects of these drugs 
on epileptogenesis, studies with larger numbers of animals are needed and 
longitudinal studies of longer duration are needed in order to assess the potential 
development of chronic epilepsy. 
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Chapter 6. General Discussion 
 
 
6.1 Overview 
 
In this thesis, behavioral, electrographic and neurobiological indicators of seizure 
severity during a period of kainic acid-induced status epilepticus (SE) on the 
C57BL/6J inbred mouse strain was investigated. The severity of epileptic 
behaviour was recorded using the Racine scale (Racine, 1972); the anatomical 
distribution of c-Fos expression in the hippocampal formation post-seizure was 
quantified using immunohistochemistry, and electrographic indicators of seizure 
severity including a qualitative analysis of EEG and quantification of epileptiform 
spikes and the power of oscillations distributed in gamma frequencies (20 – 
70Hz) were assessed using implanted electrodes. Further to assessing the 
severity of SE, subsequent changes in EEG activity associated with 
epileptogenesis was assessed for one week following KA-induced SE and 
neurobiological indicators of the emergence of chronic epilepsy, including 
reactive gliosis and synaptogenesis were assessed at 24 and 72 hours post 
seizure.  
 
The effect of a range of pharmacological interventions on the severity of KA-
induced SE and on the development of chronic epilepsy were investigated, 
including an nNOS inhibitor, L-NPA, an NR2B specific antagonist, Ro 25-6981,. 
An iNOS inhibitor, 1400W and a synthesised peptide targetted at disrupting PDZ 
223 
 
binding sites on PSD-95, Tat-NR2B9c were given as post-treatments after the 
induction of SE in order to investigate the potential for targetting iNOS and 
downstream signalling pathways from the NMDAR associated with excitotoxicity 
in order to reduce the development of chronic epilepsy following an initial 
precipitating event. An incremental KA dosing regimen was developed for studies 
investigating post-SE epileptogenesis, in order to standardise and maximise 
seizure severity whilst reducing mortality.  
 
6.2 Strain comparison 
 
Minor differences were found between strains in the anatomical distribution of 
GAD-67, SST, nNOS and CB. C57BL/6J mice generally have a lower tolerance 
to kainic acid than CD-1, however c-Fos expression in CD-1 mice is more 
widespread in the hippocampal formation following status epilepticus. 
Epileptiform spiking continues for at least 7 days following kainic acid injection, in 
the absence of any behavioural indicators and that reactive gliosis in the CA3 
region and reactive synaptogenesis in the outer molecular layer of the dentate 
gyrus occur 72 hours after induction of SE with diazepam.  
 
C57BL/6J mice were more sensitive to KA-induced SE, however, this was 
unlikely to be related to the minor differences between the two strains in the 
distribution of  GAD-67, SST, nNOS and CB in the hippocampal formation. 
Despite their greater tolerance of KA, c-Fos expression in CD-1 mice was more 
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widespread in the hippocampal formation following status epilepticus, suggesting 
that our understanding of the mechanisms underlying the expression of 
immediate early genes in response to excitotoxicity is insufficient. Epileptiform 
spiking continues for at least 7 days following kainic acid injection, in the absence 
of any behavioural indicators. Reactive gliosis occured in the CA3 region of the 
hippocampus at an earlier timepoint following SE than has previously been 
reported and that reactive synaptogenesis in the molecular layer of the dentate 
gyrus precedes mossy fibre sprouting by a significant period of time.  
While a fairly consistent response between animals caged together was found, 
between cages, there was greater variation. It is possible that this is due to an 
increased sensitivity to environmental factors resulting from isogenicity. Subtle 
differences between laboratory can manifest themselves in different behavioural 
responses in inbred mouse strains. It may be that the same is true for responses 
to KA, perhaps accounting for the variation in responses reported across 
laboratories and between studies.  
 
Our data indicates that at 2 hours following KA administration, in C57/BL6J mice, 
c-Fos in excitatory circuits is largely restricted to dentate granule cells, whereas 
in CD-1 mice, c-Fos expression extends in the pyramidal cell layers of CA3, CA2 
and CA1 of the hippocampus. This is indicative of neurons in these regions being 
exposed to high levels of excitotoxic stress. However, it may not be entirely 
appropriate to infer information about the spatial evolution of epileptiform activity 
from c-Fos distribution. Rather, the anatomical distribution of c-Fos proceeds 
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according to the severity of the seizure and the time interval. Rather than an 
anatomical distinction between the two strains in epileptiform activity, this is more 
likely to represent an increased severity of epileptiform activity per se in the 
hippocampi in CD-1 mice in comparison with C57BL/6J, in contrast to 
behavioural observations of motor seizures. 
 
6.3 Status epilepticus 
 
Our qualitative observations of epileptiform activity in the EEG trace corresponds 
strongly with that observed by Trieman et al (1990) and Medvedev et al (2000) 
following KA-induced SE in rats. The gradually increasing power of γ-frequency 
over the 2 hour period of analysis conforms to the findings of Lehmuke et al 
(2009) using a similar model and method of analysis in rats.  
 
6.4 Epileptogenesis 
 
Electrographic markers of epileptogenesis include the re-emergence of IEDs 
following an initial post-SE decline in IED frequency (Williams et al., 2009). The 
reduced frequency of IEDs in L-NPA pre-treated mice, when compared with 
vehicle pre-treated controls provides evidence that the suppression of 
neurobiological changes associated with epileptogenesis is accompanied by 
changes in the pattern of neuronal network activity.  
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Regardless of the extent to which gliosis plays a pro- or anti- epileptogenic role, 
the activation and proliferation of glial cells is a well characterised feature of the 
early stages of epileptogenesis and strongly predictive of neuronal loss and the 
development of spontaneous seizures (Vezzani et al., 2000; 2009; Foresti et al., 
2009). The increased number of both astrocytes and microglia, the morphological 
changes described and the invasion of these cells into stratum lucidum and the 
pyramidal cell layer of CA3 at 72 hours (figure 3.6) is predictive of both neuronal 
loss in this region and a decreased threshold for seizure generation. Strong 
evidence was found of astro- and microgliosis in areas CA3 and CA1 from 72h 
onwards, correlating with the sites where neuronal loss has been reported in the 
hippocampus, both of TLE patients (Wieser, 2004) and in rodents following a 
period of status epilepticus (Nitecka et al, 1984). Our studies show that at 72h 
post KA, these areas of high SYN immunoreactivity remain unchanged, while a 
modest increase in SYN immunoreactivity occurs in the OML of the dentate hilus 
within 72h of KA administration, indicating reactive synaptogenesis in this region 
(figure 3.7).   
 
6.5 Status epilepticus – Pharmacological interventions 
 
L-NPA, when administered prior to the induction of SE was found to profoundly 
suppress the emergence of epileptiform activity, including behavioural, 
electrographic and neurobiological indicators. Further, L-NPA’s modulation of the 
precipitating event lead to a decrease in neurobiological changes associated with 
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epileptogenesis, such as reactive gliosis in the CA3 region of the hippocampus 
and elevated synaptogenesis in th molecular layer of the hippocampus. This 
correlated with a marked decrease in epileptiform discharges in the EEG trace. 
 
The acute effects of L-NPA on SE were characterised by a reduction in; the 
duration of CMS (figure 4.3), the power of the γ-frequency band (20 - 70Hz) EEG 
(figure 4.6) associated with seizure severity, the frequency of epileptiform 
discharges (figure 4.5), and a decrease in the expression of c-Fos (figure 4.4), 
suggesting that nNOS is involved in seizure susceptibility and in the 
manifestation of CMS in the KA model. nNOS, activated during seizures by high 
levels of Ca2+ influx, may influence seizure severity through paracrine, autocrine 
and synaptic signaling from nNOS anchored at the PSD, or all three 
mechanisms. These results support the findings of Rajesekaran (2005), who 
suggested abnormal nNOS activity as a major trigger for seizure generation. 
While RO 25-6981 has previously been reported to have a protective effect 
against spontaneous seizures in animal models after a period of epileptogenesis 
(Wang et al, 2004), no effect of the drug was found on epileptiform behaviour 
during a period of KA-induced SE, nor on the subsequent expression of c-Fos in 
the dentate gyrus. 
 
Our data indicates that, in the C57BL/6J strain, c-Fos expression in excitatory 
circuits is largely restricted to dentate granule cells 2h post-SE. The significant 
reduction of c-Fos expression in this region associated with L-NPA treatment is 
228 
 
consistent with the view that our intervention reduced the severity of SE and 
profoundly reduced the exposure of neurons in the region to excitotoxic stress.  
 
6.6 Incremental dosing regimen  
 
We present evidence that by administering KA in incremental doses, titrated 
according to behaviour, a highly consistent period of SE, with a prolonged period 
of repeated class V tonic-clonic seizures can be achieved in C57BL/6J mice. 
These findings are similar to those reported using a repeated low-dose of KA in 
rats by Hellier et al (1998).  This group administered systemic injections of KA at 
a concentration of 5mg/kg per hour until animals showed class IV Racine 
seizures, increasing the consistency of post-SE events and reducing the mortality 
observed in a single dose model. Glien et al (2001) also found similar results with  
a repeated low dose induction method using pilocarpine. Incremental KA dosing 
regimens have also been reported in mice. McKhann et al (2003) gave 
subcutaneous injections of 6 – 12mg/kg KA every 30 – 90 minutes until Class II 
seizures were observed. In all these studies, an increase in severity and inter-
individual uniformity was reported along with a decrease in mortality. 
 
We also provide evidence that the effect of prolonging the period of severe SE 
extends to an effect during the ‘latent period’. Following an incremental dosing 
regimen approximately doubles the frequency of IEDs between 3 and 7 days 
post-SE. The frequency of IEDs is a strong predictor of chronic epilepsy (Staley 
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et al, 2011). Longitudinal studies investigating neuronal loss, mossy fibre 
sprouting and spontaneous seizures would offer confirmation of whether this 
method has the potential to offer a useful model of TLE in the C57BL/6J strain, in 
which current methods induce only mild epileptogenic indicators. Because this 
strain is the most popular background for genetic manipulations, the development 
of a more useful model of chronic epilepsy would be a major step forward. 
 
6.7 Epileptogenesis – Pharmacological interventions 
 
In the early epileptogenic period, L-NPA treatment reduced the frequency of IEDs 
(figure 4.7), suppressed reactive gliosis in the CA3 region (figure 4.8) and 
reactive synaptogenesis in the OML and MML of the dentate gyrus (figure 4.9) 
These observations might suggest a potential disease-modifying action of L-NPA 
on the epileptogenic process by modulation of the initiating event. Recently, an 
increase in nNOS expression following early-life seizures has been reported 
(Kim, 2010), which increased susceptibility to spontaneous seizures later in life in 
an nNOS-dependent manner, giving further evidence for how nNOS may play a 
role in the development of chronic epilepsy from a precipitating event.  
 
The administration of Tat-NR2B9c post-SE reduces the frequency of IEDs during 
the ‘latent period’ in comparison with placebo treated controls and slightly 
reduces reactive gliosis, involving both astrocytes and microglia, in the CA3 
region of the hippocampus associated with epileptogenesis three days after the 
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induction of SE with an incremental dosing regimen of KA. This adds to the work 
of Dykstra et al (2009) who reported that Tat-NR2B9c administration could 
reduce neuronal loss in the rat hippocampus following a period of pilocarpine-
induced SE and suggests that perturbing NMDA receptor-PSD-95 protein 
interactions can retard disease progression in animal models of TLE. 
 
High levels of glutamate signalling associated with seizures, and particularly, the 
excessive stimulation of NMDA receptors, can lead to a series of potentially 
neurotoxic events (Hellier et al, 2009). The Ca2+ influx, vital to normal signalling, 
when in excessive quantities, can lead to neurodegeneration and the perturbation 
of neural networks, leading to a chronic state of seizure susceptibility (Mody & 
Macdonald, 1995). By dissociating PSD-95 from the NR2B subunit of the NMDA 
receptor, the neurotoxic effects of Ca2+ influx can be reduced whilst largely 
retaining the normal functioning of the synapse. PSD-95 is linked to the C-
terminal PDZ ligand of NR2B, and also binds to nNOS. When the interaction of 
NR2B and PSD-95 is disrupted, the NMDAR becomes uncoupled from nNOS 
activation. As reported in chapter 4, nNOS signalling is involved in modulating the 
severity of seizures. By uncoupling NMDAR signalling from nNOS, NMDAR-
dependent excitotoxicity can be reduced (Doucet et al, 2012). 
 
We found that systemic administration with 1400W decreased the frequency of 
IEDs between three and seven days post-SE, suggesting that the drug has some 
ability to modulate disease progression. However, no effect was found on 
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neuronal cell loss at either 7 or 14 days post SE, nor did 1400W administration 
have any effect on the epileptogenic proliferation in nNOS expression. 
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